A paradigm shift in fatty liver disease nomenclature has introduced steatotic liver disease (SLD) as an umbrella term, encompassing metabolic dysfunction–associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol-related liver disease (MetALD), and alcohol-associated liver disease (ALD). These SLD subtypes exist along a dynamic continuum shaped by the synergistic interplay of metabolic dysfunction and alcohol exposure. Accumulating evidence indicates that SLD exhibits distinct outcome-based clusters reflecting heterogeneity in pathogenic drivers and clinical trajectories. Cardiometabolic clusters, most prominently observed in MASLD, are characterized by systemic metabolic dysfunction and confer increased risks of cardiovascular disease (CVD). In contrast, liver-specific clusters demonstrate progressive fibrosis and cirrhosis, hepatic decompensation, and hepatocellular carcinoma. In large-scale cohorts, CVD accounts for 40-50% of deaths in MASLD, while liver-related mortality predominates in ALD (>60%). The relative dominance of cardiometabolic versus liver-specific clusters shifts progressively across the MASLD-MetALD-ALD spectrum. While CVD remains a major driver of mortality, particularly in MASLD, hepatic outcomes increase stepwise with advancing fibrosis and greater alcohol exposure. Advanced fibrosis is the predominant shared determinant amplifying both CVD and hepatic risks across subtypes. This review synthesizes cardiovascular and hepatic outcome patterns across the MASLD-MetALD-ALD spectrum, highlighting the prognostic reorientation across the continuum, in which hepatic outcomes rise stepwise with alcohol exposure while cardiovascular risk remains an important but less subtype-differentiated burden. These findings advocate outcome-oriented risk stratification integrating noninvasive fibrosis assessment, alcohol biomarkers (PEth), and cardiovascular risk calculators within the Cardiovascular-Kidney-Metabolic framework. Understanding SLD as a modifiable continuum enables individualized management to optimize multisystem outcomes.
Metabolic dysfunction–associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide and is closely linked to systemic metabolic disorders. In addition to their classical role in hemostasis, platelets are increasingly recognized as active regulators of inflammation and immune responses, yet their contribution to MASLD pathogenesis remains incompletely defined. This review synthesizes current knowledge on how metabolic disturbances and gut microbiota dysbiosis trigger platelet hyperactivation and intrahepatic recruitment. We examined the mechanisms by which activated platelets exacerbate steatosis, amplify inflammation through interactions with immune cells, promote fibrogenic remodeling through hepatic stellate cell activation, and contribute to hepatocarcinogenesis. In the context of MASLD-associated hepatocellular carcinoma, platelet involvement may occur through both inflammation/fibrogenic remodeling–mediated and direct tumor-regulatory mechanisms. Furthermore, the therapeutic potential of antiplatelet agents, particularly aspirin, in attenuating disease progression has been evaluated. We conclude that targeting platelet-related pathways may represent a promising therapeutic strategy to interrupt the interplay between metabolic dysfunction and liver injury in MASLD.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of hepatic decompensation and liver-related death, but most patients with MASLD do not develop these liver-related complications. Risk prediction and care pathways are crucial to identify which patients with MASLD are highest risk and link them to appropriate care. Risk prediction is usually done with blood-based algorithms such as Fibrosis-4 (FIB4), AST/platelet ratio index (APRI), and more recent scores such as steatotic-associated fibrosis estimator (SAFE) and LiverRisk Score. Second-line tests include Enhanced Liver Fibrosis (ELF) and imaging-based tests such as vibration-controlled transient elastography, shear wave elastography, or magnetic resonance elastography. We propose a consensus risk stratification care pathway that can be adapted for different clinical settings. We also discuss key needs to improve upon the state of the art: improving diagnosis/prognostic accuracy especially of blood-based models, optimizing calibration, and ensuring interpretability of predictive models. Finally, we discuss recent advances in clinical decision support systems including best practice advisories, dashboards, and dynamic guidelines. We highlight factors critical to clinical decision support systems including integration with existing systems and clinician workflows, minimizing additional burden to clinicians, provision of decision support and recommendations at the time/place of decision making, and continuous evaluation and local user involvement.
Hyun Ahm Sohn, Hanyong Go, Tae Hyeon An, Jun Min Lee, Hee-Jin Kim, Keeok Haam, Amal Magdy, Hyo-Jung Jung, Yang-Ji Shin, Hyun Jung Lim, Yujin Jeong, Yejin Bae, Youngae Jung, Seong-Hwan Park, Kyung Chan Park, Myeong Jun Song, Eun-Wie Cho, Eun-Soo Kwon, Jeong Hwan Park, Murim Choi, Geum-Sook Hwang, Dong Hyeon Lee, Stefano Romeo, Kyoung-Jin Oh, Won Kim, Mirang Kim
Received September 25, 2025 Accepted January 23, 2026 Published online January 27, 2026
Background/Aims Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide. Aberrant DNA methylation, which is primarily maintained by DNA methyltransferase 1 (DNMT1), has been linked to metabolic dysregulation; however, its contribution to MASLD pathogenesis remains poorly defined. This study aimed to elucidate the role of DNMT1-mediated methylation in transcriptional regulation during MASLD progression and to determine whether DNMT1 inhibition can reverse disease-associated epigenetic and transcriptional alterations.
Methods We conducted integrated analyses of the liver transcriptome (n = 131) and DNA methylome (n = 106) of patients with biopsy-proven MASLD. We evaluated the effect of DNMT1 inhibition with 5-aza-4′-thio-2′-deoxycytidine (Aza-TdC) on a diet-induced MASLD mouse model. Multiomics approaches, including DNA methylome profiling, lipidomics, bulk and single-nucleus RNA sequencing, and chromatin immunoprecipitation sequencing, were applied to elucidate the role of DNMT1-mediated DNA methylation in regulating pathogenic gene expression.
Results DNA methylome profiling revealed increased methylation variability associated with increased DNMT1 expression in MASLD patients. DNMT1 inhibition ameliorated dysregulated lipid metabolism by reducing hepatic triacylglycerol accumulation and inflammation. Aza-TdC treatment partially reversed MASLD-related hypermethylation of hepatocyte nuclear factor 4 alpha (HNF4α)- and peroxisome proliferator-activated receptor alpha (PPARα)-regulated genes, restoring their transcriptional activity. Notably, Aza-TdC reactivated the gluconeogenic enzyme-encoding gene phosphoenolpyruvate carboxykinase 1 (PCK1), which was hypermethylated and transcriptionally repressed in MASLD. Targeted DNA methylation of the PCK1 promoter using CRISPRoff confirmed the direct epigenetic regulation of PCK1 expression.
Conclusions Targeting DNMT1 may mitigate lipid dysregulation and inflammation by reversing hypermethylation and restoring HNF4α- and PPARα-dependent gene transcription, highlighting DNMT1 as a potential therapeutic target for MASLD.
Christian Brion, Stephen Aurelien Hoang, Guangliang Wang, Faridodin Mirshahi, Jessie Ang, Matthew Ray Long, Zheng Zhu, Bhanu Sakhamuri, Molly Anderson Srour, Mohammad Shadab Siddiqui, Amon Asgharpour, David John Hayes, Neal Charles Foster, David William Salzman, Arun Jayant Sanyal
Clin Mol Hepatol 2026;32(2):706-720. Published online December 26, 2025
Background/Aims MicroRNA (miRNA) isoforms (isomiRs) broaden the regulatory landscape of canonical miRNAs, but their role in metabolic dysfunction-associated steatotic liver disease (MASLD) remains unknown. We aimed to characterize the hepatic isomiR landscape in MASLD and define their association with disease activity and fibrosis.
Methods Small RNA (sRNA) sequencing was performed on liver biopsies from 79 patients across the histological spectrum of MASLD. IsomiRs were annotated and quantified. Their association to disease activity and fibrosis score was assessed by differential expression, ordinal regression, and machine learning. Parallel mRNA sequencing and pathway enrichment were used to map isomiR–mRNA interactions and regulatory networks, which were validated against an independent dataset.
Results MiRNAs accounted for 75% of sRNAs in liver tissue, of which 67% were isomiRs. Across MASLD severity, 173 isomiRs correlated with disease activity and 58 with fibrosis stage. Key findings included a miR-122 isomiR uniquely targeting INSIG1 (cholesterol metabolism) and a miR-21 isomiR targeting PPARA and HMGCS2 (lipid and fibrosis pathways). Integration with mRNA data revealed 33 dysregulated pathways, including PPAR signaling, insulin resistance, and TGF-β response. Several novel isomiRs from miR-26b, let-7c, and miR-32 families were also linked to lipid metabolism and fibrosis progression.
Conclusions IsomiRs represent the majority of hepatic miRNAs and uncover novel regulatory networks masked by canonical miRNA analysis. These findings provide new insights into the molecular heterogeneity of MASLD, highlight candidate pathways driving disease progression, and identify potential biomarkers and therapeutic targets for precision hepatology.
Citations
Citations to this article as recorded by
The Role of MicroRNAs in the Progression of Metabolic Dysfunction-associated Steatotic Liver Disease Jang Hyun Choi Journal of Digestive Cancer Research.2026; 14(1): 82. CrossRef
High Prevalence of Metabolic Dysfunction–Associated Steatohepatitis With Significant Fibrosis in Primary Care and Endocrinology Clinics Srilaxmi Kalavalapalli, Eddison Godinez Leiva, Andrea Ortiz Rocha, Anu Sharma, Diana Barb, Nathaly Cuervo‐Pardo, Kelly Y. Chun, Toni R. Prezant, Margery A. Connelly, Jens T. Rosenberg, Joseph R. Grajo, Fernando Bril, Kenneth Cusi Diabetes, Obesity and Metabolism.2026;[Epub] CrossRef
Jonggi Choi, Daniel Fulop, Vy H. Nguyen, Eric Przybyszewski, Jiunn Song, Allison Carroll, Megan Michta, Erik Almazan, Tracey G. Simon, Raymond T. Chung
Clin Mol Hepatol 2026;32(1):305-317. Published online November 11, 2025
Background/Aims Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing cause of cirrhosis and its complications. Given its close association with type 2 diabetes mellitus (T2DM), evaluating whether sodium-glucose cotransporter-2 inhibitors (SGLT2is) can mitigate the progression of liver fibrosis is clinically important. We examined the association between SGLT2i use and liver fibrosis progression in patients diagnosed with MASLD and T2DM.
Methods We conducted a target trial emulation study using a retrospective, active comparator new-user design among adults with MASLD, T2DM, and low-to-intermediate Fibrosis-4 (FIB-4≤2.67) scores who initiated treatment with either SGLT2is or dipeptidyl peptidase-4 inhibitors (DPP-4is) at Mass General Brigham or Asan Medical Center from 2013 to 2023. The primary outcome was the progression to advanced fibrosis (FIB-4>2.67), confirmed on ≥2 occasions within 1 year. The secondary outcome was the development of major adverse liver outcomes (MALO), including incident cirrhosis, decompensation events, hepatocellular carcinoma, or liver transplantation.
Results Among 16,901 eligible patients, 2,571 propensity score-matched pairs were identified with balanced baseline characteristics. During follow-up (median, 3.7 years), fibrosis progression occurred at a rate of 3.46/100 personyears in SGLT2i users and 4.44 in DPP4i users. SGLT2i use was associated with a lower risk of fibrosis progression (HR 0.78, 95% CI 0.67–0.89; P<0.001). No significant difference in MALO incidence was observed. Subgroup analyses showed a consistent association among users of metformin, statins, and aspirin.
Conclusions SGLT2i use was associated with reduced risk of fibrotic progression compared to DPP4i use in adults with MASLD and T2DM.
Background/Aims The first metabolic dysfunction-associated steatotic liver disease (MASLD) drug was approved with an unsatisfactorily small effect size. This study aimed to determine key factors impacting the cost-effectiveness of a new hypothetical MASLD drug as well as its treatment efficacy.
Methods A Markov model reflecting the natural history of MASLD was developed, incorporating fibrosis progression, cardiovascular disease risk, and mortality. Treatment effect of drug X (with $20,000 of annual cost) was assumed to achieve a ≥1 stage fibrosis regression, with a 25% gap of effect size in regression rate over non-treatment in the first year. The incremental cost-effectiveness ratio (ICER) over a 20-year horizon was estimated. And sensitivity analyses were conducted to explore uncertainty and identify influential factors.
Results In the base case analysis, drug X provided an incremental gain of 1.32 quality-adjusted life years (QALYs) and 1.20 life years compared to the non-treatment, with an ICER of $68,010/QALY–below the $100,000/QALY willingnessto- pay threshold, indicating that drug X treatment is cost-effective. Two-way sensitivity analysis further highlighted that the drug should achieve at least a 15% initial regression gap and maintain a minimum 3% sustained durability gap to remain cost-effective. In addition baseline fibrosis stage distribution also acted as an influencing factor.
Conclusions Long-term sustained durability of the hypothetical drug, patient distribution based on baseline fibrosis stage, as well as initial treatment response rate are key factors that influence the cost-effectiveness of new MASLD drugs.
Citations
Citations to this article as recorded by
The MASLD Journey in the General Population: Linkage‐to‐Care and Patient‐Reported Uptake of Fibrosis Risk Assessment Joo Hyun Oh, Jun‐Hyuk Lee, Sang Bong Ahn, Eunjoo Kwon, Eileen L. Yoon, Hyo Young Lee, Seon Cho, Dae Won Jun Liver International.2026;[Epub] CrossRef
Reply to correspondence on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study” Xingyu Yao Clinical and Molecular Hepatology.2026; 32(2): e267. CrossRef
Impact of Documented Social Vulnerability on Clinical Outcomes in Metabolic Dysfunction‐Associated Steatotic Liver Disease Pojsakorn Danpanichkul, Yanfang Pang, Maria Inggriani, Supapitch Sirimangklanurak, Matheus Souza, Ahmad Anouti, Andrew F. Ibrahim, Nikki Duong, Thomas G. Cotter, Thomas A. Kerr, Donghee Kim, Mazen Noureddin, Karn Wijarnpreecha Liver International.2026;[Epub] CrossRef
Improved survival and reduced alcohol‐associated hepatitis risk with renin‐angiotensin‐aldosterone system inhibitors in alcohol‐associated liver disease Pojsakorn Danpanichkul, Yanfang Pang, Donghee Kim, Andrew F. Ibrahim, Primrose Tothanarungroj, Omar Al Ta'ani, Narathorn Kulthamrongsri, Kwanjit Duangsonk, Robert J. Wong, Daniel Q. Huang, Karn Wijarnpreecha, Mazen Noureddin, Suthat Liangpunsakul Alcohol, Clinical and Experimental Research.2026;[Epub] CrossRef
Extrahepatic mortality associated with chronic liver disease with or without cirrhosis from 2014 to 2024 Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed Clinical and Molecular Hepatology.2026; 32(2): e194. CrossRef
The global epidemiology of alcohol-associated liver disease Pojsakorn Danpanichkul, Francisco Idalsoaga, Frank Murray, Juan Pablo Arab, Luis Antonio Díaz Hepatology Communications.2026;[Epub] CrossRef
Reply to correspondence on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study” Xingyu Yao Clinical and Molecular Hepatology.2026; 32(2): e267. CrossRef
Correspondence to letter to the editor 2 on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study Xianhua Mao, Mindie H. Nguyen Clinical and Molecular Hepatology.2026; 32(2): e249. CrossRef
Impaired Thyroid Hormone Sensitivity is Associated with Increased
Risk of Liver Fibrosis in Euthyroid Population: A Cross-Sectional Analysis of
NHANES Xingyu Yao, Kaiwen Xiao, Hein Ko Oo Hormone and Metabolic Research.2025; 57(09): 511. CrossRef
Correspondence to editorial on “Downregulation of the MARC1 p.A165 risk allele reduces hepatocyte lipid content by increasing beta-oxidation” Ester Ciociola, Tanmoy Dutta, Rosellina M. Mancina, Stefano Romeo Clinical and Molecular Hepatology.2026; 32(2): e216. CrossRef
Metabolic dysfunction-associated steatotic liver disease: On track to become the dominant etiology of hepatocellular carcinoma: Reply to correspondence on “Downregulation of the MARC1 p.A165 risk allele reduces hepatocyte lipid content by increasing beta- Jian Xu, Wei Zhang, Guo Wu, Jingdong Li Clinical and Molecular Hepatology.2026; 32(2): e257. CrossRef
Correspondence to letter to the editor 1 on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study Xianhua Mao, Mindie H. Nguyen Clinical and Molecular Hepatology.2026; 32(2): e231. CrossRef
Background/Aims Metabolic dysfunction-associated steatotic liver disease (MASLD) may progress to liver inflammation, fibrosis, cirrhosis and hepatocellular carcinoma. So far, genome-wide association studies explain a small fraction of MASLD heritability.
Methods We sought to identify novel genetic determinants of MASLD by exploring interactions between genetic variants and body mass index (BMI). First, we examined genome-wide interactions with BMI for circulating alanine aminotransferase (ALT) levels using UK Biobank data. For identified loci, we next examined associations with hepatic proton density fat fraction (PDFF) in 35,146 independent UK Biobank participants. Associations with PDFF were replicated in four independent European cohorts, followed by a phenome-wide association study. Finally, we used human liver epigenomic maps and CRISPR/Cas9 experiments in vitro and in vivo to functionally characterize the CYP7A1 locus.
Results Thirteen loci interact with BMI for ALT (P<5E-8), including eight well-known genetic modulators of MASLD. Two loci—UBXN2B/CYP7A1 and GIPR—are additionally associated with PDFF. For the intronic rs34783010 in GIPR, the minor T allele is associated with lower BMI and higher HbA1c and liver triglyceride content in humans. The UBXN2B/CYP7A1 locus is associated with PDFF in four additional European cohorts. Epigenomic data and in vitro experiments in human liver cells prioritise rs10504255 and CYP7A1 as the functional effectors in this locus. Perturbation of CYP7A1 orthologues using CRISPR/Cas9 results in less liver fat in 10-day-old, metabolically challenged zebrafish larvae.
Conclusions A genome-wide single nucleotide polymorphism×BMI design fuelled identification of two MASLD genes: CYP7A1 and GIPR.
Citations
Citations to this article as recorded by
Germline mutations and somatic mosaicism in steatotic liver diseases and related liver carcinogenesis Eric Trépo, Jessica Zucman-Rossi, Jean-Charles Nault Nature Reviews Gastroenterology & Hepatology.2026;[Epub] CrossRef
Genetic risk of steatotic liver disease: Pathogenesis, prognosis, and implications for treatment Julia Kozlitina, Stefano Romeo, Helen H. Hobbs Hepatology.2026;[Epub] CrossRef
Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach Beom Kyung Kim The Kaohsiung Journal of Medical Sciences.2026;[Epub] CrossRef
Longitudinal changes in fatty liver index, genetic susceptibility, and incident atrial fibrillation Siyang Liu, Houde He, Hualan Chen, Hualin Duan, Ying Sun, Dan Deng, Zihao Gui, Lan Liu, Ningjian Wang, Jie Shen, Heng Wan Clinica Chimica Acta.2026; 589: 121028. CrossRef
Mapping the genomic landscape of MASLD: A framework for molecular subtyping and precision hepatology Carlos José Pirola, Silvia Sookoian Med.2026; : 101131. CrossRef
Human genetics of steatotic liver disease: insights into insulin resistance and lipid metabolism Rosellina M. Mancina, Luca Valenti, Stefano Romeo Nature Metabolism.2025; 7(11): 2199. CrossRef
Advancing policy and practice in alcohol-associated liver disease and alcohol-attributable cancer: Correspondence to the editorial on “Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the Unite Pojsakorn Danpanichkul, Donghee Kim, Karn Wijarnpreecha, Amit G. Singal, Ju Dong Yang Clinical and Molecular Hepatology.2026; 32(1): e96. CrossRef
Contemporary trends in extrahepatic mortality of chronic liver disease in the United States from 2014 to 2023 Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed Clinical and Molecular Hepatology.2026; 32(1): e24. CrossRef
Liver, Cardiovascular and Infectious Outcomes in Alcohol‐Associated Liver Disease With Cardiometabolic Risk Factors Pojsakorn Danpanichkul, Kwanjit Duangsonk, Yanfang Pang, Krittameth Rakwong, Peerapun Jit‐are‐roon, Phuuwadith Wattanachayakul, Thitiphan Srikulmontri, Benjamin Nah, Vincent L. Chen, Donghee Kim, Christos S. Mantzoros, Mazen Noureddin, Karn Wijarnpreecha Liver International.2026;[Epub] CrossRef
The global epidemiology of alcohol-associated liver disease Pojsakorn Danpanichkul, Francisco Idalsoaga, Frank Murray, Juan Pablo Arab, Luis Antonio Díaz Hepatology Communications.2026;[Epub] CrossRef
Rising drug overdose deaths in chronic liver disease in the United States, 2015–2023 Donghee Kim, Brittany B Dennis, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(3): e277. CrossRef
Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease Anoushka Shenoy, Aijaz Ahmed, Donghee Kim Metabolism and Target Organ Damage.2025;[Epub] CrossRef
Reply to correspondence on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023” Jeayeon Park, Su Jong Yu Clinical and Molecular Hepatology.2025; 31(2): e221. CrossRef
Neonatal liver-derived FTH1-enriched extracellular vesicles attenuate ferroptosis and ameliorate MASLD pathogenesis Xin Zeng, Wei Jiang, Tian Wu, Lan Li, Fudong Fu, Han Yao, Dongbo Wu Free Radical Biology and Medicine.2025; 240: 693. CrossRef
Liver-Related COVID-19 Consequences: Dynamics of Liver Health in 2.5 Years Ieva Vanaga, Oksana Kolesova, Aleksandrs Kolesovs, Maija Radzina, Davis Simanis Putrins, Jelena Egle, Sniedze Laivacuma, Jelena Storozenko, Ludmila Viksna Journal of Clinical Medicine.2025; 14(21): 7604. CrossRef
Prevalence of MASLD and fibrosis assessed by transient elastography in U.S. adolescents: insights from NHANES 2017-2023 Jialin Wu, Junlong Huang, Shiyu Cao, Yang Lyu, Peiyao Yu, Tiejun Feng, Bonan Chen, Fuda Xie, Ge Zhang, Kangmin Zhuang, Aimin Li, Ka Fai To, Wei Kang Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef
HCC predictors in routine practice for patients with chronic liver diseases: Correspondence to editorial on “High SAFE scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction associated steatotic liver disease” Tung-Hung Su, Jia-Horng Kao Clinical and Molecular Hepatology.2026; 32(1): e52. CrossRef
Correspondence to editorial 1 on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis” Haiyu Wang, Jinjun Chen Clinical and Molecular Hepatology.2026; 32(1): e58. CrossRef
Editorial: Residual HCC Risk After Hepatitis C Cure—Can Polygenic Risk Scores Refine Surveillance? Heechul Nam, Sung Won Lee Alimentary Pharmacology & Therapeutics.2026; 63(10): 1427. CrossRef
Reply to correspondence on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis” Jing Zeng, Jian-Gao Fan Clinical and Molecular Hepatology.2025; 31(2): e218. CrossRef
Longitudinal changes in fatty liver index, genetic susceptibility, and incident atrial fibrillation Siyang Liu, Houde He, Hualan Chen, Hualin Duan, Ying Sun, Dan Deng, Zihao Gui, Lan Liu, Ningjian Wang, Jie Shen, Heng Wan Clinica Chimica Acta.2026; 589: 121028. CrossRef
Associations between systemic inflammatory biomarkers and metabolic dysfunction associated steatotic liver disease: a cross-sectional study of NHANES 2017–2020 Xin Qiu, Shuang Shen, Nizhen Jiang, Yifei Feng, Guodong Yang, Donghong Lu BMC Gastroenterology.2025;[Epub] CrossRef
Correspondence to letter to the editor 2 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study” Seogsong Jeong, Won Kim, Sang Min Park Clinical and Molecular Hepatology.2025; 31(2): e210. CrossRef
Background/Aims Metabolic dysfunction-associated steatotic liver disease (MASLD) is a global epidemic. The disease has a strong genetic component, and a common missense variant (rs2642438) in the mitochondrial amidoxime-reducing component 1 (MARC1) gene confers protection against its onset and severity. However, there are contrasting results regarding the mechanisms that promote this protection.
Methods We downregulated MARC1 in primary human hepatocytes (PHHs) using short interfering RNA (siRNA). We measured neutral lipid content by Oil-Red O staining and fatty acid oxidation by radiolabeled tracers. We also performed RNA-sequencing and proteomic analysis using LC-MS. Additionally, we analyzed data from 239,075 participants from the UK Biobank.
Results Downregulation of MARC1 reduced neutral lipid content in PHHs homozygous for the wild type (p.A165, risk), but not for the mutant (p.T165, protective), allele. We found that this reduction was mediated by increased fatty acid utilization via β-oxidation. Consistent with these results, we found that the levels of 3-hydroxybutyrate, a by-product of β-oxidation, were higher in carriers of the rs2642438 minor allele among samples from the UK biobank, indicating higher β-oxidation in these individuals. Moreover, downregulation of the MARC1 p.A165 variant resulted in a more favorable phenotype by reducing ferroptosis and reactive oxygen species levels.
Conclusions MARC1 downregulation in carriers of the risk allele results in lower hepatocyte neutral lipids content due to higher β-oxidation, while upregulating beneficial pathways involved in cell survival.
Citations
Citations to this article as recorded by
Loss of Mtarc1 Protects Against Steatotic Liver Disease in Mice Xiaofei Yin, Caroline Bickerton, Bryan MacDonald, Alessandro Arduini, Yunlong Shi, Mary Haas, Amy Deik, Mark Chaffin, Erika Kovacs‐Bogdan, Julian Avila Pacheco, Maiwen Amegadjie, Bidur Bhandary, Shayan Sadre, Thomas Rathjen, Irinna Papangeli, Raymond T. C Liver International.2026;[Epub] CrossRef
MTARC1 Inactivation Remodels Lipid Droplets to Protect Against Metabolic Fatty Liver Disease Meng Tie, Liwei Hu, Yunzhi Yang, Shaoxuan Song, Qihan Zhu, Jun Li, Wenjing Wang, Peng Xu, Juan Yu, Mengyue Wu, Tianheng Zhao, Delong Yuan, Hongyu Bao, Xiuyun Wang, Irfan J. Lodhi, Yong Chen, Yali Chen, Anyuan He Liver International.2026;[Epub] CrossRef
Lactobacillus plantarum-fermented persimmon juice alleviates alcohol-induced hepatic ferroptosis by activating the Keap1/Nrf2 antioxidant axis Huijuan Kuang, Qingyuan Ye, Juan Tong, Hong Fu, Zhiqiang Shi, Bin Zhu, Guotai Yang Frontiers in Microbiology.2026;[Epub] CrossRef
The many pathways driving liver inflammation in MASH Herbert Tilg, Timon E. Adolph, Stefano Romeo, Rohit Loomba Cell Metabolism.2026;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease: On track to become the dominant etiology of hepatocellular carcinoma: Reply to correspondence on “Downregulation of the MARC1 p.A165 risk allele reduces hepatocyte lipid content by increasing beta- Jian Xu, Wei Zhang, Guo Wu, Jingdong Li Clinical and Molecular Hepatology.2026; 32(2): e257. CrossRef
Opportunities and challenges in controlling metabolic dysfunction-associated steatotic liver disease: Editorial on “Downregulation of the MARC1 p.A165 risk allele reduces hepatocyte lipid content by increasing beta-oxidation” Jian Xu, Gang Shi, Tao Sheng, Jingdong Li Clinical and Molecular Hepatology.2026; 32(2): 919. CrossRef
MTARC1 p.A165 ablation reduces hepatocellular carcinoma aggressiveness in vitro and in vivo Lohitesh Kovooru, Jingjing Zhang, Francesco Giuseppe Monni, Tanmoy Dutta, Xiangdong Gongye, Bernice Asiedu, Patrizia Infelise, Emelie Barreby, Oveis Jamialahmadi, Margit Mahlapuu, Rosellina M. Mancina, Stefano Romeo Clinical and Molecular Hepatology.2026; 32(2): 829. CrossRef
Correspondence to editorial on “Downregulation of the MARC1 p.A165 risk allele reduces hepatocyte lipid content by increasing beta-oxidation” Ester Ciociola, Tanmoy Dutta, Rosellina M. Mancina, Stefano Romeo Clinical and Molecular Hepatology.2026; 32(2): e216. CrossRef
Genetic risk of steatotic liver disease: Pathogenesis, prognosis, and implications for treatment Julia Kozlitina, Stefano Romeo, Helen H. Hobbs Hepatology.2026;[Epub] CrossRef
Mapping the genomic landscape of MASLD: A framework for molecular subtyping and precision hepatology Carlos José Pirola, Silvia Sookoian Med.2026; : 101131. CrossRef
Evolutionäre Aspekte der mit metabolischer Dysfunktion assoziierten steatotischen Lebererkrankung (MASLD) Andreas Geier, Stephan Schiffels, Marcin Krawczyk Die Gastroenterologie.2025; 20(2): 94. CrossRef
Identification of Novel Therapeutic Targets for MAFLD Based on Bioinformatics Analysis Combined with Mendelian Randomization Jialin Ren, Min Wu International Journal of Molecular Sciences.2025; 26(7): 3166. CrossRef
Lipid metabolism in liver transplantation: from challenge to chance Yuguan Zhang, Wang Rui, Xinhao Liu, Ya Ye, Sicheng Pu, Kezhen Zong, E Yang, Shanshan Li, Zuotian Huang, Zhongjun Wu Metabolism and Target Organ Damage.2025;[Epub] CrossRef
Human genetics of steatotic liver disease: insights into insulin resistance and lipid metabolism Rosellina M. Mancina, Luca Valenti, Stefano Romeo Nature Metabolism.2025; 7(11): 2199. CrossRef
Background/Aims Multi-society experts proposed the adoption of new terminology, metabolic dysfunctionassociated steatotic liver disease (MASLD) and steatotic liver disease (SLD). We studied the current prevalence of SLD and its subcategories in the US.
Methods Using the recent National Health and Nutrition Examination Survey from 2017 to 2023, we analyzed data from 12,199 participants (≥18 years) who completed transient elastography. SLD and its subcategories, including MASLD, metabolic and alcohol-related liver disease (MetALD), and alcohol-related liver disease (ALD), were categorized according to consensus nomenclature.
Results The age-adjusted prevalence of SLD (cut-off: 285 dB/m) was 35.0% (95% confidence interval [CI] 33.4–36.7). Within this category, the age-adjusted prevalence for MASLD was 31.9% (95% CI 30.4–33.4), MetALD 2.2% (95% CI 1.8–2.6), and ALD 0.8% (95% CI 0.6–1.1). The prevalence of SLD and MASLD showed a statistically insignificant decrease during COVID-19, while ALD increased without significance. In contrast, the prevalence of advanced fibrosis in SLD was significantly higher during the COVID-19 era, at 9.8% for 285 dB/m and 7.8% for 263 dB/m, compared to 7.4% (P=0.039) and 6% (P=0.041) in the pre-COVID-19 era. The proportion of advanced fibrosis and cirrhosis in individuals with ALD was two-fold higher than MASLD and MetALD, largely due to increases during the COVID-19 era.
Conclusions While the prevalence of SLD and its subcategories remained stable, there was a significant increase in advanced fibrosis among SLD individuals during the COVID-19 era, with ALD having a proportion of advanced fibrosis and cirrhosis that was twice as high as MASLD and MetALD.
Citations
Citations to this article as recorded by
Advancing policy and practice in alcohol-associated liver disease and alcohol-attributable cancer: Correspondence to the editorial on “Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the Unite Pojsakorn Danpanichkul, Donghee Kim, Karn Wijarnpreecha, Amit G. Singal, Ju Dong Yang Clinical and Molecular Hepatology.2026; 32(1): e96. CrossRef
A Novel Risk Prediction Model for Hepatocellular Carcinoma in MASLD: A Multinational, Multicenter Cohort Study Ho Soo Chun, Minjong Lee, Hye Ah Lee, Eun Seo Park, Jeong Yoon Choi, Hyo Song Baek, Tae Hun Kim, Huapeng Lin, Terry Cheuk-Fung Yip, Hye Won Lee, Emmanuel Tsochatzis, Salvatore Petta, Elisabetta Bugianesi, Masato Yoneda, Ming-Hua Zheng, Hannes Hagström, Jé Clinical Gastroenterology and Hepatology.2026; 24(3): 688. CrossRef
Dietary vitamin E intake in metabolic dysfunction–associated steatotic liver disease and all-cause/cause-specific mortality Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed European Journal of Gastroenterology & Hepatology.2026; 38(1): 63. CrossRef
Letter to the editor on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023” Sisi Yang, Zhenxuan Ma Clinical and Molecular Hepatology.2026; 32(1): e4. CrossRef
Non‐Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis Nadir Abbas, Rachel Smith, Ellina Lytvyak, Miki Scaravaglio, Neil Halliday, Amal Almahroos, Nadia Eden, Diane Lloyd‐Madden, Sanchit Sharma, James Ferguson, Jessica K. Dyson, Douglas Thorburn, David Jones, Aldo J. Montano‐Loza, Marco Carbone, Pietro Invern Alimentary Pharmacology & Therapeutics.2026; 63(4): 494. CrossRef
Social Determinants of Health in Metabolic Dysfunction‐Associated Steatotic Liver Disease and All‐Cause/Cause‐Specific Mortality Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Rohit Loomba, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2026; 63(5): 662. CrossRef
Diagnostic Performance of Ultrasound-Derived Fat Fraction and Automated Point Shear Wave Elastography for Hepatic Steatosis and Fibrosis in Suspected Steatotic Liver Disease: A Prospective Multicenter Study Jing Liang, Xueqi Li, Guangwen Cheng, Huixiong Xu, Yuli Zhu, Zhe Ma, Dong Jiang, Hao Han, Lin Chen, Liyun Xue, Xiaohui Qiao, Hong Ding Ultrasound in Medicine & Biology.2026; 52(1): 227. CrossRef
Editorial: Understanding How Social Determinants of Health Impact Mortality in MASLD—Insights From a National Analysis. Authors' Reply Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Rohit Loomba, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2026; 63(5): 752. CrossRef
SGLT‐2 Inhibitors Are Associated With Lower Mortality and Decompensation in Patients With MASH Cirrhosis and Type 2 Diabetes Do Han Kim, Donghyun Ko, Vincent L. Chen, Jose A. Porres, Carlos Elizondo Alatorre, Luis M. Nieto, Pedro Palacios Argueta, Paul T. Kröner, Frank J. Lukens, Donghee Kim, Raffi Karagozian, Meena B. Bansal, Karn Wijarnpreecha Liver International.2026;[Epub] CrossRef
Serum uric acid and the risk of MASLD in Americans: A cross-sectional study combined with Mendelian randomization and network toxicology analysis Xusheng Zhang, Wenyan Zhou, Bendong Chen, Qi Wang Medicine.2026; 105(1): e46841. CrossRef
Contemporary trends in extrahepatic mortality of chronic liver disease in the United States from 2014 to 2023 Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed Clinical and Molecular Hepatology.2026; 32(1): e24. CrossRef
Management of metabolic dysfunction and cardiovascular risk in patients with MASLD Pojsakorn Danpanichkul, Hanna Blaney, Javiera Perelli, Paula Huerta, Francisco Idalsoaga, Marco Arrese, Juan Pablo Arab, Rohit Loomba, Luis Antonio Díaz Metabolism and Target Organ Damage.2026;[Epub] CrossRef
The impact of the COVID-19 pandemic on liver health: exploring shifts in social and psychosocial determinants of steatosis and fibrosis Yuan Zhao, Xuanhui Li, Jiacheng Cheng, Dongyu Hu, Huili Cao, Xiaojuan Wang, Junhua He, Yikun Zhu, Jin Li Frontiers in Medicine.2026;[Epub] CrossRef
Diagnostic value of LPRI for assessing advanced liver fibrosis in patients with chronic hepatitis B and non-alcoholic fatty liver disease Min Wang, Huaxiao Chen, Jiaen Yang, Xueting Huang, Runyan He, Baohui Pei, Xiaolu Wu, Yanneng Kang, Longhao Xu BMC Gastroenterology.2026;[Epub] CrossRef
The Role of Race and Ethnicity in the Response to Metabolic Dysfunction-Associated Steatotic Liver Disease Treatment: A Review Aoun Laurence, Shruti M. Gandhi, Eric S. Nylen, Sabyasachi Sen Endocrine Practice.2026;[Epub] CrossRef
LiverRisk score (LRS) predicts long-term liver-related outcomes in a cohort of Veterans without evidence of liver disease Ruben Hernaez, Yan Liu, Miquel Serra-Burriel, Kavish R. Patidar, Adrià Juanola, Isabel Graupera, Elisa Pose, Núria Fabrellas, Avegail G. Flores, Jennifer R. Kramer, Fasiha Kanwal, Pere Gines Hepatology.2026;[Epub] CrossRef
Liver Stiffness Directs Intrahepatic Cholesterol Accumulation Through YAP/TAZ in Metabolic Dysfunction‐Associated Steatotic Liver Disease Na Young Lee, Myeung Gi Choi, Ho Jae Ryu, Young Jin Min, Seon Min Kim, Yeonseok Chung, Bo Kyung Koo, Yun Pyo Kang, Won Kim, Ja Hyun Koo Advanced Science.2026;[Epub] CrossRef
Distinct Laboratory and Clinical Features of Metabolic and Alcohol-Related Liver Disease (MetALD): A Systematic Review and Meta-Analysis Maria Tampaki, Vasileios Lekakis, Christos Chologkitas, Stergios Α. Polyzos, Evangelos Cholongitas Current Obesity Reports.2026;[Epub] CrossRef
Alcohol consumption exacerbates high-fat diet-mediated disruptions in myelopoiesis and osteoclastogenesis in mouse models of metabolic dysfunction-associated liver diseases Hami Hemati, Madison B. Blanton, Lauren Rutt, Nicholas Keiran, Rebecca Geron, Florence Lima, Rebecca L. McCullough, Ilhem Messaoudi Frontiers in Endocrinology.2026;[Epub] CrossRef
Liver, Cardiovascular and Infectious Outcomes in Alcohol‐Associated Liver Disease With Cardiometabolic Risk Factors Pojsakorn Danpanichkul, Kwanjit Duangsonk, Yanfang Pang, Krittameth Rakwong, Peerapun Jit‐are‐roon, Phuuwadith Wattanachayakul, Thitiphan Srikulmontri, Benjamin Nah, Vincent L. Chen, Donghee Kim, Christos S. Mantzoros, Mazen Noureddin, Karn Wijarnpreecha Liver International.2026;[Epub] CrossRef
Extrahepatic mortality associated with chronic liver disease with or without cirrhosis from 2014 to 2024 Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed Clinical and Molecular Hepatology.2026; 32(2): e194. CrossRef
Correspondence to letter to the editor on “Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the United States” Pojsakorn Danpanichkul, Luis Antonio Diaz, Juan Pablo Arab, Amit G. Singal, Ju Dong Yang Clinical and Molecular Hepatology.2026; 32(2): e246. CrossRef
Association between metabolic dysfunction-associated steatotic liver disease and overactive bladder: A cross-sectional study Shengqi Zheng, Xu Cui, Longyao Xu, Hong Chen, Liang Zheng, Chaoming Zhou Continence.2026; : 102466. CrossRef
Current Burden of Lean Metabolic Dysfunction‐Associated Steatotic Liver Disease Among US Adults, 2017–2023 Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2025; 61(5): 891. CrossRef
Editorial: Steatotic Liver Diseases Emerge as Rapidly Growing Drivers of Primary Liver Cancer in the United States—Author's Reply Pojsakorn Danpanichkul, Donghee Kim, Chun Wei Pan, Amit G. Singal, Ju Dong Yang, Karn Wijarnpreecha Alimentary Pharmacology & Therapeutics.2025; 61(6): 1059. CrossRef
Cigarette Smoke Contributes to the Progression of MASLD: From the Molecular Mechanisms to Therapy Jiatong Xu, Yifan Li, Zixuan Feng, Hongping Chen Cells.2025; 14(3): 221. CrossRef
Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States Pojsakorn Danpanichkul, Kwanjit Duangsonk, Markos Kalligeros, Michael B. Fallon, Chawinthorn Vuthithammee, Chun Wei Pan, Preenapun Saokhieo, William Derrick, Yanfang Pang, Vincent L. Chen, Donghee Kim, Amit G. Singal, Ju Dong Yang, Karn Wijarnpreecha Alimentary Pharmacology & Therapeutics.2025; 61(6): 959. CrossRef
Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2025; 61(11): 1785. CrossRef
Revealing the importance of a multidisciplinary approach to reducing the global burden of SLD through the COVID-19 pandemic: Editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023” Jeayeon Park, Su Jong Yu Clinical and Molecular Hepatology.2025; 31(2): 625. CrossRef
The burden of steatotic liver disease before and during the COVID-19 pandemic: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023” Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(2): e183. CrossRef
Reply to correspondence on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023” Jeayeon Park, Su Jong Yu Clinical and Molecular Hepatology.2025; 31(2): e221. CrossRef
Vibration-controlled transient elastography in shaping the epidemiology and management of steatotic liver disease: Editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023” Xiao-Dong Zhou, Terry Cheuk-Fung Yip, Daniel Q Huang, Mark Dhinesh Muthiah, Mazen Noureddin, Ming-Hua Zheng Clinical and Molecular Hepatology.2025; 31(2): 620. CrossRef
Addressing the burden of steatotic liver disease: The role of transient elastography: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023” Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(2): e180. CrossRef
Correspondence to editorial on “Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000-2021” Pojsakorn Danpanichkul, Luis Antonio Diaz, Kanokphong Suparan, Karn Wijarnpreecha, Juan Pablo Arab Clinical and Molecular Hepatology.2025; 31(2): e200. CrossRef
Advances in identifying risk factors of metabolic dysfunction-associated alcohol-related liver disease Rui-Qi Ye, Yi-Fan Chen, Chang Ma, Xi Cheng, Wei Guo, Sha Li Biomedicine & Pharmacotherapy.2025; 188: 118191. CrossRef
The Role of Global Physical Capacity Score in Key Parameters of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Nicola Verrelli, Caterina Bonfiglio, Isabella Franco, Claudia Beatrice Bagnato, Dolores Stabile, Endrit Shahini, Antonella Bianco Journal of Clinical Medicine.2025; 14(11): 3821. CrossRef
Evolving Public Attention to Steatotic Liver Disease: A 20‐Year Analysis (2004–2024) Pojsakorn Danpanichkul, Charat Thongprayoon, Kanokphong Suparan, Donghee Kim, Ornpailin Wanichthanaolan, Phuuwadith Wattanachayakul, Yanfang Pang, Mark D. Muthiah, Anand V. Kulkarni, Ju Dong Yang, Apichat Kaewdech, Wisit Cheungpasitporn, Karn Wijarnpreech Journal of Gastroenterology and Hepatology.2025; 40(8): 2053. CrossRef
The association between sedentary behavior and MASLD in overweight and obese adults: investigating the role of inflammatory markers using NHANES data (2017–March 2020) Zehong Zhou, Linfang Li, Chusi Wang, Shiqi Li, Pengfei Chen, Jiesheng Huang, Ming Peng Frontiers in Nutrition.2025;[Epub] CrossRef
Current burden of MASLD, MetALD, and hepatic fibrosis among US adults with prediabetes and diabetes, 2017–2023 Donghee Kim, Rohit Loomba, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(3): e235. CrossRef
Contemporary burden of mortality from chronic liver disease by sex and race/ethnicity in the United States Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(3): e268. CrossRef
Persistent Binge Drinking History Associated With Advanced Liver Fibrosis and All‐Cause Mortality in MetALD Zhe‐Kun Xiong, Ru‐Tao Lin, Bi‐Wei Chen, Xin Xin, Tao‐Ying Deng, Qin‐Mei Sun, Yi‐Yang Hu, Li‐Ming Gan, Qin Feng Alimentary Pharmacology & Therapeutics.2025; 62(11-12): 1100. CrossRef
Effect of varenicline on major adverse liver outcomes in alcohol‐associated liver disease: An exploratory analysis Pojsakorn Danpanichkul, Yanfang Pang, Donghee Kim, Thanathip Suenghataiphorn, Donghyun Ko, Andrew F. Ibrahim, Vitchapong Prasitsumrit, Kwanjit Duangsonk, Mazen Noureddin, Karn Wijarnpreecha, Suthat Liangpunsakul Alcohol, Clinical and Experimental Research.2025; 49(11): 2451. CrossRef
The effects of ellagic acid in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: a randomized, add-on, double-blind, controlled trial Mohammad Mahmoudi Azar, Matin Shirazinia, Mohsen Nematy, Vafa Baradaran Rahimi, Motahare Bateni, Fateme Tafaghodi Piadeh Gheibi, Farnood Rajabzadeh, Ladan Goshayeshi, Sara Honari, Mehran Mottahedi, Vahid Reza Askari Inflammopharmacology.2025; 33(9): 5583. CrossRef
Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease Anoushka Shenoy, Aijaz Ahmed, Donghee Kim Metabolism and Target Organ Damage.2025;[Epub] CrossRef
Class-Specific Effects of ARBs Versus ACE Inhibitors on Survival and Cardiovascular Outcomes in MASLD Tom Ryu, Yeon Joo Seo, Jaejun Lee, Ji Won Han, Hyun Yang, Keungmo Yang International Journal of Molecular Sciences.2025; 26(20): 10061. CrossRef
Stable Nationwide Sepsis-Related Mortality Does Not Extend to Individuals with Alcohol-Associated Liver Disease Pojsakorn Danpanichkul, Kwanjit Duangsonk, Claire S. Faulkner, Supapitch Sirimangklanurak, Tulaton Sodsri, Natchaya Polpichai, Shu-Yen Chan, Yanfang Pang, Omar Y. Mousa, Donghee Kim, Suthat Liangpunsakul, Karn Wijarnpreecha Digestive Diseases and Sciences.2025;[Epub] CrossRef
Prevalence of MASLD and fibrosis assessed by transient elastography in U.S. adolescents: insights from NHANES 2017-2023 Jialin Wu, Junlong Huang, Shiyu Cao, Yang Lyu, Peiyao Yu, Tiejun Feng, Bonan Chen, Fuda Xie, Ge Zhang, Kangmin Zhuang, Aimin Li, Ka Fai To, Wei Kang Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef
One-third of adults across the globe exhibit metabolic dysfunction-associated steatotic liver disease (MASLD)―formerly known as nonalcoholic fatty liver disease (NAFLD). To date, MASLD is the fastest-growing etiology of chronic liver disease and hepatocellular carcinoma (HCC). Besides the population with obesity, MASLD can also be found in lean populations, accounting for 13% of the global population, especially Asians. Notably, individuals with lean MASLD face equal or higher overall mortality rates compared to their non-lean counterparts. Risk modifiers encompass advanced age, hepatic fibrosis, and type 2 diabetes mellitus (T2DM). Moreover, the population with lean MASLD is associated with an increased risk of HCC, while their non-lean counterparts are more prone to cardiovascular outcomes and T2DM. Existing evidence indicates a similar risk of liver-related events and extrahepatic cancer between the two groups. However, MASLD-related genetic variants, such as PNPLA3 and TM6SF2, did not significantly affect mortality between the two populations. Still, underreporting alcohol consumption and regional representation limits the study’s comprehensiveness. Longitudinal studies and mechanistic explorations are needed to understand differences in lean versus non-lean MASLD populations. This review highlights the need for awareness and tailored interventions in managing MASLD, considering lean individuals’ unique risks.
Citations
Citations to this article as recorded by
Dietary vitamin E intake in metabolic dysfunction–associated steatotic liver disease and all-cause/cause-specific mortality Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed European Journal of Gastroenterology & Hepatology.2026; 38(1): 63. CrossRef
Social Determinants of Health in Metabolic Dysfunction‐Associated Steatotic Liver Disease and All‐Cause/Cause‐Specific Mortality Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Rohit Loomba, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2026; 63(5): 662. CrossRef
The Influence of Metabolic Dysfunction-Associated Steatotic Liver Disease and Body Mass Index on the Incidence of Alzheimer Disease: A Nationwide Cohort Study Tae Seop Lim, Seok Jong Chung, Jimin Jeon, Ja Kyung Kim, Jinkwon Kim Gut and Liver.2026; 20(1): 107. CrossRef
Contemporary trends in extrahepatic mortality of chronic liver disease in the United States from 2014 to 2023 Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed Clinical and Molecular Hepatology.2026; 32(1): e24. CrossRef
Association of Metabolic Dysfunction–Associated Steatotic Liver Disease With Features of Cerebral Small‐Vessel Disease on Magnetic Resonance Images: A Large Cross‐Sectional Study Yaqin Wang, Kui Chen, Changfa Wang, Zhongyang Hu, Xiaoling Zhu, Lei Liu Journal of the American Heart Association.2026;[Epub] CrossRef
Epigenetic Aging Biomarkers in Lean MAFLD Ziyan Pan, Shadi Zerehpoosh, Mohammed Eslam Liver International.2026;[Epub] CrossRef
Challenges in defining MASLD in lean individuals: the impact of the Fatty Liver Index on phenotypic characterisation Sherlot Juan Song, Yiwei Liu, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip Gut.2026; : gutjnl-2026-338216. CrossRef
Providing holistic care for patients with metabolic dysfunction‐associated steatotic liver disease/metabolic dysfunction‐associated steatohepatitis: Key aspects of clinical assessment and how to develop individualised care plans for surveillance and inter Lanlan Chen, Paul Horn, Frank Tacke Diabetes, Obesity and Metabolism.2026; 28(S2): 46. CrossRef
Disparities in Liver Transplantation Among Native Americans and Hispanic Individuals: Insights from a Southwest Region Center in the United States of America Anandalakshmi Ponnaluri, Pooja Rangan, Pojsakorn Danpanichkul, Andrew Bell, Rebecca Postagate, Moises Ilan Nevah Rubin, Michael B. Fallon, Karn Wijarnpreecha Journal of Clinical Medicine.2026; 15(3): 953. CrossRef
Human milk fat substitutes improve obesity-related NAFLD by enriching LPC 18:2 to activate hepatic GPR119–AMPK signaling Yangzheng He, Jing Li, Zhigang Wen, Yong Sun, Liufeng Zheng, Hongyan Li, Zeyuan Deng Journal of Advanced Research.2026;[Epub] CrossRef
Revisiting the Obesity Paradox in Metabolic Dysfunction-associated Steatotic Liver Disease: Longitudinal Trajectory Analysis Reveals Time-varying Mortality Risks Zhen Sun, Jinhao Li, Xuefei Yu, Yuchen Jiang, Jiaojiao Zheng, Yuan Ouyang, Ming Guan, Xuan Deng, Bo Li, Haojie Jin Clinical Gastroenterology and Hepatology.2026;[Epub] CrossRef
Increased Cardiovascular and Cerebrovascular Events in Patients With Lean vs Non-lean MASLD: A Multicenter Analysis Omar Al Ta'ani, Yahya Alhalalmeh, Mohammad Alabdallat, Abdallah Naser, Saqr Alsakarneh, Saleh Saleh, Pojsakorn Danpanichkul, Dushyant Dahiya Singh, Basile Njei, Nikki Duong Clinical and Translational Gastroenterology.2026; 17(4): e00974. CrossRef
Impact of Documented Social Vulnerability on Clinical Outcomes in Metabolic Dysfunction‐Associated Steatotic Liver Disease Pojsakorn Danpanichkul, Yanfang Pang, Maria Inggriani, Supapitch Sirimangklanurak, Matheus Souza, Ahmad Anouti, Andrew F. Ibrahim, Nikki Duong, Thomas G. Cotter, Thomas A. Kerr, Donghee Kim, Mazen Noureddin, Karn Wijarnpreecha Liver International.2026;[Epub] CrossRef
Liver, Cardiovascular and Infectious Outcomes in Alcohol‐Associated Liver Disease With Cardiometabolic Risk Factors Pojsakorn Danpanichkul, Kwanjit Duangsonk, Yanfang Pang, Krittameth Rakwong, Peerapun Jit‐are‐roon, Phuuwadith Wattanachayakul, Thitiphan Srikulmontri, Benjamin Nah, Vincent L. Chen, Donghee Kim, Christos S. Mantzoros, Mazen Noureddin, Karn Wijarnpreecha Liver International.2026;[Epub] CrossRef
Normal-weight metabolic dysfunction-associated steatotic liver disease: reclassification, characteristics, and adverse liver outcomes across diverse populations Sherlot Juan Song, Eileen Laureal Yoon, Vincent Wai-Sun Wong, Ae Jeong Jo, Grace Lai-Hung Wong, Jimmy Che-To Lai, Dae Won Jun, Terry Cheuk-Fung Yip Clinical and Molecular Hepatology.2026; 32(2): 646. CrossRef
Body Roundness Index and All‐Cause Mortality in Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Dual‐Cohort Study Zijian Li, Shishu Yin, Jian Cui, Jinxin Shi, Fuhai Ma, Tianming Ma, Qi An, Tao Yu, Danian Tang, Xianglong Cao, Gang Zhao Diabetes, Obesity and Metabolism.2026;[Epub] CrossRef
Central obesity measured by weight-adjusted waist index is associated with lean MASLD Ziteng Wang, Wentao Tan, Zhe Yu, Herui Wei, Jing Luo, Wen An, Mengqi Li, Qi Gao, Lijuan Sun, Aqian Song, Lingling He, Jiali Ma, Fan Xiao, Hong Liu, Hui Zhong, Hongshan Wei Clinics and Research in Hepatology and Gastroenterology.2026; 50(5): 102822. CrossRef
Burden and Health System Challenges in MASLD Across East and Southeast Asia: A Narrative Review Jonathan Jaime G. Guerrero, Paolo C. Encarnacion, Wan‐Yu Wang, Shu‐Fen Liao, Ching‐Wen Chang Health Science Reports.2026;[Epub] CrossRef
Integrated bioinformatics analysis and experimental validation of SRF as a potential senescence biomarker in MASLD Mengyue Li, Chang Gao, Yuhui Shi, Wenyu Peng, Yuan Yin, Bin Lu, Zhang Fu Frontiers in Molecular Biosciences.2026;[Epub] CrossRef
Multicenter Prospective Cohort Study on Clinical Outcomes and Fibrosis Patterns in Biopsy-Proven Steatotic Liver Disease Subtypes Gi-Ae Kim, Heejoon Jang, Moon Young Kim, Jeong Hwan Park, Jung Gil Park, Eun-Young Cho, Jae Yoon Jeong, Seogsong Jeong, Seul Ki Han, Heesu Kwon, Youngae Jung, Geum-Sook Hwang, Yu Rim Lee, Soo Young Park, Sang Gyune Kim, Won Kim Gastroenterology.2026;[Epub] CrossRef
Outcomes of liver and cardiovascular metabolic diseases among lean vs non-lean individuals with metabolic dysfunction-associated steatotic liver disease Mexan Mapouka, Evariste Pabingui, Nkengeh N Tazinkeng, Milkessa Gurmessa, Ulrich Vickos, Nkafu Bechem Ndemazie, Serge Magloire Camengo Police World Journal of Gastroenterology.2026;[Epub] CrossRef
Phthalates exposure, biological aging, and increased risks of insulin resistance, prediabetes, and diabetes in adults with metabolic dysfunction-associated steatotic liver disease Yueru Yang, Shuhui Wan, Linling Yu, Wei Liu, Jiahao Song, Da Shi, Yongfang Zhang, Weihong Chen, Weihong Qiu, Bin Wang Diabetes & Metabolism.2025; 51(1): 101602. CrossRef
Increased MASH-associated liver cancer in younger demographics Pojsakorn Danpanichkul, Yanfang Pang, Kanokphong Suparan, Thanida Auttapracha, Supapitch Sirimangklanurak, Abdelrahman M. Attia, Chanattha Thimphitthaya, Michelle Shi Ni Law, Zhenning Yu, Mostafa A. Soliman, Natchaya Polpichai, Chanakarn Kanitthamniyom, D Hepatology Communications.2025;[Epub] CrossRef
Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States Pojsakorn Danpanichkul, Kwanjit Duangsonk, Markos Kalligeros, Michael B. Fallon, Chawinthorn Vuthithammee, Chun Wei Pan, Preenapun Saokhieo, William Derrick, Yanfang Pang, Vincent L. Chen, Donghee Kim, Amit G. Singal, Ju Dong Yang, Karn Wijarnpreecha Alimentary Pharmacology & Therapeutics.2025; 61(6): 959. CrossRef
Current Burden of Lean Metabolic Dysfunction‐Associated Steatotic Liver Disease Among US Adults, 2017–2023 Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2025; 61(5): 891. CrossRef
Comparative application of MAFLD and MASLD diagnostic criteria on NAFLD patients: insights from a single-center cohort Maha Elsabaawy, Madiha Naguib, Ahmed Abuamer, Ahmed Shaban Clinical and Experimental Medicine.2025;[Epub] CrossRef
Advanced lung cancer inflammation index: a key predictor of hepatic steatosis and fibrosis severity Yajie Liu, Ruilin Wang BMC Gastroenterology.2025;[Epub] CrossRef
Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2025; 61(11): 1785. CrossRef
Addressing the burden of steatotic liver disease: The role of transient elastography: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023” Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(2): e180. CrossRef
Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023 Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(2): 382. CrossRef
Liver cirrhosis in metabolic dysfunction-associated steatohepatitis Donghyun Ko, Do Han Kim, Pojsakorn Danpanichkul, Masahito Nakano, Chitchai Rattananukrom, Karn Wijarnpreecha, Cheng Han Ng, Mark D Muthiah Gastroenterology Report.2025;[Epub] CrossRef
Advances in identifying risk factors of metabolic dysfunction-associated alcohol-related liver disease Rui-Qi Ye, Yi-Fan Chen, Chang Ma, Xi Cheng, Wei Guo, Sha Li Biomedicine & Pharmacotherapy.2025; 188: 118191. CrossRef
Increased Mortality Among Lean Versus Non‐Lean Adults With MASLD: A Multicenter Study Leith Ghani, Majd B. Aboona, Claire S. Faulkner, Pooja Rangan, Moises Nevah Rubin, Ma Ai Thanda Han, Michael B. Fallon, Vincent L. Chen, Karn Wijarnpreecha Journal of Gastroenterology and Hepatology.2025; 40(8): 1919. CrossRef
Evolving Public Attention to Steatotic Liver Disease: A 20‐Year Analysis (2004–2024) Pojsakorn Danpanichkul, Charat Thongprayoon, Kanokphong Suparan, Donghee Kim, Ornpailin Wanichthanaolan, Phuuwadith Wattanachayakul, Yanfang Pang, Mark D. Muthiah, Anand V. Kulkarni, Ju Dong Yang, Apichat Kaewdech, Wisit Cheungpasitporn, Karn Wijarnpreech Journal of Gastroenterology and Hepatology.2025; 40(8): 2053. CrossRef
Meta‐Analysis: Effects of Steatotic Liver Disease‐Associated Genetic Risk Alleles on Longitudinal Outcomes Matthew Kubina, Vitchapong Prasitsumrit, Jarell Tan, Joo Wei Ethan Quek, Dhiraj Peddu, Ankit Mishra, Pojsakorn Danpanichkul, Jake P. Mann, Eric Trépo, Stephan Buch, Daniel Q. Huang, Cheng Han Ng, Mark D. Muthiah, Yu Jun Wong, Karn Wijarnpreecha, Vincent L Alimentary Pharmacology & Therapeutics.2025; 62(3): 244. CrossRef
Metabolic Impact of Alcohol Consumption in MASLD: Understanding MetALD and Beyond Eva Juárez-Hernández, Montserrat Berrospe-Alfaro, Misael Uribe, Iván López-Mendez Journal of Clinical and Experimental Hepatology.2025; 15(6): 103114. CrossRef
Current burden of MASLD, MetALD, and hepatic fibrosis among US adults with prediabetes and diabetes, 2017–2023 Donghee Kim, Rohit Loomba, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(3): e235. CrossRef
Predicting the risk of lean non-alcoholic fatty liver disease based on interpretable machine models in a Chinese T2DM population Shixue Bao, Qiankai Jin, Tieqiao Wang, Yushan Mao, Guoqing Huang Frontiers in Endocrinology.2025;[Epub] CrossRef
Effect of varenicline on major adverse liver outcomes in alcohol‐associated liver disease: An exploratory analysis Pojsakorn Danpanichkul, Yanfang Pang, Donghee Kim, Thanathip Suenghataiphorn, Donghyun Ko, Andrew F. Ibrahim, Vitchapong Prasitsumrit, Kwanjit Duangsonk, Mazen Noureddin, Karn Wijarnpreecha, Suthat Liangpunsakul Alcohol, Clinical and Experimental Research.2025; 49(11): 2451. CrossRef
Paradoxical association between steatotic liver disease and favorable hepatic outcomes in HCV patients with SVRs Ming-Ling Chang, Jur-Shan Cheng, Jennifer Tai, Wei-Ting Chen, Sien-Sing Yang, Cheng-Hsun Chiu, Rong-Nan Chien, Chia-Lin Hsu, Shang-Jung Wu, Cathy SJ Fann Hepatology International.2025; 19(6): 1347. CrossRef
Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease Anoushka Shenoy, Aijaz Ahmed, Donghee Kim Metabolism and Target Organ Damage.2025;[Epub] CrossRef
Obesity-Driven Metabolic Disorders: The Interplay of Inflammation and Mitochondrial Dysfunction Wooyoung Choi, Gun Ha Woo, Tae-Hwan Kwon, Jae-Han Jeon International Journal of Molecular Sciences.2025; 26(19): 9715. CrossRef
Metabolic dysfunction-associated steatotic liver disease: Prevalence and progression in lean patients Gerard Stupecki, Emilia Kowalczyk, Agnieszka Ciba-Stemplewska, Magdalena Dolecka-Ślusarczyk, Iwona Gorczyca-Głowacka Polish Annals of Medicine.2025; : 1. CrossRef
Increasing Prevalence of Steatotic Liver Disease in a Japanese Health Checkup Population, 2004–2022 Yuki Nakahata, Takao Miwa, Akihiro Obora, Takao Kojima, Nobuaki Yagi, Masahito Shimizu Liver International.2025;[Epub] CrossRef
The global landscape of lean metabolic dysfunction-associated steatotic liver disease: insight from Asia and the West Hery Djagat Purnomo, Randy Adiwinata, Cecilia Oktaria Permatadewi, Hesti Triwahyu Hutami, Didik Indiarso Frontiers in Gastroenterology.2025;[Epub] CrossRef
Role of ChREBP–PPARα–FGF21 Axis in Metabolic Dysfunction of MASLD Karina Mireya Palacios Girón, Zamira Helena Hernandez Nazara, Montserrat Maldonado-González, Erika Martínez-López, Martha P. Sánchez Muñoz, Carlos Alfredo Bautista López, Ma. Soledad Aldana Aguiñaga, Jose Alfredo Dominguez-Rosales, Belinda Vargas-Guerrero International Journal of Molecular Sciences.2025; 26(23): 11425. CrossRef
Implication of the Androgen Receptor in Muscle–Liver Crosstalk: An Overlooked Mechanistic Link in Lean-MASLD Eleni Myrto Trifylli, Christiana Charalambous, Nikolaos Spiliotopoulos, Nikolaos Papadopoulos, Anastasia Oikonomou, Spilios Manolakopoulos, Melanie Deutsch Livers.2025; 5(4): 65. CrossRef
Intestinal NLRP3 Deficiency Exacerbates MASLD in Male Mice via Reduced Butyrate Production Li Chen, Jing Li, Hao Yu Jia, Chun Liu, Shan Shan Li, Feng Shang Zhu, Chang Qing Yang Journal of Digestive Diseases.2025; 26(11-12): 544. CrossRef
Poor Sensitivity of the Fatty Liver Index Among Lean Individuals Mohammed Rifat Shaik, Yaron Rotman American Journal of Gastroenterology.2025;[Epub] CrossRef
PNPLA3 as a driver of steatotic liver disease: navigating from pathobiology to the clinics via epidemiology Ralf Weiskirchen, Amedeo Lonardo Journal of Translational Genetics and Genomics.2024; 8(4): 355. CrossRef
Background/Aims Evidence suggests that the gastrointestinal microbiome plays a significant role in the biology of metabolic dysfunction-associated steatotic liver disease (MASLD). However, it remains unclear whether disparities in the gut microbiome across intestinal tissular compartments between the sexes lead to MASLD pathogenesis.
Methods Sex-specific analyses of microbiome composition in two anatomically distinct regions of the gut, the small intestine and colon, were performed using an experimental model of MASLD. The study involved male and female spontaneously hypertensive rats and the Wistar-Kyoto control rat strain, which were fed either a standard chow diet or a high-fat diet for 12 weeks to induce MASLD (12 rats per group). High-throughput 16S sequencing was used for microbiome analysis.
Results There were significant differences in the overall microbiome composition of male and female rats with MASLD, including variations in topographical gut regions. The beta diversity of the jejunal and colon microbiomes was higher in female rats than in male rats (PERMANOVA p-value=0.001). Sex-specific analysis and discriminant features using LEfSe showed considerable variation in bacterial abundance, along with distinct functional properties, in the jejunum and colon of animals with MASLD. Significantly elevated levels of lipopolysaccharide and protein expression of Toll-like receptor 4 were observed in the livers of male rats with MASLD compared with their female counterparts.
Conclusions This study uncovered sexual dimorphism in the gut microbiome of MASLD and identified microbial heterogeneity within intestinal compartments. Insights into sex-specific variations in gut microbiome composition could facilitate customised treatment strategies.
Citations
Citations to this article as recorded by
Sex and gender differences in metabolic dysfunction-associated liver disease Rishitha Penmetsa, Sasha Kapil, Lisa B. VanWagner Indian Journal of Gastroenterology.2026; 45(2): 192. CrossRef
New Definition, New Point of View: Sex and Gender Interpretation of MASLD—Interpretation of Guidelines and Review of the Literature Massimo De Luca, Rita Verdoliva, Anna Lombardi, Antonio Giorgio Gastroenterology Insights.2026; 17(1): 7. CrossRef
The Gut–Liver Axis in MASLD: From Host–Microbiome Crosstalk to Precision Therapeutics Ji Zhou, Bowen Zhu, Ziqian Bing, Tingting Wang, Yue Zhao Microorganisms.2026; 14(2): 471. CrossRef
Sex-specific dynamics of MASLD reveal early hepatic and extrahepatic metabolic deterioration in females despite long-term protection Maria Repollés-de-Dalmau, Anna Marsal-Beltran, Catalina Núñez-Roa, Joan Vendrell, Victòria Ceperuelo-Mallafré, Sonia Fernández-Veledo Biology of Sex Differences.2026;[Epub] CrossRef
Sex-specific cardiometabolic phenotypes in MASLD: 3PM-centric stratification and trajectory mapping for proactive risk assessment Carlos José Pirola, Luis Diambra, Tomas Fernández Gianotti, Silvia Sookoian EPMA Journal.2026;[Epub] CrossRef
Dysregulation of the Gut-Adipose Tissue-Liver Axis: a Possible Mechanism Behind the Relationship Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes Susanna Longo, Tommaso Giovanni Rinaldi, Jose Manuel Fernández-Real, Massimo Federici Current Diabetes Reports.2026;[Epub] CrossRef
Correspondence to letter to the editor on “Role of amino acids in the regulation of hepatic gluconeogenesis and lipogenesis in metabolic dysfunctionassociated steatotic liver disease” Eiji Kakazu, Masaaki Mino, Tatsuya Kanto Clinical and Molecular Hepatology.2026; 32(2): e235. CrossRef
MASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women Ilaria Milani, Marianna Chinucci, Frida Leonetti, Danila Capoccia Biomedicines.2025; 13(4): 855. CrossRef
Characteristics of serum bile acid profiles among individuals with metabolic dysfunction-associated steatotic liver disease Sheng Lyu, Jiani Yang, Xin Xin, Qinmei Sun, Beiyu Cai, Xin Wang, Ziming An, Jian Sun, Yiyang Hu, Lei Shi, Qin Feng, Xiaojun Gou BMC Gastroenterology.2025;[Epub] CrossRef
Gut-Liver Axis: The Role of Intestinal Microbiota and Their Metabolites in the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease Chao Cui, Shuai Gao, Jingfei Shi, Kai Wang Gut and Liver.2025; 19(4): 479. CrossRef
Triglyceride-glucose-waist circumference index: A powerful tool for metabolic dysfunction-associated steatotic liver disease Bryan Adrian Priego-Parra, Berenice M Román-Calleja, Rocio Gallego-Duran, Jordi Gracia-Sancho, Jose Antonio Velarde Ruiz-Velasco, Jose Maria Remes-Troche World Journal of Hepatology.2025;[Epub] CrossRef
Animal models of lean metabolic dysfunction-associated steatotic liver disease (MASLD): bridging pathogenesis and novel drug discovery Stavros P. Papadakos, Chara Georgiadou, Eva Kassi, Rallia-Iliana Velliou, Antonios Chatzigeorgiou Expert Opinion on Drug Discovery.2025; 20(12): 1683. CrossRef
Correspondence to editorial on “DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease” Amal Magdy, Hee-Jin Kim, Won Kim, Mirang Kim Clinical and Molecular Hepatology.2025; 31(1): e70. CrossRef
PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD: Correspondence to editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD” Baokai Sun, Likun Zhuang Clinical and Molecular Hepatology.2025; 31(1): e67. CrossRef
The correlation between the polymorphism of lysolecithin acyltransferase (MBOAT7) rs641738 and liver fibrosis Yuxia Yang, Xiang Chen, Huiqin Zhang, Gang Yang, Xiaoyun Zhu, Xiujing Si, Feilong Chen, Yan Zhao, Feng Jin, Juanjuan Lu Personalized Medicine.2025; 22(2): 113. CrossRef
Advancing precision medicine in metabolic dysfunction-associated steatotic liver disease Bryan A. Priego-Parra, Rocío Gallego-Durán, Berenice M. Román-Calleja, José Antonio Velarde-Ruiz Velasco, Manuel Romero-Gómez, Jordi Gracia-Sancho Trends in Endocrinology & Metabolism.2025; 36(11): 1000. CrossRef
Telomere length and metabolic dysfunction-associated steatotic liver disease risk and progression: A systematic review and meta-analysis Chunfeng Sun, Ping Qiu, Shuo Huang, Qihan Luo, Qing Ma, Piao Hu, Fangming Chen, Hongyan Wu, Chunxiao Chen Experimental Gerontology.2026; 214: 113036. CrossRef
Biological aging across the metabolic dysfunction–associated steatotic liver disease spectrum: A systematic review Chukwuemeka E. Ogbu, Stella C. Ogbu, Chidera P. Ogbu, Chinazor Umerah iLIVER.2026; 5(1): 100222. CrossRef
Increased MASH-associated liver cancer in younger demographics Pojsakorn Danpanichkul, Yanfang Pang, Kanokphong Suparan, Thanida Auttapracha, Supapitch Sirimangklanurak, Abdelrahman M. Attia, Chanattha Thimphitthaya, Michelle Shi Ni Law, Zhenning Yu, Mostafa A. Soliman, Natchaya Polpichai, Chanakarn Kanitthamniyom, D Hepatology Communications.2025;[Epub] CrossRef
Metabolic Dysfunction‐Associated Steatotic Liver Disease After Hepatitis C Virus Cure Chung‐Feng Huang, Jee‐Fu Huang, Ming‐Lung Yu, Wan‐Long Chuang The Kaohsiung Journal of Medical Sciences.2026;[Epub] CrossRef
Impact of Cardiometabolic Risk Factors and Steatotic Liver Disease on Liver‐Related Outcomes in Patients With Chronic Hepatitis C After Curative Antiviral Therapy Chung‐Feng Huang, Yi‐Hung Lin, Pei‐Chien Tsai, Ming‐Lun Yeh, Chih‐Wen Wang, Tyng‐Yuan Jang, Po‐Cheng Liang, Yu‐Ju Wei, Nai‐Jen Hou, Ming‐Yen Hsieh, Chao‐Kuan Huang, Tzu‐Chun Lin, Jee‐Fu Huang, Chia‐Yen Dai, Wan‐Long Chuang, Ming‐Lung Yu The Kaohsiung Journal of Medical Sciences.2026;[Epub] CrossRef
Hepatocellular carcinoma surveillance after sustained virological response in chronic hepatitis C: Editorial on “Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus: A systematic review and meta-ana Ho Soo Chun, Minjong Lee Clinical and Molecular Hepatology.2025; 31(1): 261. CrossRef
Hepatitis C virus and cardiovascular disease: Current knowledge and unmet needs Chih-Wen Wang, Jee-Fu Huang, Ming-Lung Yu, Wan-Long Chuang Tzu Chi Medical Journal.2025; 37(4): 371. CrossRef
As the rates of obesity and type 2 diabetes (T2D) continue to increase globally, so does the prevalence of metabolic dysfunction–associated steatotic liver disease (MASLD). Currently, 38% of all adults and 7–14% of children and adolescents have MASLD. By 2040, the MASLD prevalence rate for adults is projected to increase to more than 55%. Although MASLD does not always develop into progressive liver disease, it has become the top indication for liver transplant in the United States for women and those with hepatocellular carcinoma (HCC). Nonetheless, the most common cause of mortality among patients with MASLD remains cardiovascular disease. In addition to liver outcomes (cirrhosis and HCC), MASLD is associated with an increased risk of developing de novo T2D, chronic kidney disease, sarcopenia, and extrahepatic cancers. Furthermore, MASLD is associated with decreased health-related quality of life, decreased work productivity, fatigue, increased healthcare resource utilization, and a substantial economic burden. Similar to other metabolic diseases, lifestyle interventions such as a heathy diet and increased physical activity remain the cornerstone of managing these patients. Although several obesity and T2D drugs are available to treat co-morbid disease, resmetirom is the only MASH-targeted medication for patients with stage 2–3 fibrosis that has approved by the Food and Drug Administration for use in the United States. This review discusses MASLD epidemiology and its related risk factors and outcomes and demonstrates that without further global initiatives, MASLD incidence could continue to increase.
Citations
Citations to this article as recorded by
Early burden, enduring risk: The alarming outcomes of pediatric MASLD Marialena Mouzaki Hepatology.2026; 83(3): 445. CrossRef
Association between dietary amino acid intake and the risk of metabolic dysfunction-associated steatotic liver disease Ruoqi Zhou, Xinrong Zhang, Xinxin Liu, Rui Huang, Yuwei Wang, Dajing Xia, Xue Li, Yihua Wu, Yu Shi Journal of Advanced Research.2026; 80: 893. CrossRef
Population perspectives on benefits and harms of screening for metabolic dysfunction–associated steatotic liver disease Alina M. Allen, W. Ray Kim, Patrizia Carrieri, Rachel Canning, Fang-Shu Ou, Joanne Benson, Jessica L. Olson, Sudhakar K. Venkatesh, Jiahui Li, Meng Yin, Maysa Eslami, Richard L. Ehman, Jennifer Hunter Berg, Jeffrey V. Lazarus Hepatology.2026; 83(2): 362. CrossRef
A Novel Risk Prediction Model for Hepatocellular Carcinoma in MASLD: A Multinational, Multicenter Cohort Study Ho Soo Chun, Minjong Lee, Hye Ah Lee, Eun Seo Park, Jeong Yoon Choi, Hyo Song Baek, Tae Hun Kim, Huapeng Lin, Terry Cheuk-Fung Yip, Hye Won Lee, Emmanuel Tsochatzis, Salvatore Petta, Elisabetta Bugianesi, Masato Yoneda, Ming-Hua Zheng, Hannes Hagström, Jé Clinical Gastroenterology and Hepatology.2026; 24(3): 688. CrossRef
The OGT–TFF2 axis mediates intrahepatic crosstalk and MASH pathogenesis Lei Zhang, Cuijuan Han, Man Mohan Shrestha, Jiamei Le, Wilhelm K. Berger, Yiheng Huang, Reina Desrouleaux, Eric Wang, Laszlo Nagy, Xiaoyong Yang Hepatology.2026; 83(5): 1215. CrossRef
Socioeconomic Factors Impact the Perception of Healthcare Experiences in Patients with Cirrhosis Nicole Ng, Subhanik Purkayastha, Xiaohan Ying, Arun Jesudian, Russell Rosenblatt Digestive Diseases and Sciences.2026; 71(2): 486. CrossRef
Intersections of vitamin D deficiency, HIV and chronic liver diseases Francesca Farina, Aurgho Datta, Suzanne N. Morin, Sahar Saeed, Bertrand Lebouche, Giovanni Guaraldi, Salvatore Petta, Giada Sebastiani HIV Medicine.2026; 27(1): 4. CrossRef
Hepatocellular carcinoma arising from ectopic liver tissue: a systematic review of the literature Sami Akbulut, Tevfik Tolga Sahin European Journal of Gastroenterology & Hepatology.2026; 38(3): 243. CrossRef
Pubertal exposure to glyphosate-based herbicide aggravates diet-induced steatosis and hormonal dysregulation in adult mice Jakeline Liara Teleken, Ana Paula Farina Rosolen, Joseane Morari, Sandra Lucinei Balbo, Rosane Aparecida Ribeiro, Maria Lúcia Bonfleur Naunyn-Schmiedeberg's Archives of Pharmacology.2026; 399(3): 3589. CrossRef
Reliable Monitoring of Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease Using Imaging: A Systematic Literature Review and Meta-Analysis on Measurement Repeatability Michael Ndaa, Prashant K. Pandya, Jordan Swensson, Niharika Samala, Saima Ajaz, Deepak Joshi, Walid S. Ayoub, Fatih Akisik Endocrine Practice.2026; 32(2): 258. CrossRef
Semaglutide, the first approved GLP-1 receptor agonist for the management of metabolic dysfunction-associated steatohepatitis Chrysoula Boutari, Michael A. Hill, Christos S. Mantzoros Metabolism.2026; 174: 156397. CrossRef
The Bubble-Destruction Curve Obtained Using Contrast-Enhanced Ultrasound is Useful for Assessing Liver Fibrosis and Identifying At-risk MASH in Patients With MASLD Noritaka Wakui, Yu Ogino, Naohisa Kamiyama, Takuma Oguri, Tomoya Uchimura, Takahide Kudo, Kenichi Maruyama, Hideki Nagumo, Naoyuki Yoshimine, Kunihide Mouri, Kojiro Kobayashi, Takanori Mukozu, Teppei Matsui, Hidenari Nagai, Yoshinori Igarashi, Takahisa Ma Ultrasound in Medicine & Biology.2026; 52(1): 237. CrossRef
Outcome-Specific Cardiovascular and Hypertensive Risk Profiles in Metabolic Dysfunction-Associated Steatotic Liver Disease: Insights From a Competing Risk Cohort Analysis Masashi Hirooka, Teruki Miyake, Ryo Yano, Yoshiko Nakamura, Yuki Okazaki, Toyoki Shimamoto, Atsushi Yukimoto, Yasunori Yamamoto, Takao Watanabe, Osamu Yoshida, Kana Hirooka, Yoshio Tokumoto, Masanori Abe, Takeru Iwata, Yoichi Hiasa Gastro Hep Advances.2026; 5(1): 100806. CrossRef
Diabetes and the liver Ebo Dadey, Tiong Yeng Lim, Janine Makaronidis Clinical Medicine.2026; 26(1): 100528. CrossRef
Valproic Acid Exacerbates Lipid Accumulation in High‐Fat Hepatocytes Induced by Oleic Acid: Insights From Lipidomic Analysis Shansen Xu, Xianglei Ma, Lingli Huang, Tingting Yue, Ya'nan Chen Lipids.2026; 61(1): 163. CrossRef
Metabolic Dysfunction–Associated Steatotic Liver Disease in Adults Herbert Tilg, Salvatore Petta, Norbert Stefan, Giovanni Targher JAMA.2026; 335(2): 163. CrossRef
Recognizing the Burden of Metabolic Liver Disease in IBD Raseen Tariq, Richard K Sterling Inflammatory Bowel Diseases.2026; 32(3): 584. CrossRef
Editorial: Understanding How Social Determinants of Health Impact Mortality in MASLD—Insights From a National Analysis Joyce Lui, Yesung Kweon, Mohamed I. Elsaid Alimentary Pharmacology & Therapeutics.2026; 63(5): 750. CrossRef
Advances in Incretin‐Based Therapies for MAFLD: Mechanisms and Clinical Evidence Wenqi Dong, Haiming Zhang, Shaowei Mu, Shuyi Shi, Junli Zhang, Keshu Xu Clinical Pharmacology & Therapeutics.2026; 119(2): 336. CrossRef
Protective effect of vitamin D on high-fat-diet-induced metabolic dysfunction-associated steatotic liver disease in mice Amal A. Mohamed, Wael Hafez, Said El-Feky, Mona G. Khalil, Amina S. Soliman, Karima Nasraldin, Ingy M. Ibrahim, Hanan A. Hegazy, Weam Shaheen, Abbas M. Abbas, Hager Shaheen, Marian FL. Abdelmalak, Hany N. Azzam, Omnia Ezzat, Noheir Ashraf Ibrahem Fathy Ha Steroids.2026; 225: 109718. CrossRef
The adipokine Isthmin-1 in obesity and its complications: recent research advances Yuting Zhuang, Jialuo Liu, Yanling Sui, Jiamin Song, Guoyue Yuan, Li Zhao Life Sciences.2026; 384: 124092. CrossRef
Integrated network toxicology, molecular docking and transcriptomics reveal the mechanistic role of phthalate esters in metabolic disease pathogenesis Yuancheng Shao, Qi Liu, Yicheng Jiang, Gang Zhou, Xihan Gu, Shufan Zhang, Shuai Chen, Jiaming Xue, Liming Tang Food and Chemical Toxicology.2026; 207: 115855. CrossRef
Commercial glyphosate formulations exceed active ingredient toxicity via mitochondrial ROS and transcriptomic disruption Jakeline Liara Teleken, Leticia Prates Roma, Rosane Aparecida Ribeiro, Alex Rafacho, Maria Lúcia Bonfleur Toxicology in Vitro.2026; 111: 106178. CrossRef
Effects of bariatric surgery on neurological disturbances and quality of life in patients with metabolic dysfunction-associated steatotic liver disease and obesity: a prospective longitudinal study Concepción Gómez, Juan José Gallego Roig, María Lapeña, Clara Alfaro-Cervelló, Alessandra Fiorillo, Adrià López-Gramaje, Raquel Alfonso Ballester, Norberto Casinello, María Capilla Lozano, María Desamparados Escudero-García, Cristina Montón, Amparo Urios Surgery for Obesity and Related Diseases.2026; 22(1): 113. CrossRef
Effect of Weight Loss on Clinical Outcomes in Patients With Chronic Gastrointestinal and Liver Diseases Nicola Pugliese, Matteo Spertino, Miriana Mercurio, Stefano Ciardullo, Gianluca Perseghin, Cesare Hassan, Roberto Vettor, Salvatore Petta, Alessio Aghemo Clinical Gastroenterology and Hepatology.2026; 24(3): 583. CrossRef
Novel dual AMPK/NRF2 activation by leucocyanidin from Hawthorn (Crataegus) for mitochondria repair-Targeted therapy of hepatic steatosis Yunheng Li, Minghua Ye, Qiaojun He, Bo Yang, Peihua Luo, Xiaochun Yang Phytomedicine.2026; 150: 157614. CrossRef
The role of liver sinusoidal endothelial cells in liver diseases: Key players in health and pathology Eric Felli, Yeldos Nulan, Martí Ortega-Ribera, Anabel Fernández-Iglesias, Jordi Gracia-Sancho Journal of Hepatology.2026; 84(3): 655. CrossRef
A comparative study between ultrasound-guided-attenuation-parameter (UGAP), controlled attenuation parameter (CAP), and proton density fat fraction (PDFF) for assessment of hepatic steatosis Marie Byenfeldt, Christer Grönlund, Patrik Nasr, Anna Lindam, Mattias Ekstedt, Peter Lundberg, Johan Kihlberg Scandinavian Journal of Gastroenterology.2026; 61(1): 124. CrossRef
Hepatic steatosis can accurately be measured during free breathing using ultrasound-guided attenuation parameter (UGAP) technology. Technical note Marie Byenfeldt, Patrik Nasr, Anna Lindam, Christer Grönlund, Mattias Ekstedt, Peter Lundberg, Johan Kihlberg European Journal of Radiology.2026; 195: 112602. CrossRef
Platelet Proteomics: A Glimpse Into Metabolic Dysfunction‐Associated Steatotic Liver Disease Pathogenesis Iulia Minciuna, Maria Iacobescu, Ioana Rusu, Oana Nicoara‐Farcau, Petra Fischer, Andreea Maria Soporan, Ioana Ecaterina Pralea, Horia Stefanescu, Cristina Adela Iuga, Bogdan Procopet Hepatology Research.2026; 56(4): 446. CrossRef
The nexus of environmental endocrine-disrupting chemical exposure and metabolic dysfunction-associated steatotic liver disease: An emerging public health challenge Hongxia Chen, Hong Cui, Zhongji Meng Ecotoxicology and Environmental Safety.2026; 309: 119513. CrossRef
Transient elastography during pregnancy: a glimpse into maternal liver health Seung Mi Lee, Won Kim The Lancet Obstetrics, Gynaecology, & Women's Health.2026; 2(1): e2. CrossRef
Elevated adipose inflammation, but reduced hepatic triacylglycerol storage in diet-induced obese Plin4−/− mice Atanaska Ivanova Doncheva, Ryoko Higa, Prabhat Khanal, Martine Villemo Øksenvåg Ingebrigtsen, Yuchuan Li, Shrikant Kolan, Pratibha Kolan, Ales Kvasnicka, Ingunn Jermstad, Shaista Khan, Bjørn Steen Skålhegg, Svein Olav Kolset, Hilde Nebb, Marit Hjorth, Fro Journal of Biological Chemistry.2026; 302(2): 111043. CrossRef
Endohepatology: Evolving Indications, Challenges, Unmet Needs and Opportunities Akash Roy, Mithun Sharma, Anand V. Kulkarni, Sundeep Lakhtakia, Aniruddha Pratap Singh, Rakesh Kalapala, Gregory G. Ginsberg, D.Nageshwar Reddy, K. Rajender Reddy Gastro Hep Advances.2026; 5(2): 100838. CrossRef
Effectiveness and safety of saroglitazar in managing dyslipidaemia and liver enzymes in patients with type 2 diabetes, MASLD, and Stage 3 chronic kidney disease: A 12‐month observational study Gaurab Bhaduri, Shambo S. Samajdar, Sanjay Bandyopadhyay, Shatavisa Mukherjee, Shashank R. Joshi Diabetes, Obesity and Metabolism.2026; 28(3): 2449. CrossRef
Association of Liver Fibrosis Fibrosis-4 Score with Perioperative Complications and Mortality: A Retrospective Multicenter Analysis Shira Zelber-Sagi, Vikas N. O’Reilly-Shah, Ashish K. Khanna, Peter Rock, Itay Bentov Anesthesiology.2026; 144(2): 365. CrossRef
Distinct and complementary metabolic effects of GLP-1 and glucagon receptor agonism in diet-induced obese mice Marie Winther-Sørensen, Christine Rasmussen, Samuel A.J. Trammell, Caroline Hansen, Mogens Vyberg, Reza Serizawa, Erik A. Richter, Trisha J. Grevengoed, Lise Lotte Gluud, Rune E. Kuhre, Nicolai J. Wewer Albrechtsen Peptides.2026; 195: 171462. CrossRef
Nutrition in MASLD: a patient focused, evidence-based clinician’s guide Katrina Pekarska, Paul N Brennan, Dana Ivancovsky Wajcman, Jennifer Towey, Leah Cox, Katie Weatherby, Stuart McPherson, Jonathan Stine, Jose Willemse, Wenhao Li, William Alazawi, Jeffrey V Lazarus, Richard Parker Frontline Gastroenterology.2026; 17(3): 262. CrossRef
Noninvasive Assessment of Hepatic Steatosis in Metabolic Dysfunction‐Associated Steatotic Liver Disease Patients by Using Ultrasound Attenuation Imaging Kun Wang, Qun Liu, Jing Wang, Minghui Wang, Jinqiao Zhang, Yanjie Yu, Ling Liu, Hairong Liu Journal of Ultrasound in Medicine.2026; 45(6): 1209. CrossRef
Hepatic adaptation to chronic metabolic stress primes tumorigenesis Constantine N. Tzouanas, Jessica E.S. Shay, Marc S. Sherman, Adam J. Rubin, Benjamin E. Mead, Tyler T. Dao, Junyan Tao, Brandon M. Lehrich, George Eng, Jeffrey Patterson-Fortin, Titus Butzlaff, Miyeko D. Mana, Kellie E. Kolb, Chad Walesky, Brian J. Pepe-M Cell.2026; 189(2): 435. CrossRef
Two‐Step Machine Learning Model Enhances Identification of High‐Risk Metabolic Dysfunction‐Associated Steatotic Liver Disease Zheng'ao Xu, Yongfen Zhu, Fengjuan Chen, Qiongyue Fan, Ruiqi Wang, Yilong Fu, Xunxun Wu, Li Zhu, Fushuang Ha, Qing Ye, Chunyan Ye, Xiaoming Chen, Meijie Chen, Jiale Niu, Yangyang Xie, Kaixin Chang, Jiakun Miao, Weili Liu, Junping Shi, Zhongjie Hu, Minghua Liver International.2026;[Epub] CrossRef
Risk of Microvascular and Macrovascular Complications in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatohepatitis: A Retrospective Cohort Study Semiu O. Gbadamosi, David Shi, Abdalla Aly, Caichen K. Zhong, Husam Albarmawi, Aidan McGovern, Anthony Hoovler, Carlos Campos Diabetes Therapy.2026; 17(2): 251. CrossRef
Risk stratification for hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: Editorial on “High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic Ho Soo Chun, Minjong Lee Clinical and Molecular Hepatology.2026; 32(1): 368. CrossRef
Linked Intronic Polymorphisms of the PNPLA3 Gene Are Associated with Serum Markers of Liver Injury in Patients with Spontaneous HCV Clearance Karina Gonzalez-Aldaco, Luis A. Torres-Reyes, Arturo Panduro, Sonia Roman International Journal of Molecular Sciences.2026; 27(1): 473. CrossRef
Liver Stiffness Rises Early in MASLD and Drives Inflammation, Lipid Dysmetabolism, and Fibrosis via Piezo1–YAP Mechanotransduction Juan Ma, Ning Xie, Ziwei Wang, Xiru Liang, Yulong Han, Qiang Zhao, Ming Wang, Hongwei Lu, Wanyi Kou, William Alazawi, Jinhai Wang, Lu Li, Ning Liu, Na Liu, Haitao Shi, Feng Xu Advanced Science.2026;[Epub] CrossRef
A sex-specific brake on liver oestrogen signalling Pamela Kakimoto, Natalie Krahmer Nature Metabolism.2026; 8(1): 8. CrossRef
Mesenchymal Stromal/Stem Cell-Based Therapies for Liver Regeneration: Current Status and Future Directions Seohyun Choi, Jaemin Jeong International Journal of Molecular Sciences.2026; 27(2): 619. CrossRef
The burden and mortality impact of cardiovascular disease–metabolic dysfunction–associated steatotic liver disease comorbidity Siyuan Tan, Ting Huang, Zixi Zhang, Jiabao Zhou, Hao Chen, Tao Tu, Qiuzhen Lin, Yichao Xiao, Qiming Liu Diabetes Research and Clinical Practice.2026; 232: 113092. CrossRef
Non-alcoholic fatty liver disease in Northeast India: a narrative review of rising metabolic syndrome Shiludi Longkumer, Maitrayee Dutta Swargiary Egyptian Liver Journal.2026;[Epub] CrossRef
Dose‒response relationship between exercise and hepatic steatosis: A systematic review with Bayesian network meta-analysis of randomized controlled trials Xinyun Tan, Huihui Zou, Manjie Guo, Jiayu Liu, Xinjuan Huang, Ruoling Yu, Xuelian Liu, Chunxiang Qin Journal of Sport and Health Science.2026; 15: 101125. CrossRef
Kefiran, a polysaccharide from kefir grain, modulates gut microbiota and hepatic metabolism to mitigate metabolic dysfunction-associated steatotic liver disease Yuanyuan Cui, Jiajia Zhu, Jun Xi, Changhe Ding, Jun Meng International Journal of Biological Macromolecules.2026; 341: 150147. CrossRef
Assessment of the Diagnostic Performance and Clinical Impact of AI in Hepatic Steatosis: Systematic Review and Meta-Analysis Jiamei Song, Dan Liu, Jitong Li, Haoru Cong, Ruixue Deng, Yihan Lu, Jiayi Sun, Jingzhou Zhang Journal of Medical Internet Research.2026; 28: e78310. CrossRef
Semaglutide-Induced Weight Loss Is the Main Determinant for the Improvement of Hepatic Biochemistry and Elastographic Repeated Measurements with FibroScan® in Patients with Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Dise Savvoula Savvidou, Elektra Augousti-Varela, Aikaterini Damianakou, Miltiadis Chalkias, Ioannis Stergiou Metabolic Syndrome and Related Disorders.2026; 24(3): 121. CrossRef
Oxidative stress in metabolic dysfunction-associated steatohepatitis: Mechanisms and emerging therapeutic strategies Yidan Chen, Hui Yu, Xinyu Kai, Runting Yin, Zhen Ouyang, Yuan Wei, Cai Zhang Biochemical Pharmacology.2026; 246: 117702. CrossRef
Diet intervention altered DNA methylation of potassium voltage-gated channel subfamily Q member 1 in metabolic dysfunction-associated steatohepatitis Xinyu Shi, Hualing Song, Xinying Xiong, Shuang Wei, Lei Zhang, Shengfu You, Wenjun Zhou, Guang Ji, Baocheng Liu, Na Wu Clinical Epigenetics.2026;[Epub] CrossRef
Mechanisms of scramblases in regulating hepatic lipoprotein secretion and autophagy Allen Chen, Chen Zhang, Wen-Xing Ding, Hong-Min Ni Journal of Lipid Research.2026; 67(2): 100979. CrossRef
Artificial Intelligence for Fibrosis Diagnosis in Metabolic-Dysfunction-Associated Steatotic Liver Disease: A Systematic Review Neilson Silveira de Souza, Théo Cordeiro Veiga Vitório, Raphael Augusto de Souza, Marcos Antônio Dórea Machado, Helma Pinchemel Cotrim Diagnostics.2026; 16(2): 261. CrossRef
Tirzepatide versus SGLT2 inhibitors for MASLD: a multi-institutional propensity score-matched cohort study Jheng-Yan Wu, Yu-Min Lin, Wan-Hsuan Hsu, Ting-Hui Liu, Ya-Wen Tsai, Po-Yu Huang, Min-Hsiang Chuang, Tsung Yu, Chih-Cheng Lai Hepatology International.2026; 20(2): 292. CrossRef
Diagnostic Utility of Serum Activating Transcription Factor 4 and Toll-like Receptor 4 as Early Biomarkers of Inflammation in Metabolic Dysfunction–Associated Steatotic Liver Disease Isa Yalcinkaya, Iskender Ekinci, Seyma Dumur, Eda Nur Duran, Hafize Uzun, Melda Yalcinkaya, Elif Kadioglu Yeniyurt, Omer Vehbi Alpaydin, Gulden Anataca, Omur Tabak Journal of Clinical Medicine.2026; 15(2): 559. CrossRef
Use of Artificial Intelligence-Assisted Histopathology for Evaluation of Sex-Specific Progression and Regression of Hepatocellular Carcinoma Related to Metabolic Dysfunction-Associated Fatty Liver Disease Ke Yin, Yuyun Song, Ran Fei, Xu Cong, Baiyi Liu, Zilong Wang, Xin Ai, Minjun Liao, Yayun Ren, Kutbuddin Akbary, Wei Wang, Qiang Yang, Xiao Teng, Nan Wu, Huiying Rao, Xiaoxiao Wang, Feng Liu Diagnostics.2026; 16(2): 234. CrossRef
Effect of SGLT-2 inhibitors on liver fibrosis progression in patients with MASLD: an updated meta-analysis based on RCTs Lei Yang, Jiale Ruan, Yingying Fang, Anyi Xu Frontiers in Medicine.2026;[Epub] CrossRef
Immune Determinants of MASLD Progression: From Immunometabolic Reprogramming to Fibrotic Transformation Senping Xu, Zhaoshan Zhang, Zhongquan Zhou, Jiawei Guo Biology.2026; 15(2): 148. CrossRef
Phosphatidylserine Supplementation Improves Metabolic Liver Disease and Glycemic Control in the Presence of Suppressed Oxidative Glucose Metabolism Li Dong, Sihan Lin, John Slavin, Satya Gunnam, Zhili Cheng, Shuai Nie, Michael G. Leeming, Nicholas A. Williamson, Magdalene K. Montgomery Diabetes.2026; 75(2): 273. CrossRef
Integrating multi-omics and machine learning systematically deciphers cellular heterogeneity and fibrotic regulatory networks in the progression from MASLD to MASH Weiheng Wen, Zenghui Liu, Wenliang Tan, Yingzheng Tan, Wei Li, Jian Wan, Hongsai Hu, Zhengwu Jiang, Xing Tang, Jing Yang, Jiao Xiao, Xiongjin Tan, Xun Chen, Peili Wu, Yukun Li npj Digital Medicine.2026;[Epub] CrossRef
Morphological characterization of a novel model of steatohepatitis in the
FAH
-/-
pig
Silvana N. Wilken, Philipp Felgendreff, Anna Minshew, Boyukkhanim Ahmadzada, Seyed M. Hosseiniasl, Sara Kazeminia, Kachi Ezenekwe, Ameya Patil, Byoung U. Park, Ahmer Sultan, Lindsey Smith, Julio Cisneros Correa, Kamal Hussein, Harmeet Malhi, Roger K. More Veterinary Pathology.2026;[Epub] CrossRef
Association of cholesterol, high-density lipoprotein and glucose (CHG) index with mortality risk in metabolic dysfunction-associated steatotic liver disease (MASLD) adults: results from two prospective cohorts Huangxin Zhu, Lihua Liu, Sicheng Yang, Yunfeng Fu, Yating Pan, Qingan Fu, Fan Du, Xiaodong Zhou Cardiovascular Diabetology.2026;[Epub] CrossRef
Stemness CD24 activation promotes hepatocellular carcinoma progression via an immune escape mechanism Yin Cai, Lu-Yin Liu, Xiao-Xiao Xia, Hao Tang, Min Xu, Wen-Li Sai, Deng-Fu Yao, Min Yao World Journal of Gastroenterology.2026;[Epub] CrossRef
Targeting the 4-HNE–H₂S pathway as a therapeutic strategy for placental injury in pregnancy with MAFLD Tianxiao Hu, Jiayu Qi, Yinuo Xu, Jia He, Qingying Tan, Jie Hao, Jing Wang, Jiewei Hong, Jianwei Wang, Lin Chen, Xiaobing Dou International Immunopharmacology.2026; 172: 116245. CrossRef
Association of the Triglyceride-Glucose Index With Established Cardiovascular Disease in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Cross-Sectional Study Soumayan Mondal, Sidharth S Pattnaik, Nihar Ranjan Mohanty, Sailendra Nayak, Ambika Mohanty, Shubhransu Patro Cureus.2026;[Epub] CrossRef
Dysregulation of the AMPK-SREBP1-FASN axis in MASLD: driving a vicious cycle of lipotoxicity and metabolic-immune crosstalk Qiqi Zhao, Shengwen Lu, Yu Guan, Zhiwen Sun, Shi Qiu, Aihua Zhang Lipids in Health and Disease.2026;[Epub] CrossRef
Prognostic value of non-invasive fibrosis assessment scores in predicting mortality among individuals with metabolic dysfunction-associated steatotic liver disease Lingjie Wu, Shunling Cai, Zhongbin Lin, Ruilie Chen, Yuanfeng Zhang, Xiaobing Gong BMC Public Health.2026;[Epub] CrossRef
Dapagliflozin‐Associated Reduction in Liver Fat Is Independent of Weight Loss in Patients With Type 2 Diabetes Anna V. Naumova, Guilherme Moura Cunha, Nicole J. Kim, Jie Lu, Daniel Isquith, Baocheng Chu, Charles Maynard, Arash Mahdavi, Negar Firoozeh, Karen Ordovas, Xue‐Qiao Zhao, Francis Kim Obesity.2026; 34(3): 622. CrossRef
Association Between Metabolically Associated Steatotic Liver Disease (MASLD) and Cardiovascular Risk Scores in Urban Adults FARIS HUSSAIN, KELVIN KANAYO NWABUEZE, FATIMA IJAZ, SONIA OUTALEB, MAHMUDUL HASAN NAHID, SYED ABID, MARIAM SALEEM, KHANT NYI ZAYA, SAIFULLAH SYED, HUMAIRA JANANTH, MANAHIL ZARIEF Juntendo Medical Journal.2026; 72(1): 54. CrossRef
Metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus in Tanzania: prevalence and predictors Evangelista Malindisa, Illuminata Kafumu, Allen Rweyendera, Elisha Mkemangwa, David Majinge, Igembe Nkandala, Paulina Manyiri, Semvua Kilonzo BMC Endocrine Disorders.2026;[Epub] CrossRef
Body mass index and metabolic dysfunction associated steatotic liver disease remission among Chinese adults in a retrospective cohort study Jiwen Zhang, Yuyin Guo, Bi’e Li, Jiaqian Zhu, Chuang Gao, Qiongdan Zhang, Yong Han, Chuxuan Gu Scientific Reports.2026;[Epub] CrossRef
12,13-diHOME ameliorates MASLD by regulating Sestrin2-mediated AMPK/ULK1/Lipophagy in obese mice Kexin Zhang, Chengxia Kan, Hongyan Qiu, Junfeng Shi, Jian Chen, Tianpeng Zheng, Jingwen Zhang, Yujie Ma, Sufang Sheng, Ningning Hou, Fang Han, Xiaodong Sun Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2026; 1872(4): 168186. CrossRef
Burden of MASLD and liver fibrosis: evidence from Phenome India cohort Meghana Arvind, Anshul Verma, Sreeshma Raj K, Satyartha Prakash, Vignesh S. Kumar, Mohammad Azhar Uddin, Ayushi Narayan, Mamta Rathore, Nancy Rawat, Ankita Sahu, Yogesh Kumar, Pulkit Hasmukhbhai Leuva, Monika Sharma, Rajesh S, Dwaipayan Saha, Ankita Mridh The Lancet Regional Health - Southeast Asia.2026; 45: 100723. CrossRef
Understanding liver and digestive diseases: a paved road to improve diagnosis, management, and treatment Ina Bergheim, Jean Francois Cadranel, Jianguo Chen, Wenxing Ding, Robert Eferl, Carmen Garcia-Ruiz, Hartmut Jaeschke, Firouzeh Kazerouni, Amedeo Lonardo, Derek A. Mann, Nahum Méndez-Sánchez, Camelia Mokhtari, Han Moshage, Chiara Raggi, Pavel Strnad, Oren Exploration of Digestive Diseases.2026;[Epub] CrossRef
Prevalence and risk factors for metabolic dysfunction–associated steatotic liver disease in Sweden: Insights from the SCAPIS cohort Oumarou Nabi, Jonas Spaak, Göran Bergström, Gunnar Engström, Carl Johan Östgren, Andrei Malinovschi, Joel Kullberg, Anders Blomberg, Tomas Jernberg, Daniel P. Andersson, Hannes Hagström Journal of Internal Medicine.2026; 299(4): 481. CrossRef
Interactions Between the Gut Microbiome and Genetic and Clinical Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Patients with Type 2 Diabetes Mellitus from Different Geographical Regions of Argentina Bárbara Suarez, Adriana Mabel Álvarez, María Florencia Mascardi, Ana Laura Manzano Ramos, Dong Hoon Woo, María Mercedes Gutiérrez, Guillermo Alzueta, María del Carmen Basbus, Santiago Bruzone, Patricia Cuart, Guillermo Dieuzeide, Teresita García, Olga Esc Life.2026; 16(2): 283. CrossRef
Can ammonia scavenging treat MASLD? Evaluating the evidence for L‐ornithine L‐aspartate—A systematic review Abdulrahman Ismaiel, Vera Ciornolutchii, Stefan‐Lucian Popa, Dan L. Dumitrascu European Journal of Clinical Investigation.2026;[Epub] CrossRef
Predictive factors of metabolic dysfunction associated steatotic liver disease (MASLD) among individuals with cardio-metabolic risk factors, multicenter cross-sectional study, North East Ethiopia Getachew Bizuneh Aydagnuhm, Aklile Semu Tefera, Gebru Tesfaw Getahun, Ermiyas Endewunet Melaku BMC Gastroenterology.2026;[Epub] CrossRef
Temporal trends and racial/ethnic disparities in hepatocellular carcinoma incidence in the US between 2000-2022 Wenzhan Jing, Hang Pham, Samuel So JHEP Reports.2026; 8(4): 101754. CrossRef
Pirfenidone as a Pleiotropic Antifibrotic Agent in Metabolic Steatohepatitis: From Mechanisms to Clinical Evidence Mariana M. Ramírez-Mejía, Guadalupe Ponciano-Rodríguez, Jorge L. Poo, Nahum Méndez-Sánchez Archives of Medical Research.2026; 57(4): 103387. CrossRef
Long-term dementia risk in metabolic dysfunction-associated steatotic liver disease: a population-based study Andreas Bartholdy, Kristine Frøsig Moseholm, Pernille Yde Nielsen, Nicolai J. Wewer Albrechtsen, Lise Lotte Gluud, Majken Karoline Jensen Metabolic Brain Disease.2026;[Epub] CrossRef
Outils diagnostiques de la fibrose hépatique dans la stéatohépatite dysmétabolique Candice Gea, Guillaume Feugray, Valéry Brunel Revue Francophone des Laboratoires.2026; 2026(579): 36. CrossRef
Mitochondrial dysfunction in MASH: Focusing on chronic inflammation and intercellular communication Wanyi Luo, Muxin Yu, Chuwei Zheng, Xiaowen Li, Xiaotian Ma, Guocheng Zeng, Jinming Zhang, Xia Ji, Liyan Sun Biochemical and Biophysical Research Communications.2026; 804: 153356. CrossRef
Noninvasive Testing for Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis Markos Kalligeros, Laurent Castera, Emmanuel A. Tsochatzis, Naim Alkhouri Clinics in Liver Disease.2026;[Epub] CrossRef
La ballonisation hépatocytaire : une nouvelle cible thérapeutique dans la Physiopathologie de la MASH Arthur Cens, Bart Staels, Réjane Paumelle Revue Francophone des Laboratoires.2026; 2026(579): 28. CrossRef
Febuxostat Improves MASLD in Male Rats: Roles of XOR Inhibition and Associated JNK/NRF2/HO-1 Pathway Changes Zhiyu Pu, Yangyang Cen, Bowen Yang, Kaijun Xing, Linxi Lian, Xi Chi, Jianjun Yang, Yannan Zhang International Journal of Molecular Sciences.2026; 27(2): 1069. CrossRef
Association between blood heavy metal levels and subtypes of steatotic liver disease: A nationally representative cross-sectional analysis in South Korea Ji Hye Choi, Juyeong Kim, Yesol Yim, Hyunjee Kim, Jiyoung Hwang, Ho Geol Woo, Sang Youl Rhee, Yerin Hwang, Dong Keon Yon Medicine.2026; 105(4): e47365. CrossRef
Biological aging across the metabolic dysfunction–associated steatotic liver disease spectrum: A systematic review Chukwuemeka E. Ogbu, Stella C. Ogbu, Chidera P. Ogbu, Chinazor Umerah iLIVER.2026; 5(1): 100222. CrossRef
Fermented Foods and the Gut–Liver Axis: Modulation of MASLD Through Gut Microbiota Agnieszka Wesołek-Leszczyńska, Dawid Rosiejka, Kalina Bogdańska, Paweł Bogdański Nutrients.2026; 18(3): 542. CrossRef
Association of four insulin resistance indices with liver‐related adverse outcomes: A prospective cohort study Xiao‐Meng Wang, Hao Yan, Wen‐Fang Zhong, Jia‐Hao Xie, Huan Chen, Jun‐Jie Wang, Wei‐Qi Song, Dong Shen, Pei‐Dong Zhang, Xi‐Ru Zhang, Jiao‐Jiao Ren, Dan Liu, Zhi‐Hao Li, Chen Mao Diabetes, Obesity and Metabolism.2026; 28(5): 3598. CrossRef
Efficacy of empagliflozin in patients with metabolic dysfunction-associated steatotic liver disease with or without diabetes: a systematic review and meta-analysis of randomized controlled trials Khalid I. AlHussaini Frontiers in Medicine.2026;[Epub] CrossRef
Association of Metabolic Dysfunction-Associated Steatotic Liver Disease with Extrahepatic Cancers and Sarcopenia Yusuf Yilmaz, Alina M. Allen, Jérôme Boursier, Juan P. Arab Clinics in Liver Disease.2026;[Epub] CrossRef
Associations of relative fat mass with metabolic dysfunction–associated steatotic liver disease and liver fibrosis: evidence from the U.S. NHANES 2017–2023 Hai-Yuan Zhong, Ling-Dan Ma, Jin-Cheng Li, Dan Jiang, Yu-Mei Qin, Ming-Yu Lai, Guang Xiong BMC Gastroenterology.2026;[Epub] CrossRef
Gut microbiota, liver disease, and perioperative anesthesia: interactions, risks, and therapeutic opportunities Lei Shi, Ye Yu, Zihan Ma, Weiyi Jiang Frontiers in Cellular and Infection Microbiology.2026;[Epub] CrossRef
Lessons learned from viral hepatitis testing that inform law and policy responses to steatotic liver disease Jeffrey V. Lazarus, Christopher J. Kopka, Aina Nicolàs, Safura Abdool Karim, Meena B. Bansal, Michael Betel, John F. Dillon, Pere Gines, Aleksander Krag, Veronica Miller, Cynthia A. Moylan, Alisa Pedrana, Paula Petrone, Jörn M. Schattenberg, Sunil S. Solo Nature Reviews Gastroenterology & Hepatology.2026; 23(4): 355. CrossRef
SIRT3 ameliorates hepatic inflammation, oxidative stress, and fibrosis in HFD- or MCD diet-fed mice Huifang Lv, Wenyue Sun, Cuixia Tian, Chunyong Bian, Zhongting Lu, Xin Guo The Journal of Nutritional Biochemistry.2026; 152: 110276. CrossRef
Paulobutalipin, a Lipid Accumulation Inhibitor from a Streptomyces sp. Thanh-Hau Huynh, Hoseo Lee, Sangwook Kang, Jeong-Hyeon Kim, Huiyeong Ju, Ki-Bong Oh, Sang-Jip Nam, Ja Hyun Koo, Dong-Chan Oh Journal of Natural Products.2026; 89(2): 682. CrossRef
MASLD, MASH, and the CKM Spectrum Faiez Zannad, Muhammad Shahzeb Khan, Nisha Bansal, Michael Böhm, Sven M. Francque, Nicolas Girerd, James L. Januzzi, Veronica Miller, Marie-Eve Piché, Vlad Ratziu, Bart Staels, Harriette G.C. Van Spall, Arun J. Sanyal, Javed Butler JACC.2026; 87(15): 2006. CrossRef
Polyunsaturated fatty acids as a potential preventive and therapeutic intervention for metabolic dysfunction–associated steatotic liver disease and its progression to hepatocellular carcinoma Thomai Kouti, Panayiota Christodoulou, Stephanos Christodoulides, Foula Protopapa, Charalambos Michaeloudes, Paraskevi A. Farazi Frontiers in Nutrition.2026;[Epub] CrossRef
Providing holistic care for patients with metabolic dysfunction‐associated steatotic liver disease/metabolic dysfunction‐associated steatohepatitis: Key aspects of clinical assessment and how to develop individualised care plans for surveillance and inter Lanlan Chen, Paul Horn, Frank Tacke Diabetes, Obesity and Metabolism.2026; 28(S2): 46. CrossRef
MASH in Type 2 Diabetes: Pathophysiology, Diagnosis, and Therapeutic Management—A Narrative Review Adela Gabriela Ştefan, Adina Mitrea, Diana Clenciu, Ionela Mihaela Vladu, Maria Magdalena Roşu, Diana Cristina Protasiewicz-Timofticiuc, Theodora Claudia Radu-Gheonea, Ion-Cristian Efrem, Anca Maria Amzolini, Beatrice Elena Vladu, Ana-Maria Efrem, Delia-V Medicina.2026; 62(2): 325. CrossRef
The active components of the Danshen-Shanzha herb-pair exert a protective effect on MASLD by synergistically promoting fatty acid oxidation via the activation of PPARα, Plin-5 and Plin-2 Ying Yang, Yaxing Li, Zirong Zhou, Hui Li, Yihan Ma, Wenjie Bi, Mengjiao Li, Xiaoli Liu, Qiang Jia, Liwen Han, Songsong Wang Journal of Ethnopharmacology.2026; 362: 121374. CrossRef
Efficacy and Safety of Statins in MASLD and Other Chronic Liver Diseases I. Commins, D. Clayton-Chubb, N. Janko, A. Majeed, W. Kemp, S. K. Roberts Medical Sciences.2026; 14(1): 84. CrossRef
Detection of hepatic steatosis with ultrasound-guided attenuation parameter (UGAP) in metabolic dysfunction-associated steatotic liver disease (MASLD) compared with proton density fat fraction (PDFF): Impact of measurement number and region of interest (R Marie Byenfeldt, Christer Grönlund, Patrik Nasr, Anna Lindam, Mattias Ekstedt, Peter Lundberg, Johan Kihlberg Ultrasound.2026;[Epub] CrossRef
Artificial intelligence and digital transformation of gastroenterology and hepatology: A critical review of clinical applications and future challenges Miguel Suarez, Raquel Martínez, Félix González-Martínez, Ana María Torres, Jorge Mateo World Journal of Hepatology.2026;[Epub] CrossRef
Efficacy of ursodeoxycholic acid in metabolic dysfunction-associated steatotic liver disease: an umbrella review of meta-analyses on liver enzymes Alsu R. Khurmatullina, Dmitrii N. Andreev, Igor V. Maev, Andrey V. Zaborovsky, Yury A. Kucheryavyy, Petr A. Beliy, Philipp S. Sokolov Frontiers in Medicine.2026;[Epub] CrossRef
Panax notoginseng Saponins Ameliorate High‐Fat Diet‐Induced Liver Injury via Mechanisms Involving TLR4‐Mediated Signaling and Lipid Metabolism Rong Li, Junyu Ma, Mengyao Li, Bangzhao Zeng, Xuexun Li, Xiaoyan Bi, Xin Zhao, Qin Gao, Yanling Yao, Yang Jiang, Chunmei Zhang, Fuli Ya Food Science & Nutrition.2026;[Epub] CrossRef
MicroRNA-146a Protects against Hepatocellular Carcinoma through Suppression of CCL5 Morgan C. Nelson, Liam C. O’Malley, Soh-Hyun Lee, Kaylyn M. Bauer, Arevik Ghazaryan, William W. Tang, Chad VanSant-Webb, Van B. Tran, Colton Hernandez, Ben Battistone, Amber Thibeaux, June L. Round, Micah J. Drummond, H. Atakan Ekiz, Kimberley J. Evason, Cancer Research Communications.2026; 6(2): 359. CrossRef
Imaging in MASLD Sudhakar K. Venkatesh Expert Review of Gastroenterology & Hepatology.2026; 20(3): 257. CrossRef
Beyond Taste: The Impact of Chocolate on Cardiovascular and Steatotic Liver Disease Risk Factors Júlia Mayumi Tomaru, Iara Ribeiro Nunes, Caroline Fernandes de Souza Santiago, Alda Maria Machado Bueno Otoboni, Claudemir Gregorio Mendes, Adriana Maria Ragassi Fiorini, Elen Landgraf Guiguer, Claudia Cristina Teixeira Nicolau, Antonelly Cassio Alves Car Nutrients.2026; 18(4): 636. CrossRef
Occurrence and prognosis of metabolic dysfunction-associated steatosis liver disease and gastrointestinal tumors: a systematic review and meta-analysis Siyu Duan, Yiyi Wei, Zhuoyu Ding, Chaomin Pan, Li Yang, Yan Gu, Xinke Wang PeerJ.2026; 14: e20616. CrossRef
Liver involvement in dengue virus infection: a narrative review Madunil Anuk Niriella, Ravini Amila Premaratna, Shashini Hathurusinghe, Ranjan Premaratna, Anuradha Supun Dassanayake, Hithanadura Janaka de Silva Journal of Clinical Virology Plus.2026; 6(2): 100247. CrossRef
Toll Like Receptor 4: A Potential Link Between Obesity and Metabolic Diseases Ghadeer Alhamar, Joanna Razafiarison, Fawaz Alzaid, Fahd Al‐Mulla, Rasheed Ahmad Obesity Reviews.2026;[Epub] CrossRef
Editorial: Pharmacological and nutritional approaches to metabolic associated fatty liver disease: a step towards achieving SDG 3 Mahmut Bodur, Bojana Vidović, Anastasios Nikolaou, Birsen Yilmaz Frontiers in Pharmacology.2026;[Epub] CrossRef
Impact of newer antihyperglycemic agents on hepatic complications: A systematic review and meta-analysis of data from 5.3 million patients with type 2 diabetes mellitus Jiwon Yang, Yeongseok Hwang, Jin-Sung Ju, Seungbong Han, Jihyun An, Ju Hyun Shim Hepatology.2026;[Epub] CrossRef
Altered Tryptophan–Kynurenine Pathway and Low-Grade Inflammation in Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD): Insights from LC–MS/MS–Based Metabolite Profiling Kübranur Ünal, Leyla İbrahimkhanlı, Mehmet Emre Erol, Nemat İbrahimkhanlı, Sabri Engin Altıntop, Mahi Nur Cerit, Ethem Turgay Cerit, Halit Nahit Şendur International Journal of Tryptophan Research.2026;[Epub] CrossRef
Modulation of metabolic, inflammatory, fibrotic, and cell death pathways by resmetirom in metabolic dysfunction-associated steatohepatitis (MASH): a transcriptomic profiling study Chen-yang He, Zhi-hua Wang, Jian-ping Weng, Hans Strijdom, Suo-wen Xu Acta Pharmacologica Sinica.2026; 47(4): 1070. CrossRef
From HBV to MASLD Cirrhosis: Mechanistic Insights and Therapeutic Strategies Hanqi Yu, Hongfan Ding, Yang Huang, Haoze Cao, Yuan Ding, Weilin Wang Portal Hypertension & Cirrhosis.2026;[Epub] CrossRef
Inflammation burden index as a complementary marker for the assessment of hepatic steatosis and fibrosis: evidence from NHANES 2017–2018 Shaoguang Chen, Lixiao Zhu, Yulou Jiang Abdominal Radiology.2026;[Epub] CrossRef
Deubiquitinase USP2 promotes hepatic stellate cell activation via p300 stabilization Seunghee Byun, Hyunsik Kim, Sun‐Ho Lee, Jae‐Hwan Kwon, Hyunseung Kim, Jung‐Yoon Yoo, Soo‐Yeon Park, Ho‐Geun Yoon FEBS Letters.2026; 600(9): 1318. CrossRef
Epidemiological Trajectories and Quality of Care Disparities of MASLD in Asia, 1990–2023 Kexin Zhang, Wei Xu, Chengxia Kan, Sufang Sheng, Fang Han, Jian Chen, Xuan Li, Ningning Hou, Xiaodong Sun, Ying Xue Digestive Diseases and Sciences.2026;[Epub] CrossRef
Impact of different subtypes of steatotic liver disease on immune checkpoint inhibitor-related drug-induced liver injury: a retrospective study Tianyi Ma, Zhanfang Guo, Haijia Bi, Huawei Yuan, Yu Li, Mei Sun European Journal of Gastroenterology & Hepatology.2026; 38(3): 351. CrossRef
Triglyceride glucose index—a body shape index (TyG-ABSI) outperforms traditional obesity indices in predicting all-cause and cardiovascular mortality in metabolic-dysfunction associated steatotic liver disease: the mediating role of biological aging Guodong Yang, Wenli He, Xin Qiu, Shuang Shen, Peishu Li, Yifei Feng, Jiayuan Zhang, Bangde Xiang Cardiovascular Diabetology.2026;[Epub] CrossRef
The relationship between acromegaly and hepatic steatosis: insights from FibroScan imaging Tugce Apaydin, Haluk Tarik Kani, Caglayan Keklikkiran, Yusuf Yilmaz, Dilek Gogas Yavuz Journal of Endocrinological Investigation.2026; 49(5): 1029. CrossRef
From Childhood to Old Age: Current Knowledge and Practical Approaches to Metabolic Dysfunction-Associated Steatotic Liver Disease Iwona Gorczyca-Głowacka, Michał Tarnowski, Anna Zmelonek-Znamirowska, Przemysław Wolak Journal of Clinical Medicine.2026; 15(4): 1536. CrossRef
Development of a Lipidomics-Based Cell Screening Platform for Indirect Antioxidants Targeting Oxidized Lipid Droplet Formation and Mitochondrial Membrane Abnormality Yuzu Shibata, Toshihiro Sakurai, Akiko Sakurai, Misuzu Sato, Shu-Ping Hui Nutrients.2026; 18(5): 719. CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Multisystemic Narrative Review of Cardiovascular and Oncological Implications Menatalla M. A. Mohamed, Maha M. M. I. Taha, Mohnd M. M. R. Ibrahim ASIDE Gastroenterology.2026; 2(2): 15. CrossRef
Effects of pemafibrate on liver fibrosis in patients with MASLD and hypertriglyceridemia: A 2-year retrospective observational study using MR elastography Hidenao Noritake, Takafumi Inoue, Takashi Yonekura, Hiroki Tamakoshi, Yuya Ida, Moe Matsumoto, Tomohiko Hanaoka, Maho Yamashita, Masahiro Umemura, Kazuyoshi Ohta, Takeshi Chida, Kazuhito Kawata Journal of Clinical Lipidology.2026;[Epub] CrossRef
Fecal microbiota transplantation alleviates steatosis and inflammation in high-fat and high-sugar diet-induced fatty liver in mice Fangxia Mi, Jinglu Guo, Wentao Zheng, Jianwei Shen, Hua Ye Frontiers in Cell and Developmental Biology.2026;[Epub] CrossRef
Coagulation protease-activated receptor-2 (PAR2) promotes dyslipidemia, obesity and MASLD through repression of the hepatic pioneer factor HNF4α Xinru Chen, Nga Nguyen, Susan E. Turner, Albert K. Tai, Manal F. Abdelmalek, Lidija Covic, Athan Kuliopulos JHEP Reports.2026; 8(6): 101796. CrossRef
Real-world comparison of GLP-1 agonists versus physical activity in metabolic dysfunction-associated steatotic liver disease Jason N. Chen, Bulent Tolga Delibasi, James Wang, Thomas Tran, Connie Hu, Charles W. Randall BMC Gastroenterology.2026;[Epub] CrossRef
Rab5 nucleotide binding promotes oxidative metabolism to fuel hepatocellular carcinoma cell proliferation Kelly O. Otakhor, Mohd Ali Abbas Zaidi, Rebecca E. Oberley-Deegan, Moorthy P. Ponnusamy, Kurt W. Fisher, Micah B. Schott Journal of Biological Chemistry.2026; 302(4): 111321. CrossRef
Using an integrative multi-omics and in vitro approach to investigate the role of tris(2-butoxyethyl) phosphate in promoting hepatic steatosis Gang Zhou, Xihan Gu, Xinyao Zhou, Shuai Chen, Hanyang Liu, Jing Wang BMJ Open Gastroenterology.2026; 13(1): e002123. CrossRef
Epigenetic regulation in MASLD – insight for therapeutic target discovery Jan H. Britsemmer, Nuria Lopez Alcantara, Henriette Kirchner Epigenomics.2026; 18(3): 311. CrossRef
Astaxanthin alleviates altered hepatic lipid metabolism and oxidative stress in animals fed a high-sucrose diet Matias Rodrigo Vargas, María del Rosario Ferreira, Paola Inés Ingaramo, Pablo Collins, María Eugenia D’Alessandro Frontiers in Nutrition.2026;[Epub] CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease in Africa Mohamed El-Kassas, C. Wendy Spearman, Manal El-Sayed, Zobair M. Younossi Clinics in Liver Disease.2026;[Epub] CrossRef
Patients’ Experience of Stigma as the Hidden Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Descriptive Qualitative Study with Thematic Analysis Johanne Lisa Jensen-LeBlanc, Pernille Andreassen, Mette Munk Lauridsen, Lea Ladegaard Grønkjær Healthcare.2026; 14(5): 579. CrossRef
Targeting magnesium homeostasis: a novel therapeutic strategy for liver diseases Lili Ji, Hanhan Yu, Ruwen Wang, Hongmei Yan, Xiaofeng Yin, Shanshan Guo, Ru Wang Frontiers in Nutrition.2026;[Epub] CrossRef
The Role of Butyrate in People with Metabolic Dysfunction-Associated Steatotic Liver Disease and Related Metabolic Comorbidities: A Systematic Review Alicia González-González, Virginia Soria-Utrilla, María Isabel Fontalba-Romero, María Ángeles Núñez-Sánchez, Antonio Adarve-Castro, María Isabel Queipo-Ortuño, Bruno Ramos-Molina, José Ignacio Martínez-Montoro, José Carlos Fernández-García Current Obesity Reports.2026;[Epub] CrossRef
Creatinine-to-body weight ratio as an independent predictor of hepatic steatosis severity in metabolic dysfunction-associated steatotic liver disease: a cross-sectional study Xiaoning Sun, Xiaozhong Wang, Ayesha Younas, Shuanghu Wang, Muhammad Sohail, Jiaojian Lv, Zuxiu Huang, Yunxiao Liu BMC Gastroenterology.2026;[Epub] CrossRef
Metabolic liver imaging: What you need to know Luigi Asmundo, Amirkasra Mojtahed, Samay Prakash, Theodore T. Pierce, Jingwei Wei, Angelo Vanzulli Digestive and Liver Disease.2026; 58(4): 433. CrossRef
Gut microbiota supportive dietary pattern associated with reduced MASLD risk mediated by metabolomic profiles: a prospective cohort study Dong-Run Li, Ke-Ru Li, Ying Wang, Jia-Qi Zheng, Wen-Rui Zheng, Bang-Quan Liu, Jia-Cheng Liu, Rui-Han Bao, Ting-Ting Gong, Qiu-Ju Sheng, Shan-Yan Gao, Qi-Jun Wu Nutrition Journal.2026;[Epub] CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease in Latin America Claudia P. Oliveira, Mario Guimarães Pessoa, Luis Antonio Diaz, Juan Pablo Arab, Adrian Gadano, Marco Arrese Clinics in Liver Disease.2026;[Epub] CrossRef
Integrated lifestyle management to mitigate MASLD risk in patients with chronic kidney disease: a prospective cohort study Chao Yan, Xinxin Shen, Shaojie Han, Jinzheng He, Tongxu Wang, Xiaobing Gong, Jindong Ding Petersen Journal of Translational Medicine.2026;[Epub] CrossRef
Retatrutide in type 2 diabetes mellitus and obesity: an overview Theodoros Panou, Evanthia Gouveri, Djordje S. Popovic, Nikolaos Papanas Expert Review of Clinical Pharmacology.2026; 19(4): 313. CrossRef
Impact of Documented Social Vulnerability on Clinical Outcomes in Metabolic Dysfunction‐Associated Steatotic Liver Disease Pojsakorn Danpanichkul, Yanfang Pang, Maria Inggriani, Supapitch Sirimangklanurak, Matheus Souza, Ahmad Anouti, Andrew F. Ibrahim, Nikki Duong, Thomas G. Cotter, Thomas A. Kerr, Donghee Kim, Mazen Noureddin, Karn Wijarnpreecha Liver International.2026;[Epub] CrossRef
Optimal screening criteria for metabolic dysfunction-associated steatotic liver disease with fibrosis Byeong Geun Song, Myung Ji Goh, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Dong Hyun Sinn Annals of Hepatology.2026; 31(2): 102199. CrossRef
The role and possible mechanism of intestinal fungi in the progression of chronic liver diseases Yirui Hu, Ye Yang, Shuyan Wang, Huikuan Chu npj Biofilms and Microbiomes.2026;[Epub] CrossRef
Effect of Hormone Replacement Therapy on Liver and Cardiometabolic Outcomes in Peri‐Menopausal MASLD Alex E. Henney, Jo Wilson, David R. Riley, Uazman Alam, Daniel J. Cuthbertson Liver International.2026;[Epub] CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Risk of Gynecologic Cancer: A Nationwide Cohort Study Min Jin Jeong, Yong Seok Lee, Youn Jin Choi, Kyung Do Han Cancers.2026; 18(6): 894. CrossRef
Association of Metabolic Dysfunction-Associated Steatohepatitis with Metabolic-Related Diseases Leonidas Diamantopoulos, Markos Kalligeros, Scott D. Isaacs, Didac Mauricio Clinics in Liver Disease.2026;[Epub] CrossRef
Hospitalization Trends Due to Chronic Liver Diseases: Vicious Circle of Co-Morbidities and Hospitalization Length Ivana Pantic, Nikola Grubor, Sofija Lugonja, Nina Rajovic, Svetlana Miltenovic, Marija Brankovic, Tijana Gmizic, Tamara Milovanovic Clinics and Practice.2026; 16(3): 57. CrossRef
Integrated multi-omics analysis identifies and validates endoplasmic reticulum stress and mitophagy-related biomarkers in MASLD Quanrun Chen, Limin Liu, Jinqiu Feng, Chong Zhang, Zongming Zhang Scientific Reports.2026;[Epub] CrossRef
Non-invasive risk stratification of metabolic dysfunction-associated steatotic liver disease and liver fibrosis in adults with type 1 diabetes Manuel Ramón García-Sáenz, Marilu Cervantes-Maldonado, Luis Angel López-Cruz, Eduardo Salif Luna-Avila, Paulo César Gete Palacios, Cristina Martínez-Berdeja, Omar Jaime-Leal, Aldo Ferreira-Hermosillo Frontiers in Endocrinology.2026;[Epub] CrossRef
MEANDERLINE BASED MICROSTRIP ANTENNA DESIGN FOR LIVER TUMOR DETECTION Volkan Akdoğan, Fatih Özkan Alkurt Kahramanmaraş Sütçü İmam Üniversitesi Mühendislik Bilimleri Dergisi.2026; 29(1): 401. CrossRef
Metabolic-associated steatotic liver disease in children and adolescents: a scoping review and narrative synthesis of epidemiology, risk factors, and screening approaches with emerging implications for sub-Saharan Africa Bruno Basil, Peace Ngozi Okoro Frontiers in Endocrinology.2026;[Epub] CrossRef
The Gut‐Liver Axis in Metabolic Dysfunction‐Associated Steatotic Liver Disease: From Mechanistic Insights to Precision Therapeutics Shaoliang Zhu, Mengjie Zou, Qijun Wu, Yan Zou, Tingting Tan, Zhangnan Huang, Zheng Gong, Honglin Luo, Xiaofeng Dong The FASEB Journal.2026;[Epub] CrossRef
Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Context of Type 2 Diabetes Konstantinos Malandris, Konstantinos Charalampidis, Rohit Loomba, Emmanouil Sinakos Current Diabetes Reports.2026;[Epub] CrossRef
Association between weekend catch-up sleep and Metabolic dysfunction-associated steatotic liver disease in US adults Jinlong Chen, Wei Wang, Jie He, Xinxin Fang Clinical and Experimental Medicine.2026;[Epub] CrossRef
Ginsenoside Rg1 alleviates MASH by targeting GLS2 to enhance PINK1/Parkin-mediated mitophagy and improve mitochondrial function Zhijian Wang, Yinuo Wang, Peiyun Peng, Huating Luo, Liuling Xiao, Wenxiang Huang Biochemical Pharmacology.2026; 249: 117891. CrossRef
Heterogeneous associations of regional adipose depots with liver fibrosis in U.S. adults Kuan-Yu Lai, Chun-Yi Wang, Hsian-Han Kao, Wen-Yuan Lin, Tsung-Po Chen Metabolism Open.2026; 30: 100461. CrossRef
MASLD In Children - A Distinct Phenotype? Pervej Alom Barbhuiya, Manash Pratim Pathak Current Obesity Reports.2026;[Epub] CrossRef
DNA hypermethylation of choline kinases drives blockage of choline-phosphatidylcholine biosynthesis: lipidomic biomarkers and epigenetic insights of hepatic steatosis induced by arsenic Qiwen Fu, Qi Wang, Dingyi Song, Xingcheng Zhou, Hualin Chen, Shaofeng Wei, Lu Ma BMC Medicine.2026;[Epub] CrossRef
Comments on “Long-term serum ferritin dynamics in patients receiving antiviral treatment for hepatitis C virus infection” Preeti Lamba Journal of the Formosan Medical Association.2026;[Epub] CrossRef
Association between triglyceride glucose-body mass index and metabolic dysfunction-associated steatotic liver disease in South Korean pregnant women Yuqin Shen, Dongqian Yang, Li Zhang, Rong Shuai Scientific Reports.2026;[Epub] CrossRef
Combined effect of MASLD and low muscle strength on the risk of osteoporotic fractures: A UK Biobank cohort study Yongin Cho, Jong Hyun Jhee, Jong Ho Jhee, Hye-Sun Park European Journal of Endocrinology.2026; 194(3): 357. CrossRef
Hepatoprotective Effects of Combined Inulin-Glucomannan Non-Starch Polysaccharide Against Western Diet-Induced Metabolic Dysfunction-Associated Steatotic Liver Disease I Gede Putu Adhi Wedharga, Made Cahyani Trisna Ananda, Nadilla Faiza Richadini, Bernadette Dian Novita, Herjunianto Herjunianto, Silvia Sutandhio, Adi Pramono Hendrata, Mulya Dinata, Yu Hirata, Suryo Kuncorojakti, Hendy Wijaya, Dawei Chen, Ester Natalia D Journal of Pharmaceutical Innovation.2026;[Epub] CrossRef
Broccoli-Derived Exosome-like Nanoparticles Alleviates Metabolic Dysfunction-Associated Steatotic Liver Disease Through Modulating the Gut–Liver Axis Feng Zhang, Ruolan Liu, Tongxiao Xu, Wentao Xu, Kunlun Huang, Xiaoyun He Nutrients.2026; 18(6): 953. CrossRef
Therapeutic targets for metabolic dysfunction-associated steatohepatitis: a personalized approach to disease management Mary E. Rinella, Silvia Sookoian Nature Reviews Gastroenterology & Hepatology.2026;[Epub] CrossRef
Association of Metabolic Dysfunction-Associated Steatotic Liver Disease and Kidney Failure in the CKD Population Jin Kyung Kwon, Minsang Kim, Jinsun Lee, Jae-ik Oh, Jung Hun Koh, Min Woo Kang, Jeong Min Cho, Seong Geun Kim, Hyuk Huh, Sehyun Jung, Semin Cho, Soojin Lee, Eunjeong Kang, Yaerim Kim, Dong Ki Kim, Kyungdo Han, Sehoon Park Kidney International Reports.2026; 11(5): 106414. CrossRef
Cytoglobin in Hepatic Stellate Cells Plays Anti-Fibrotic Role in Chronic Liver Injury Norifumi Kawada Antioxidants.2026; 15(3): 383. CrossRef
Capabilities of magnetic resonance imaging in quantitative assessment hepatic steatosis in patients with different body mass index Yu. N. Savchenkov, G. E. Trufanov, V. A. Fokin, E. A. Ionova, T. A. Anosova, A. V. Anisonyan, E. S. Sbikina, O. V. Bodrova Medical alphabet.2026; (4): 40. CrossRef
MASLD as a systemic metabolic disease: expanding the scope of cardiovascular-kidney-metabolic (CKM) syndrome Xiao-Dong Zhou, Qiong-Yue Fan, Giovanni Targher, Christopher D. Byrne, Qin-Fen Chen, Michael D. Shapiro, Yuxing Dong, Ki-Chul Sung, Gregory Y. H. Lip, Jeffrey V. Lazarus, Ming-Hua Zheng Science China Life Sciences.2026;[Epub] CrossRef
Frailty, cardiovascular health, and the risk of mortality and extrahepatic diseases in patients with metabolic dysfunction-associated steatotic liver disease Jie Li, Jiang Li, Xiaoqin Xu, Ningjian Wang, Bin Wang, Yingli Lu Maturitas.2026; 208: 108917. CrossRef
Association of serum uric acid and serum uric acid/creatinine ratio with metabolic dysfunction-associated fatty liver disease in young adults: a retrospective study Yue Li, Zixian Li, Siyu Wu, Ling Cao, Beibei Qian, Junxian Tao, Zhimin Qian, Li Xie, Xiaoli Cai, Xiaofang Sun, Ying Li, Zhenwen Zhang, Caifeng Yan, Dunmin She BMC Endocrine Disorders.2026;[Epub] CrossRef
Niacin Derivatives in MASLD: Metabolic and Therapeutic Insights Marina Idalia Rojo-López, Julia Niño-Narvión, Maria Antentas, Berta Fernández-Camins, Elizabeth Martínez-Rojo, Maria Poca, María Antonia Martínez-Sánchez, Bruno Ramos-Molina, Joana Rossell, Didac Mauricio, Josep Julve Nutrients.2026; 18(6): 996. CrossRef
Metabolic Dysfunction–Associated Steatotic Liver Disease James M. Paik, Linda Henry, Khalid AlNaamani, Ariana Nader, Maria Stepanova, Mei-Hsuan Lee, Ming-Lung Yu, Zobair M. Younossi Clinics in Liver Disease.2026;[Epub] CrossRef
Assessing the Relationship Between Steatotic Liver Disease and Barrett’s Esophagus: A Cross-Sectional Analysis of 5507 Screening Participants Nikolaus Götz, Andreas Völkerer, Hannah Hofer, Sarah Wernly, Franz Singhartinger, Ewald Wöll, Elmar Aigner, Maria Flamm, Christian Datz, Bernhard Wernly Zeitschrift für Gastroenterologie.2026;[Epub] CrossRef
Prevotella‐Derived Butyrate Inhibits CD8+ T‐Cell Glycolysis via AKT/mTOR Signalling to Alleviate MASH Feixiang Xiong, Fengna Yan, Yuyong Jiang, Xiaomin Ji, Tong Wu, Yang Zhou, Xuejie Zhang, Dandan Chen, Yixin Hou Liver International.2026;[Epub] CrossRef
CT-assessed abdominal visceral adiposity and MASLD: a sex-stratified cross-sectional analysis Linying Xu, Ting Chen, Yitian Xie, Xueyu Xiang, Yupeng Liu, Chongyong Xu, Shuran Wang Frontiers in Nutrition.2026;[Epub] CrossRef
MetALD at the crossroads of metabolic and alcohol-related liver disease Gustavo Ayares, Luis Antonio Díaz, Juan Pablo Arab, Marco Arrese Trends in Endocrinology & Metabolism.2026;[Epub] CrossRef
Placebo-associated changes in MRI-PDFF and metabolic parameters in MASLD patients from phase Ib/IIa clinical trials: implications for early-phase trial design and translational endpoint interpretation Mengdi Lu, Hong Zhang, Xiaoxue Zhu, Jia Xu, Lin Xiang, Yue Hu, Jixuan Sun, Jiajia Mai, Yanhua Ding Frontiers in Pharmacology.2026;[Epub] CrossRef
Aging-related skeletal muscle loss on the incidence of chronic kidney disease in patients with metabolic dysfunction-associated steatotic liver disease Aryoung Kim, Danbee Kang, Sung Chul Choi, Dong Hyun Sinn, Hye Ryoun Jang, Geum-Youn Gwak The Journal of nutrition, health and aging.2026; 30(5): 100827. CrossRef
Multi-omics integration reveals ANXA6-high γδ T cell–endothelial communication as a potential link between periodontitis and MASLD Zhongxuan Zhang, Zihan Ma, Ruidong Zhang, Min Ye, Zhongyu Shi, Miao Yu, Lingling Ou npj Systems Biology and Applications.2026;[Epub] CrossRef
Creatinine clearance rate predicts all-cause and cardiovascular mortality in patients with MASLD: a Shanghai cohort study Yingqi Hou, Yanqiu Huang, Chenghao Zhang, Wen Gu, Yadan Xu, Shuli Li, Jugang Wu, Jibin Liu, Honglin Liu Frontiers in Medicine.2026;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease and acute leukemias
– a literature review and future directions
Tareq Salah, Maximillian Stahl, Jan Philipp Bewersdorf Leukemia & Lymphoma.2026; : 1. CrossRef
Metabolic dysfunction associated steatotic liver disease: mechanisms, diagnosis, and management in adults Tina Reinson, Josh Bilson, Caroline Childs, Ryan M Buchanan, Giovanni Targher, Christopher D Byrne BMJ Medicine.2026; 5(1): e002038. CrossRef
XBP1s-Regulated GFPT1 via Facilitating O-GlcNAcylation of FASN S509 Is Involved in Arsenic-Induced MASLD through Promoting Fatty Acid Synthesis in Hepatocytes Wenjie Li, Bowen Fan, Han Li, Qiong Du, Jiaheng Lin, Yi Yang, Xiaolin Ding, Haoran Zhang, Haibo Xia, Binafsha Manzoor Syed, Cheng Cheng, Qizhan Liu Journal of Agricultural and Food Chemistry.2026; 74(14): 11814. CrossRef
Combination Training Improves Leptin Regulation, Reduces Body Fat, and Increases Skeletal Muscle Mass in Obese Females Dwi Cahyo Kartiko, Purwo Sri Rejeki, Dono Indarto, Irmantara Subagio, Sasminta Christina Yuli Hartati, Bekir Erhan Orhan, Yuni Nurwati, Adi Pranoto Physical Education Theory and Methodology.2026; 26(2): 380. CrossRef
Current Trends in the Epidemiology of Obesity and the Association Between Obesity and Metabolic Liver Disease (MASLD/MASH) Mirjana Grocic, Madison Nguyen, Arun J. Sanyal Diabetes, Obesity and Metabolism.2026; 28(S2): 3. CrossRef
Association of environmental chemical exposure with metabolic dysfunction-associated steatotic liver disease: a cross-sectional and network toxicology analysis Guodong Yang, Wenli He, Xin Qiu, Shuang Shen, Yifei Feng, Yi Peng, Taixin Yang, Zhaochan Wen, Peishu Li, Huili Luo, Xinyuan Wu, Ze Su, Bangde Xiang European Journal of Medical Research.2026;[Epub] CrossRef
Burden of metabolic dysfunction-associated steatotic liver disease in the Asia-Pacific region from 1990 to 2023 Xiao-Dong Zhou, Qin-Fen Chen, Giovanni Targher, Christopher D Byrne, Luca Valenti, Mark D Muthiah, Seung Up Kim, Daniel Q Huang, Masato Yoneda, Wenhao Li, Yusuf Yilmaz, Herbert Tilg, Vincent Wai-Sun Wong, Ming-Hua Zheng eGastroenterology.2026; 4(1): e100369. CrossRef
Unraveling the Mechanisms of Wuling Powder Against MASLD by Integrated Metabolomics–Gut Microbiota–Serum Pharmacochemistry Huan Yang, Yan-Mei Tang, Shao-Cong Han, Peng-Quan Wang, Yu-Xuan Tao, Hui-Qiong Yang, Min Zhang, Min Li, Jie Yu, Xing-Xin Yang Pharmaceuticals.2026; 19(4): 557. CrossRef
Endocrine disruptors reprogram hepatic metabolic and immune gene networks to promote hepatocellular carcinoma Yanggang Hong, Yi Wang, Qingyu Chen, Yirong Wang npj Gut and Liver.2026;[Epub] CrossRef
Exercise-responsive skeletal muscle genes mechanistically linked to metabolic dysfunction-associated steatotic liver disease Jia-Hui Zhang, Kang Chen, Xiao-Min Zhu, Huan Zhou, Jia-Mi Jiang, Yu-Qing Zou, Ke-Rong Liu, Le Zhang, Yun Li World Journal of Gastroenterology.2026;[Epub] CrossRef
Multimodal assessment of hepatic steatosis heterogeneity: segmental MRI-PDFF and ultrasound attenuation coefficient measurement M.M. Zhaivoronok, N.V. Deresh, I. Sporea, O.B. Dynnyk, S.V. Feysa, O.A. Pushkarenko, O.A. Fedusenko, O.V. Shcherbina, N.M. Kobyliak INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2026; 22(2): 103. CrossRef
Metabolic dysfunction-associated steatotic liver disease, biomarkers, and cardiovascular risk factors in children with excess weight Elisabeth A. Machado, Beatriz L.C. Themistocles, Jorge M.R. Teixeira, Fernanda M.G. Jannuzzi, Geísa Tomaz, Cecilia L. Oliveira, Isabel R. Madeira, Carlos Terra, Maria das Graças C. Souza, Alexandra Monteiro, Eliete Bouskela, Marise E. Marsillac, Paulo F. Jornal de Pediatria.2026; 102(3): 101534. CrossRef
Ubiquitin-Specific Protease 2 (USP2) as a Modulator of Energy Metabolism: A Review of Studies Using Animal and Cellular Models Hiroshi Kitamura, Jun Okabe, Himeka Hayashi, Tomohito Iwasaki Biomedicines.2026; 14(4): 783. CrossRef
Risk Stratification of Chronic Kidney Disease in Adults Using Noninvasive Fibrosis Tests Based on the American Diabetes Association Algorithm Chan‐Young Jung, Hye Won Lee, Jung Il Lee, Han Ah Lee, Seung Up Kim Diabetes, Obesity and Metabolism.2026; 28(6): 5240. CrossRef
Longitudinal performance of vibration controlled transient elastography in pediatric metabolic dysfunction associated steatotic liver disease Naima Diop‐West, Nicholas Denson, Ana Catalina Arce‐Clachar, Julie Bonn, Kristin Bramlage, Lisa Leesman, Rashmi D. Sahay, Emrah Gecili, Andrew T. Trout, Stavra Xanthakos, Marialena Mouzaki Journal of Pediatric Gastroenterology and Nutrition.2026;[Epub] CrossRef
LPCAT3 deficiency Drives phospholipid remodeling and mitochondrial oxidative dysfunction to accelerate MASH-HCC development Gaoxuan Shao, Chenhao Ye, Chenceng Sun, Jiashu Pan, Lu Lu, Lei Wang, Tao Wu, Zemin Lin, Guang Ji, Hanchen Xu Journal of Advanced Research.2026;[Epub] CrossRef
Evidence-Based Management of MASLD: GRADE Evaluation of Pharmacological Therapies Eleni A. Karavia, Andreas Pittaras, Ourania Andreopoulou, Aikaterini Hatziri, Amalia Makrydimitri, Dimitrios Anagnostopoulos, Patroklos Vareltzis, Kyriakos E. Kypreos Pharmaceuticals.2026; 19(4): 605. CrossRef
Studying serum immunoglobulin levels in metabolic dysfunction-associated steatotic liver disease Hazem Abosheaishaa, Emad Ahmad Awad Hussein, Shereen Abou Bakr Saleh, Mahmoud Nassar, Abdulaziz Elmaradny, Mohammed Abdelwahed, Amr Ali, Khaled Elfert, Ahmed Mohamed ElGhandour Egyptian Liver Journal.2026;[Epub] CrossRef
Association Between Periodontitis and Metabolic Dysfunction–Associated Steatotic Liver Disease: A Cross‐Sectional Study Mizuki Saito, Yoshihiro Shimazaki, Saori Yoshii, Tetsuhito Kojima Clinical and Experimental Dental Research.2026;[Epub] CrossRef
Endoscopy for Metabolic Diseases Maria Valeria Matteo, Jana Kefah Ibrahim Hussein, Giorgio Carlino, Vincenzo Bove, Valerio Pontecorvi, Loredana Gualtieri, Martina De Siena, Mariachiara Di Vincenzo, Lorenzo Zileri Dal Verme, Daniele Salvi, Clarissa Ferrari, Cristiano Spada, Ivo Boskoski Journal of Clinical Medicine.2026; 15(8): 2832. CrossRef
Weekend warrior physical activity pattern and risk of all-cause and cardiovascular mortality among US adults with metabolic dysfunction-associated steatotic liver disease: A prospective cohort study of NHANES 2007–2018 Mengbiao Cai, Kai Jin, YuLong Wang, Jian Zhu, Changnan Xu, Yi Yang, Zhenxiang Guo Science Progress.2026;[Epub] CrossRef
Differential Impact of Metabolic Bariatric Surgery Versus Semaglutide on Adverse Hepatic and Extrahepatic Outcomes in Individuals With Metabolic Dysfunction‐Associated Steatotic Liver Disease and Type 2 Diabetes Weronika Stupalkowska, Alex E. Henney, David R. Riley, Eric G. Sheu, Uazman Alam, Daniel J. Cuthbertson Diabetes, Obesity and Metabolism.2026;[Epub] CrossRef
Ferroptosis in MASLD: From molecular mechanisms to therapeutic opportunities Xiao-Dong Zhou, Qiong-Yue Fan, Giovanni Targher, Christopher D. Byrne, Wei Xie, Qin-Fen Chen, Yuxing Dong, Fudi Wang, Daolin Tang, Ming-Hua Zheng Med.2026; : 101099. CrossRef
Toxic lipid-induced epigenetic activation of ICAM1 in liver sinusoidal endothelium regulates myeloid-driven fibro-inflammatory response in MASH Qianqian Guo, Nantawat Satthawiwat, Akitoshi Sano, Chady Meroueh, Asma Hamdi, Xin Dai, Khaled Warasnhe, Alexander M. Washington, Patrick P. Starlinger, Alex Krivonos, Sheng Cao, Enis Kostallari, Johan W. Jonker, Bart van de Sluis, Feda H. Hamdan, Samar H. Hepatology.2026;[Epub] CrossRef
Updates on paediatric MASLD: insights from an endocrine lens Natalie Segev, Marialena Mouzaki Diabetologia.2026;[Epub] CrossRef
An Integrated Nanozyme‐Exosome Platform for Multi‐Targeted Therapy of Metabolic‐Associated Steatotic Liver Disease Kun Yu, Xinwei Li, Yingying Liu, Haonan Zhang, Guojie Liu, Tuo Ji, Yuzhi Gao, Lin Wang, Yuwei Bian, Guohua Chen, Zhiwen Zhao, Feng Wang, Xiaoming Yu, Jiachen He, Xuzhu Gao Advanced Healthcare Materials.2026;[Epub] CrossRef
Safety and efficacy of pharmacological interventions for hepatic outcomes of metabolic dysfunction-associated steatotic liver disease: protocol for systematic review and network meta-analysis Kiavash Semnani, Farbod Semnani, Seyed Sahab Aarabi, Shirin Esmaeili, Ehsaneh Taheri, Armita Mahdavi-Gorabi, Mohsen Rajabnia, Shirin Djalalinia, Saba Goodarzi, Amir Kasaeian, Mohammad Shadab Siddiqui, Mostafa Qorbani BMJ Open.2026; 16(4): e111933. CrossRef
Cholinesterase and the association between hepatic steatosis and liver fibrosis in patients with prior hepatitis E Ziteng Wang, Zhe Yu, Wen An, Herui Wei, Jing Luo, Mengqi Li, Lingling He, Jiali Ma, Fan Xiao, Lijuan Sun, Qi Gao, Hui Zhong, Hongshan Wei European Journal of Medical Research.2026;[Epub] CrossRef
GLP-1RA plus SGLT2i combination therapy and liver fibrosis progression in MASLD with type 2 diabetes Jonggi Choi, Gabby Mitchell, Vy H. Nguyen, Eric Przybyszewski, Jiunn Song, Allison Carroll, Megan Michta, Erik Almazan, Tracey G. Simon, Raymond T. Chung Hepatology Communications.2026;[Epub] CrossRef
Analysis of B-Scan Ultrasonography Using Neural Networks to Predict Risk of Fibrosis in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Josefine Stansch, Kien Vu Trung, Valentin Blank, Jakob Nikolas Kather, Moritz Herzog, Tobias Seibel, Paul-Henry Koop, Robert Haase, Thomas Berg, Johannes Wiegand, Thomas Karlas Ultrasound in Medicine & Biology.2026; 52(7): 1346. CrossRef
Hypertension in middle childhood Mirjam Močnik, Zala Hrovat, Sonja Golob Jančič, Martina Filipič, Mladen Crnobrnja, Nataša Marčun Varda BMC Pediatrics.2026;[Epub] CrossRef
Blood-based non-invasive tests show comparable accuracy in MetALD and MASLD for MRE-defined advanced fibrosis Akash Roy, Surabhi Jajodia, Shardhya Chakraborty, Shruti Keyal, Awanish Tewari, Nikhil Sonthalia, Sourish Roy, Rajat Khandelwal, Anand Kulkarni, Uday Chand Ghoshal, Rajender Reddy, Mahesh Kumar Goenka BMC Gastroenterology.2026;[Epub] CrossRef
Current Drug Development Pipeline for MASLD and MASH: Focusing on Cardiovascular Comorbidities Veronika A. Prikhodko, Sergey V. Okovityi Biomedicines.2026; 14(4): 909. CrossRef
Apple polyphenol extract mitigates high-fat diet induced cognitive impairment in C57BL/6 mice via a sex-dependent mechanism Jieyu Ma, Jiaxin Li, Le Wang, Jinlin Ma, Shilin Chen, Wenxue Luan, Xintong Tian, Siyuan Shang, Xinli Li Food Bioscience.2026; 80: 108892. CrossRef
Current status of research on the risk factors and pathogenesis of metabolic dysfunction-associated steatotic liver disease Dan Chen, Lingling Yan, Tong Wu, Junpeng Zhao, Xuebing Xu, Weisong Xu, Hong Zhang, Mingbing Xiao Frontiers in Endocrinology.2026;[Epub] CrossRef
Patatin-like phospholipase domain-containing protein 3 rs2896019 and MASLD Susceptibility and Severity in Adults: A Systematic Review and Meta-Analysis of Case–Control Studies Wei-Yue Lim, Rosmawati Mohamed, Yuh-Fen Pung, Hak-Keith Leung, Rong-Xiang Ng, Shamsul Mohd Zain Metabolic Syndrome and Related Disorders.2026;[Epub] CrossRef
Predictors of metabolic dysfunction-associated steatotic liver diseases (MASLD) in Vietnamese population Anh Gia Pham, An Vu-Khanh Le, Yen Thi-Hai Pham, Lanh Sy Nguyen, Huong Lan Nguyen, Nghia Chinh Quach, Thau Manh Cao, Hanh Thi Nguyen, Xuan Thanh Thai, Anh Tuan Luong, Thuy Thi Pham, Hai Duy Vu, Hai Thi-Thanh Tran, Lan Thi Le, Hai Vu, Giang Binh Tran, Hung Scientific Reports.2026;[Epub] CrossRef
Lactational Western‐Style Fat Exposure in Mice Programs Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) in Male Offspring Amy Y. Zhao, Haijing Sun, Leyi Yan, Oyewale Shiyanbola, Dave Bridges, Brigid Gregg Molecular Nutrition & Food Research.2026;[Epub] CrossRef
Monocyte reprogramming and trained immunity: Linking metabolism to inflammation in non-alcoholic fatty liver disease Stanislav Kotlyarov World Journal of Hepatology.2026;[Epub] CrossRef
Exercise as a Metabolic Therapy for MASLD: Beyond Weight Loss Toward Sustainable Exercise Strategies Hee-Tae Roh, Ju-Yong Bae Medicina.2026; 62(4): 784. CrossRef
Tissue-specific roles of IGFBP2 in glucose and lipid metabolism in obesity-related metabolic diseases Xiaoyu Song, Wentao Zhong, Hao Zheng, Xinyang Ou, Dongjin Zheng, Zhuo Li Frontiers in Nutrition.2026;[Epub] CrossRef
Outcomes of oral antidiabetic drugs in metabolic dysfunction-associated steatotic liver disease: a nationwide target trial emulation study Heejoon Jang, Yeonjin Kim, Yoo Kyoung Lim, Dong Hyeon Lee, Sae Kyung Joo, Bo Kyung Koo, Gi-Ae Kim, Woojoo Lee, Stefano Romeo, Won Kim Clinical and Molecular Hepatology.2026; 32(2): 737. CrossRef
High-fat diet, gut dysbiosis, and oxidative stress: A synergistic triangle in metabolic dysfunction-associated steatotic liver disease pathogenesis Zi-Rui Zhang, Ling She, Yi-Rong Cao, Yuan-Wen Chen World Journal of Hepatology.2026;[Epub] CrossRef
Fibulin-3 as a reliable biomarker of fibrosis in obese subjects with metabolic dysfunction-associated steatotic liver disease Allen Anthony Laraño, Silvia Palmisano, Deborah Bonazza, Discipio Marina, Marica Meroni, Anna Ludovica Fracanzani, Lory S Crocè, Claudio Tiribelli, Paola Dongiovanni, Natalia Rosso, Pablo Giraudi Annals of Hepatology.2026; : 102206. CrossRef
Alcohol-driven phenotypic transition in MASLD and risk of liver-related events Seohui Jang, Jihun Song, Eun Seok Kang, Sangwook Cheon, Taeho Kwak, Yihyun Kim, Seokjin Kong, Jinhyeok Choi, Minjeong Kang, Jaewon Khil, Hye Jun Kim, Jeongin Lee, Hwamin Lee, Seogsong Jeong JHEP Reports.2026; : 101866. CrossRef
Targeting the ASB3-CPT1A axis—a new player in combating metabolic dysfunction-associated steatotic liver disease: Editorial on “Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver diseas Yueying Yang, Ying Yang, Yan Lu Clinical and Molecular Hepatology.2026; 32(2): 957. CrossRef
Editorial on “Genome-wide interaction study with body mass index identifies CYP7A1 and GIPR as genetic modulators of metabolic dysfunction-associated steatotic liver disease” Julia Kozlitina Clinical and Molecular Hepatology.2026; 32(2): 931. CrossRef
Role of MicroRNAs in Precision Hepatology Youngwoo Lee, Eunho Choi, Young-Sun Lee Journal of Digestive Cancer Research.2026; 14(1): 102. CrossRef
Longitudinal changes in fatty liver index, genetic susceptibility, and incident atrial fibrillation Siyang Liu, Houde He, Hualan Chen, Hualin Duan, Ying Sun, Dan Deng, Zihao Gui, Lan Liu, Ningjian Wang, Jie Shen, Heng Wan Clinica Chimica Acta.2026; 589: 121028. CrossRef
Bupleuri Radix ameliorates MASLD induced by high-fat diet and circadian disruption in rats: Involvement of the NR1D1–SREBF1/CYP7A1 circadian–metabolic axis Shuheng Wang, Shuaidong Bai, Tianhui Zhou, Yukun Wang, Xue Bai, Yiming Wang, Junwen Ma, Xuemei Qin, Xiaoxia Gao Journal of Ethnopharmacology.2026; 367: 121770. CrossRef
Comment on “High-normal and abnormal alanine transaminase levels linked to increased risk of hepatoma following treatment for chronic hepatitis C” Wen-Rui Li Journal of the Formosan Medical Association.2026;[Epub] CrossRef
Calorie Restriction Mitigates Steatotic Liver Disease in Obese Rats After Bariatric Surgery Yu-Ning Lin, Chin-Ying Wu, Yin-Ru Hsieh, Yi-Tung Lin, Weu Wang, Chun-Chao Chang, Shih-Yi Huang, Wei-Yu Kao Nutrition Research.2026;[Epub] CrossRef
Fucoxanthin Ameliorates MASLD by Directly Targeting GRP78 to Restore ER Homeostasis and Activate AMPK Signaling Lin Zhang, Ruifen Zhang, Yu Wu, Binbin Chen, Chao Wang, Cheng Wang, Zhengshun Wen, Jingui Zhang, Haibin Tong, Liang Hong Food Science & Nutrition.2026;[Epub] CrossRef
Familial hypobetalipoproteinemia in pediatric patients with fatty liver: an under-recognized cause Nurit Loberman Nachum, Eyal Shteyer, Hofit Cohen, Odelia Chorin, Maya Granot, Batia Weiss Frontiers in Medicine.2026;[Epub] CrossRef
The effect of a two-week low glycaemic index, higher fibre diet versus high glycaemic index diet on body composition, ectopic lipids, inflammatory biomarkers, gastrointestinal hormones and gut microbiota in metabolic dysfunction-associated steatotic liver Amina A. Al-Awadi, Jane I. Grove, Stephen Bawden, Amrita Vijay, Ana M. Valdes, Penny Gowland, Moira A. Taylor, Guruprasad P. Aithal Clinical Nutrition ESPEN.2026; 73: 103306. CrossRef
Di(2-ethylhexyl) phthalate exposure: Association with metabolic associated steatotic liver disease and underlying mechanisms Dapeng Yin, Yan Li, Wei Wu, Jiacheng Cheng, Xiaojuan Wang, Junhua He, Yikun Zhu, Jin Li Ecotoxicology and Environmental Safety.2026; 317: 120210. CrossRef
Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach Beom Kyung Kim The Kaohsiung Journal of Medical Sciences.2026;[Epub] CrossRef
Evaluation of Factors Affecting Alpha Fetoprotein Levels in Patients With Hepatocellular Carcinoma in a Large Multicenter Cohort Nicole Shu Ying Tang, Ethan Kai Jun Tham, Nicholas Syn, Ken Liu, Gang Chen, Beom Kyung Kim, Mark Muthiah, Takumi Kawaguchi, Asahiro Morishita, Sung Won Lee, Karn Wijarnpreecha, Hirokazu Takahashi, Daniel Q. Huang Journal of Gastroenterology and Hepatology.2026;[Epub] CrossRef
Integrated bioinformatics analysis and experimental validation of SRF as a potential senescence biomarker in MASLD Mengyue Li, Chang Gao, Yuhui Shi, Wenyu Peng, Yuan Yin, Bin Lu, Zhang Fu Frontiers in Molecular Biosciences.2026;[Epub] CrossRef
The Role of MicroRNAs in the Progression of Metabolic Dysfunction-associated Steatotic Liver Disease Jang Hyun Choi Journal of Digestive Cancer Research.2026; 14(1): 82. CrossRef
GCSH promotes MASH progression by regulating cuproptosis through the glycine–GSH metabolic pathway Xuan Fu, Yunmeng Li, Jing Chen, Baolong Yin, Mahbuba Nasrin, Rui Huo, Shuxin Tian Free Radical Biology and Medicine.2026; 252: 1. CrossRef
A Descriptive Analysis of Mediterranean Diet Meal Plans Using the Dietary Inflammatory Index, Dietary Antioxidant Index, and Dietary Lipid Indices: Implications for Dietary Intervention for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Melvin Bernardino, Claudio Tiribelli, Natalia Rosso Nutrients.2026; 18(8): 1281. CrossRef
From Genomic Instability to Epigenetic Signatures: The Evolving Landscape of Circulating Cell‐free DNA in Metabolic Dysfunction‐Associated Steatotic Liver Disease Wei‐Yue Lim, Rosmawati Mohamed, Yuh‐Fen Pung, Shamsul Mohd Zain Hepatology Research.2026;[Epub] CrossRef
Prediction of trajectories and outcomes in early-stage metabolic dysfunction-associated steatotic liver disease: a narrative review Brittany Bromfield, Jeremy Chimene-Weiss, Gregory Gheewalla, Theodore Feldman, Emilie K. Mitten, Piero Portincasa, Gyorgy Baffy eClinicalMedicine.2026; 95: 103921. CrossRef
Concerns about the health effects of industrially produced seed oils are without scientific foundation: a scoping narrative review of the clinical and observational evidence Matthew Nagra, David M. Goldman, Martha A. Belury, Mark Messina Critical Reviews in Food Science and Nutrition.2026; : 1. CrossRef
Neutrophils in Liver Diseases: Functions and Challenging Therapies Rui Ma, Haoran Meng, Xiutong Chen, Haiyuan Shen, Li Zuo, Hua Wang Seminars in Liver Disease.2026;[Epub] CrossRef
The Degree of Liver Steatosis Is Associated with Abnormally High Serum Levels of Markers of Blood–Brain Barrier Dysfunction and Systemic Inflammation in Patients with Morbid Obesity Gabriela Hurtado-Alvarado, Karol Iliana Ávila-Soto, Marlene Monserrat Juárez, Lucía Angélica Méndez-García, Verónica Cevallos-López, Juan Antonio Peralta-Calcaneo, Marcela Esquivel-Velázquez, Antonio González-Chávez, Julio César Zavala-Castillo, Ana Alfar Medicina.2026; 62(5): 821. CrossRef
Portal Vein Thrombosis in Cirrhotic Candidates for Liver Transplantation and Its Impact on the Transplant Accessibility Simona Parisse, Flaminia Ferri, Adriano De Santis, Fabio Melandro, Mario Corona, Quirino Lai, Pierleone Lucatelli, Gianluca Mennini, Massimo Rossi, Stefano Ginanni Corradini Journal of Clinical Medicine.2026; 15(9): 3358. CrossRef
c-FLIP as a master regulator of immune homeostasis and disease mechanisms Eliana Urbini, Annalisa Adamo, Yushu Hu, Luca Giacobazzi, Silvia Dusi, Francesco De Sanctis, Carmine Carbone, Davide Gibellini, Sara Pilotto, Vincenzo Corbo, Vincenzo Bronte, Fulvia Vascotto, Stefano Ugel Cell Death & Disease.2026;[Epub] CrossRef
Semaglutide 2.4 mg for Obese Patients with MASH: A Cost-Effectiveness Analysis from the Italian NHS Perspective Enrico Torre, Sergio Di Matteo, Chiara Martinotti, Giacomo Bruno, Alessandro Cabrino, Emma Fogliati, Andrea Giusti, Marco Barbieri, Luigi Bottaro, Giorgio Colombo ClinicoEconomics and Outcomes Research.2026; Volume 18: 1. CrossRef
Clinical differentiation between alcohol-associated and metabolic dysfunction-associated steatotic liver disease: a comparative case report Chang-Gue Son The Journal of Internal Korean Medicine.2026; 47(1): 70. CrossRef
Bacterial Extracellular Vesicles in Aging: Mechanisms and Therapeutic Prospects Junfei Tan, Muhammad Zubair, Lin Zhang, Likang Liu, Kangrong Li, Yihua Wang, Yongmin Yan, Wenyan Xu International Journal of Nanomedicine.2026; Volume 21: 1. CrossRef
Elevated liver fat content is independently associated with insulin resistance in people with type 1 diabetes Jonathan Mertens, Maarten Spinhoven, Rie Braspenning, Floris Vanhevel, Eveline Dirinck, Christophe De Block, Sven Francque JHEP Reports.2026; : 101887. CrossRef
Metabolic dysfunction-associated steatotic liver disease in cushing’s syndrome: a case controlled FibroScan study Tugce Apaydin, Caglayan Keklikkiran, Haluk Tarik Kani, Yusuf Yilmaz, Dilek Gogas Yavuz Journal of Endocrinological Investigation.2026;[Epub] CrossRef
Non-Hispanic Black Persons With HIV Have a Lower Risk of Metabolic Dysfunction–Associated Steatotic Liver Disease and Clinically Significant Fibrosis Compared to Non-Hispanic White and Hispanic Individuals Tinsay A Woreta, Samer Gawrieh, Laura A Wilson, Yuchen Xin, Eduardo Vilar-Gomez, Kathleen E Corey, Richard K Sterling, Jordan E Lake, Susanna Naggie, Sonya Heath, Holly Crandall, Jennifer C Price, Rohit Loomba, Naga Chalasani, Mark S Sulkowski Open Forum Infectious Diseases.2026;[Epub] CrossRef
Development and validation of the HABIT score: a practical and robust tool to predict hepatic steatosis using HbA1c, BMI, and triglycerides in patients with unexplained elevated liver enzymes Eike Humbert, Verena Wilkens, Semjon Bugaichuk, Karoline Horvatits, Ansgar W. Lohse, Samuel Huber, Sven Pischke, Thorben Fründt Annals of Hepatology.2026; : 102218. CrossRef
Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease Zobair M. Younossi, Markos Kalligeros, Vincent Wai-Sun Wong, Khalid M. Al-Naamani, Frank Tacke, Emmanouil Tsochatzis, Javier Crespo, Mohamed El-Kassas, Fernando Bril, Marco Arrese, Cyrielle Caussy, C. Wendy Spearman, Amalia Gastaldelli, Mário Guimarães Pe Clinical Gastroenterology and Hepatology.2026;[Epub] CrossRef
Overcoming the barriers in the screening, diagnosis, and follow-up of patients with metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH) Roberto Vettor, Maria Letizia Petroni, Idit Dotan, Gadi Lalazar, Martin Haluzík, C. Wendy Spearman, Joel A. Dave, Faisal Abaalkhail, Salah Abusnana, Ali Alshehri, Radan Bruha, Mariann Harangi, Ahmad Jazzar, Michał Kukla, Shiva Kumar, Vaia Lambadiari, Geor Reviews in Endocrine and Metabolic Disorders.2026; 27(2): 213. CrossRef
Advances in Diagnostic and Therapeutic Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease Ryan Njeim, Omar Abureesh, Ali Sohail, Ryan Tam, Liliane Deeb Livers.2026; 6(3): 35. CrossRef
The role of the resveratrol-sirtuin axis in the treatment of metabolic dysfunction-associated diseases Jiale Yang, Shuping Chen, Tiantian Zeng, Yuxuan Zhang, Zhaoxin Li, Haifang Li Exploration of Endocrine and Metabolic Diseases.2026;[Epub] CrossRef
GLP-1 receptor agonist–SGLT-2 inhibitor combination and risk of major adverse liver and cardiovascular outcomes in adults with MASLD and type 2 diabetes Xianhua Mao, Hong Fan, Man-Fung Yuen, Ramsey Cheung, Wai-Kay Seto, Mindie H. Nguyen Hepatology.2026;[Epub] CrossRef
Relevance of lipid droplets in metabolic dysfunction-associated steatotic liver disease Ralf Weiskirchen, Amedeo Lonardo Expert Opinion on Therapeutic Targets.2026; : 1. CrossRef
Weight Loss-Induced Metabolic Remodeling in Metabolic dysfunction-associated steatotic liver disease: A Cohort Study Stratified by Genetic Risk J. Troisi, P. Torre, L. Schiavo, B.M. Motta, M. Lombardi, M. Festa, T. Sarcina, M. Masarone, M. Persico Clinical Nutrition.2026; 61: 106672. CrossRef
Therapeutic efficacy, biomarker signatures, and translatability of semaglutide in the liver biopsy-confirmed GAN DIO-MASH mouse model Jens Bjelke Kristensen, Jacob Nøhr-Meldgaard, Susanne E. Pors, Jenny Norlin, Sanne S. Veidal, Kristian Moss Bendtsen, Kristoffer Niss, Maja W. Andersen, Lea M. Harder, Mathilde Teilmann Dalhoff, Martin Rønn Madsen, Kristoffer Voldum-Clausen, Markus Latta, American Journal of Physiology-Gastrointestinal and Liver Physiology.2026; 330(6): G659. CrossRef
Effectiveness of therapeutic strategies based on dietary patterns on cardiovascular and hepatic markers in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) ‒ A systematic review of clinical trials Valeria Antonia Rivera Marín, Camila Sanchez, Andrea Herrera-Santelices, Luisa Amanda Ramírez Araya, Edson Yáñez-Barros, Sebastian Cofré Nutrición Hospitalaria.2026;[Epub] CrossRef
Extracellular Vesicle from Chlorella vulgaris Alleviates Hepatic Fibrosis in a Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease Through Modulation of Inflammatory Signaling Hinata Harada, Yusuke Ohsaki, Afifah Zahra Agista, Hsin-Jung Ho, Takuo Hirose, Kotaro Yamada, Mutsumi Furukawa, Tomonori Nochi, Wan-Chun Chiu, Ya-Ling Chen, Chiu-Li Yeh, Suh-Ching Yang, Takefumi Mori, Hitoshi Shirakawa International Journal of Molecular Sciences.2026; 27(9): 3735. CrossRef
Nitric Oxide Pathway: Emerging Therapeutic Strategies for MASLD Yanling Zhang, Ying Zhang, Hongjin Chen, Fangfang Qi Pathology - Research and Practice.2026; : 156516. CrossRef
Distinct Roles of Myeloid‐ and Hepatocyte‐PLA2G6 Deletion in Mice With Metabolic Dysfunction‐Associated Steatotic Liver Disease Gang Li, Simone Staffer, Sabine Tuma‐Kellner, Uta Merle, Walee Chamulitrat Liver International.2026;[Epub] CrossRef
MASLD Management in Spain: A Nationwide Survey of Gastroenterologists Highlighting Gaps in Risk Assessment and Primary Care Coordination Carolina Jiménez-González, Paula Argos Vélez, Lorena Cayón, Ana Belén García-Garrido, Noelia Fontanillas Garmilla, Antonio Cuadrado, Paula Iruzubieta, Javier Crespo Journal of Clinical Medicine.2026; 15(9): 3259. CrossRef
Predicting MASLD in People With HIV Using Anthropometric Measures: A Multicenter Cross-Sectional Study Jihad Slim, Murad Qirem, Paul Bellafiore, Bereket Tewoldemedhin, Tala B Shahin, Kevin Leyden, Ronald Poblete, Sandhya Nagarakanti, Hugo Vargas Open Forum Infectious Diseases.2026;[Epub] CrossRef
Current Trends and Perspectives on Obesity and Metabolic Dysfunction-Associated Steatohepatitis in East Asia Soo Lim, Hui Zhou, Wataru Ogawa Journal of Obesity & Metabolic Syndrome.2026; 35(2): 130. CrossRef
The gut-liver/bile axis: Gut microbiota and bacterial extracellular vesicles remodeling hepatobiliary pathogenesis Siyang Hu, Chunhui He, Kunqi Sun, Hongye Zhou, Xueyan Liu, Hao Wang, Sen Li, Haifeng Yu, Ke Xu, Wei Li iScience.2026; 29(5): 115623. CrossRef
Effects of Animal-Based Foods on Metabolic Outcomes in Adults with MASLD and Comorbidities: A Systematic Review of Randomized Controlled Trials (2020–2026) Joanna Michalina Jurek, Katarzyna Zablocka-Slowinska, Joanna Pieczynska, Anna Lipert, Helena Clavero-Mestres, Teresa Auguet Nutrients.2026; 18(10): 1508. CrossRef
Impact of probiotics and prebiotics on glucose/lipid metabolism in metabolic dysfunction-associated steatotic liver disease: mechanisms and implications Yinan Zhao, Ziyan Li, Guoying Yu Frontiers in Nutrition.2026;[Epub] CrossRef
Association of sleep patterns and disorders with metabolic dysfunction-associated steatotic liver disease and liver fibrosis in contemporary American adults Guannan Zong, Wangjia Mao, Ming Wen, Xiaoyun Cheng, Guanghui Liu Annals of Hepatology.2025; 30(2): 101583. CrossRef
Phthalates exposure, biological aging, and increased risks of insulin resistance, prediabetes, and diabetes in adults with metabolic dysfunction-associated steatotic liver disease Yueru Yang, Shuhui Wan, Linling Yu, Wei Liu, Jiahao Song, Da Shi, Yongfang Zhang, Weihong Chen, Weihong Qiu, Bin Wang Diabetes & Metabolism.2025; 51(1): 101602. CrossRef
Hepatic Estrogen Receptor Alpha Overexpression Protects Against Hepatic Insulin Resistance and MASLD Ester S. Alves, Jessica D. M. Santos, Alessandra G. Cruz, Felipe N. Camargo, Carlos H. Z. Talarico, Anne R. M. Santos, Carlos A. A. Silva, Henrique J. N. Morgan, Sandro L. Matos, Layanne C. C. Araujo, João Paulo Camporez Pathophysiology.2025; 32(1): 1. CrossRef
Correlation of sarcopenia with progression of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: a study from two cohorts in China and the United States Fan Zhang, Longgen Liu, Wenjian Li Nutrition Journal.2025;[Epub] CrossRef
The association between working hours and working type with non-alcoholic fatty liver disease: results from the NHANES 1999-2014 Ruli Wang, Ningxi Wu, Huan Qu, Xiaowei Zheng, Haoyang Zhang, Lihong Zhu, Xiaolei Wang, Xiaodie Yao, Le Zhang Frontiers in Endocrinology.2025;[Epub] CrossRef
Genetic risk amplifies lifestyle effects on hepatic steatosis and its progression: Insights from a population-based cohort Xin Zhang, Haili Wang, Chengnan Guo, Shuzhen Zhao, Yi Li, Zhenqiu Liu, Tiejun Zhang Digestive and Liver Disease.2025;[Epub] CrossRef
Tetrahydrocurcumin Alleviates Metabolic Dysfunction-Associated Steatohepatitis in Mice by Regulating Serum Lipids, Bile Acids, and Gut Microbiota Shang Peng, Moran Meng, Ping Luo, Jiao Liu, Junjun Wang, Yong Chen International Journal of Molecular Sciences.2025; 26(3): 895. CrossRef
Novel translational mouse models of metabolic dysfunction-associated steatotic liver disease comparable to human MASLD with severe obesity Katharina L. Hupa-Breier, Heiko Schenk, Alejandro Campos-Murguia, Freya Wellhöner, Benjamin Heidrich, Janine Dywicki, Björn Hartleben, Clara Böker, Julian Mall, Christoph Terkamp, Ludwig Wilkens, Friedrich Becker, Karl Lenhard Rudolph, Michael Peter Manns Molecular Metabolism.2025; 93: 102104. CrossRef
Cigarette Smoke Contributes to the Progression of MASLD: From the Molecular Mechanisms to Therapy Jiatong Xu, Yifan Li, Zixuan Feng, Hongping Chen Cells.2025; 14(3): 221. CrossRef
Association of high-sensitivity C-reactive protein with hepatic fibrosis in patients with metabolic dysfunction-associated steatotic liver disease Yunfei Wu, Guojun Zheng, Fan Zhang, Wenjian Li Frontiers in Immunology.2025;[Epub] CrossRef
Liver fibrosis progression analyzed with AI predicts renal decline Dan-Qin Sun, Jia-Qi Shen, Xiao-Fei Tong, Ya-Yun Ren, Hai-Yang Yuan, Yang-Yang Li, Xin-Lei Wang, Sui-Dan Chen, Pei-Wu Zhu, Xiao-Dong Wang, Christopher D. Byrne, Giovanni Targher, Lai Wei, Vincent W.S. Wong, Dean Tai, Arun J. Sanyal, Hong You, Ming-Hua Zhen JHEP Reports.2025; 7(5): 101358. CrossRef
Lean MASLD and IBD: Exploring the Intersection of Metabolic Dysfunction and the Gut–Liver Axis Adrian Rotaru, Remus Stafie, Ermina Stratina, Sebastian Zenovia, Robert Nastasa, Horia Minea, Laura Huiban, Tudor Cuciureanu, Cristina Muzica, Stefan Chiriac, Irina Girleanu, Ana-Maria Singeap, Catalin Sfarti, Carol Stanciu, Anca Trifan Life.2025; 15(2): 288. CrossRef
Sex differences in diet-induced MASLD – are female mice naturally protected? Jana Meyer, Ana Mendes Teixeira, Sandy Richter, Dean P. Larner, Asifuddin Syed, Nora Klöting, Madlen Matz-Soja, Susanne Gaul, Anja Barnikol-Oettler, Wieland Kiess, Diana Le Duc, Melanie Penke, Antje Garten Frontiers in Endocrinology.2025;[Epub] CrossRef
Low HDL cholesterol levels in women and hypertriglyceridemia in men: predictors of MASLD onset in individuals without steatosis Tsubasa Tsutsumi, Takumi Kawaguchi, Hideki Fujii, Yoshihiro Kamada, Yuichiro Suzuki, Koji Sawada, Miwa Tatsuta, Tatsuji Maeshiro, Hiroshi Tobita, Takemi Akahane, Chitomi Hasebe, Miwa Kawanaka, Takaomi Kessoku, Yuichiro Eguchi, Hayashi Syokita, Atsushi Nak Journal of Gastroenterology.2025; 60(7): 891. CrossRef
Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2025; 61(11): 1785. CrossRef
A Narrative Review on the Risk Factors and Healthcare Disparities of Type 2 Diabetes Elvira Meni Maria Gkrinia, Andrej Belančić Diabetology.2025; 6(4): 25. CrossRef
Metabolic dysfunction-associated steatotic liver disease and malignancies: Unmasking a silent saboteur Stergios A. Polyzos, Christos S. Mantzoros Metabolism.2025; 168: 156253. CrossRef
Molecular Landscape and Diagnostic Model of MASH: Transcriptomic, Proteomic, Metabolomic, and Lipidomic Perspectives Yilong Chen, Shuixiu Bian, Jiamei Le Genes.2025; 16(4): 399. CrossRef
Significance of FXR agonists in MASLD treatment: a deep dive into lipid alteration by analytical techniques Pirangi Srikanth, Khaja Moinuddin Shaik, Vijay Patibandla, Deepak Kumar, Sukhendu Nandi Exploration of Endocrine and Metabolic Diseases.2025;[Epub] CrossRef
Editorial: Chrononutrition and MASLD—Its About Time (Restricted Feeding)! Hannah Mohr, Jonathan G. Stine Alimentary Pharmacology & Therapeutics.2025; 61(9): 1565. CrossRef
The socioeconomic and environmental determinants of metabolic dysfunction-associated steatotic liver disease: understanding inequalities in prevalence and outcomes Dominika Lorek, Krzysztof Łupina, Wiktoria Bisaga, Dominik Malicki, Weronika Stępień, Laura Kumor, Jakub Janczura Korean Journal of Family Medicine.2025; 46(2): 61. CrossRef
Advancing precision medicine in metabolic dysfunction-associated steatotic liver disease Bryan A. Priego-Parra, Rocío Gallego-Durán, Berenice M. Román-Calleja, José Antonio Velarde-Ruiz Velasco, Manuel Romero-Gómez, Jordi Gracia-Sancho Trends in Endocrinology & Metabolism.2025; 36(11): 1000. CrossRef
Use of Hepatoscope 2DTE for non-invasive assessment of liver stiffness among Mexican immigrant adults in a community-based setting Edgar A. Villavicencio, Cindy Serdjebi, Adriana Maldonado, Estefania Ochoa Mora, Adrien Besson, Naim Alkhouri, David O. Garcia Clinics and Research in Hepatology and Gastroenterology.2025; 49(5): 102581. CrossRef
Potential bidirectional communication between the liver and the central circadian clock in MASLD Frédéric Gachon, Elisabetta Bugianesi, Gabriele Castelnuovo, Henrik Oster, Julie S. Pendergast, Sara Montagnese npj Metabolic Health and Disease.2025;[Epub] CrossRef
Impact of Severity of Metabolism-Related Fatty Liver Disease Based on Pathologic Grading on Outcomes after Sleeve Gastrectomy 云飞 曲 Journal of Clinical Personalized Medicine.2025; 04(02): 826. CrossRef
GOLM1 and bile acid synthesis: Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers” Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Jing Lin, Jin-Hong Chen Clinical and Molecular Hepatology.2025; 31(2): e189. CrossRef
Prevalence of steatotic liver disease and associated fibrosis in the general population: An epidemiological survey: Letter to the editor on “Epidemiology of metabolic dysfunction-associated steatotic liver disease” Lin Guan, Xinhe Zhang, Shanghao Liu, Xiaolong Qi, Yiling Li Clinical and Molecular Hepatology.2025; 31(2): e145. CrossRef
Prognostic impact of body composition in hepatocellular carcinoma patients undergoing interventional and systemic therapy Yun Feng, Bingran Yu, Anxiao Liu, Chongpeng Cai, Changming Zhou, Tong Tong, Lu Wang, Qi Pan Frontiers in Nutrition.2025;[Epub] CrossRef
The Unequal Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease in 204 Countries and Territories From 1990 to 2021 Junqiao Feng, Yudan Fan Liver International.2025;[Epub] CrossRef
Chronic Hepatitis B and MASLD: Growing Awareness and Unmet Clinical Needs Nicola Pugliese, Davide Polverini, Stefano Ciardullo Liver International.2025;[Epub] CrossRef
Multi‐Center, Multi‐Vendor Validation of Simultaneous MRI‐Based Proton Density Fat Fraction and R2* Mapping Using a Combined Proton Density Fat Fraction‐R2* Phantom Jitka Starekova, David Rutkowski, Won C. Bae, Hung Do, Ananth J. Madhuranthakam, Vadim Malis, Sheng Qing Lin, Suraj Serai, Takeshi Yokoo, Scott B. Reeder, Jean H. Brittain, Diego Hernando Journal of Magnetic Resonance Imaging.2025; 62(3): 800. CrossRef
Overcoming barriers to unlock the therapeutic potential of saroglitazar for the management of metabolic dysfunction-associated steatotic liver disease Murali Krishna Moka, Deepalaxmi Rathakrishnan, D.K. Sriram, Melvin George Clinical Nutrition.2025; 49: 52. CrossRef
Targeting Metabolism: Innovative Therapies for MASLD Unveiled Weixin Wang, Xin Gao, Wentong Niu, Jinping Yin, Kan He International Journal of Molecular Sciences.2025; 26(9): 4077. CrossRef
Psoriasis, metabolic syndrome and methotrexate: Is this association suitable for a new subcategory in steatotic liver disease? Luciana Agoglia, Maria Chiara Chindamo, Cristiane Villela-Nogueira World Journal of Hepatology.2025;[Epub] CrossRef
Evaluating the RESET care program: Advancing towards scalable and effective healthcare solutions for metabolic dysfunction-associated liver disease Mariana M Ramírez-Mejía, Froylan D Martínez-Sánchez, Jacqueline Córdova-Gallardo, Nahum Méndez-Sánchez World Journal of Hepatology.2025;[Epub] CrossRef
Association between glucose time-in-range and the severity of metabolic dysfunction-associated steatotic liver disease in Chinese adults with type 2 diabetes mellitus Chun-Hua Wang, Xuan-Yao Ji, Nian Ji, Qing-Feng Yan, Hong-Qing Xu, Xue-Qin Wang, Xiang-Fan Chen, Chun-Feng Lu BMC Endocrine Disorders.2025;[Epub] CrossRef
Gut microbiota in patients with metabolic, dysfunction-associated steatotic liver disease Lissette Duarte, Fabien Magne, Martin Gotteland Current Opinion in Clinical Nutrition & Metabolic Care.2025; 28(4): 307. CrossRef
Characteristics of serum bile acid profiles among individuals with metabolic dysfunction-associated steatotic liver disease Sheng Lyu, Jiani Yang, Xin Xin, Qinmei Sun, Beiyu Cai, Xin Wang, Ziming An, Jian Sun, Yiyang Hu, Lei Shi, Qin Feng, Xiaojun Gou BMC Gastroenterology.2025;[Epub] CrossRef
Harnessing nutrition to combat MASLD: a comprehensive guide to food-based therapeutic strategies Claudia Reytor-González, Daniel Simancas-Racines, Martín Campuzano-Donoso, Janeth Castano Jimenez, Náthaly Mercedes Román-Galeano, Gerardo Sarno, Evelyn Frias-Toral Food and Agricultural Immunology.2025;[Epub] CrossRef
Association between urinary albumin-to-creatinine ratio and all-cause and cardiovascular-cause mortality among MASLD: NHANES 2001–2018 Zhengjin Wang, Zhangxin Chen, Hanxu Zhuang Frontiers in Nutrition.2025;[Epub] CrossRef
Anthropometric Measures and Mortality Risk in Individuals With Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD): A Population‐Based Cohort Study Yee Hui Yeo, Yixuan Zhu, Jingli Gao, Shanghao Liu, Wenjing Ni, Fajuan Rui, Xue Bai, Nan Geng, Rui Jin, Elizabeth K. Speliotes, Chao Wu, Junping Shi, Xiaolong Qi, Vincent L. Chen, Philip N. Newsome, Jie Li Alimentary Pharmacology & Therapeutics.2025; 62(2): 168. CrossRef
Association of gut microbiota dietary index with metabolic dysfunction-associated steatotic liver disease: the mediating roles of inflammation and body mass index Yu Pu, Zongbiao Tan, Yanrui Wu, Suqi Zeng, Haodong He, Jixiang Zhang, Weiguo Dong Frontiers in Nutrition.2025;[Epub] CrossRef
Association of sarcopenia and physical activity on the severity of metabolic dysfunction-associated steatotic liver disease among United States adults: NHANES 2017 - 2018 Xiaodie Wei, Xiaohui Liu, Jinhan Zhao, Yang Zhang, Lixia Qiu, Jing Zhang Frontiers in Aging.2025;[Epub] CrossRef
Low carbohydrate and low-calorie diets reduce liver fat and lower brain glutamate and myo-inositol levels in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Andreana P. Haley, Jack Knight-Scott, Marie Caillaud, Isabelle Gallagher, Jessica Park, Yanrong Li, Tianyu Wang, Hirofumi Tanaka, Jeffrey D. Browning Metabolic Brain Disease.2025;[Epub] CrossRef
FGF21 reverses MASH through coordinated actions on the CNS and liver Jesse P. Rose, Donald A. Morgan, Andrew I. Sullivan, Xiaorong Fu, Melissa Inigo-Vollmer, Shawn C. Burgess, David K. Meyerholz, Kamal Rahmouni, Matthew J. Potthoff Cell Metabolism.2025; 37(7): 1515. CrossRef
Liver cirrhosis in metabolic dysfunction-associated steatohepatitis Donghyun Ko, Do Han Kim, Pojsakorn Danpanichkul, Masahito Nakano, Chitchai Rattananukrom, Karn Wijarnpreecha, Cheng Han Ng, Mark D Muthiah Gastroenterology Report.2025;[Epub] CrossRef
From liver to limb: Exploring the association between fatty liver disease and peripheral artery disease—A systematic review Vera Ciornolutchii, Abdulrahman Ismaiel, Jennifer Bogdan, Stefan‐Lucian Popa, Teodora Surdea‐Blaga, Dan L. Dumitrascu European Journal of Clinical Investigation.2025;[Epub] CrossRef
Developing and validating a predictive model for all-cause mortality in patients with metabolic dysfunction-associated steatotic liver disease Fan Zhang, Longgen Liu, Wenjian Li Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef
The Roles of T Cells in the Development of Metabolic Dysfunction‐Associated Steatohepatitis Zhifa Ge, Qingwei Wu, Chengyu Lv, Qifeng He Immunology.2025; 176(2): 145. CrossRef
Chronic Inflammation and Immune Dysregulation in Metabolic-Dysfunction-Associated Steatotic Liver Disease Progression: From Steatosis to Hepatocellular Carcinoma Young-Min Jee, Jeong-Yoon Lee, Tom Ryu Biomedicines.2025; 13(5): 1260. CrossRef
Pruritus and Fatigue in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Study of Turkish Patients From the Global NASH/MASH Registry Yusuf Yilmaz, Caglayan Keklikkiran, Andrei Racila, Maria Stepanova, Zobair M. Younossi Clinical and Translational Gastroenterology.2025; 16(6): e00844. CrossRef
Impact of Metabolic Dysfunction–associated Steatotic Liver Disease on Cardiovascular Structure, Function, and the Risk of Heart Failure Bhavik Bansal, Fannie Lajeunesse-Trempe, Neil Keshvani, Carl J. Lavie, Ambarish Pandey Canadian Journal of Cardiology.2025; 41(9): 1777. CrossRef
Pathogenesis and Treatment of Hepatocellular Carcinoma Associated with Nonalcoholic Steatohepatitis 舒惟 梁 Advances in Clinical Medicine.2025; 15(05): 2063. CrossRef
Prevalence of MASLD, Met-ALD, and ALD and Associated Fibrosis Among US Adults James M. Paik, Kathryn Hobbs, Amolika Gupta, Rand Jamal Alkalbani, Manuel Alexander Reyes, Zobair M. Younossi Journal of Clinical Gastroenterology.2025;[Epub] CrossRef
Association between weight fluctuation and the risk of metabolic dysfunction-associated steatotic liver disease Jin-Ping Wang, Jia-Yang Wang, Pei-Qi Sun, Xue-Wei Wang, Ze-Ting Yuan, Qin Cao, Shu-Ming Pan, Yuan-Ye Jiang World Journal of Hepatology.2025;[Epub] CrossRef
Increased prevalence and risk of atherosclerotic cardiovascular disease in individuals with Type 1 diabetes and metabolic dysfunction-associated steatotic liver disease Jonathan Mertens, Jonas Weyler, Eveline Dirinck, Luisa Vonghia, Wilhelmus J. Kwanten, Luc F. Van Gaal, Benedicte Y. De Winter, Sven Francque, Christophe De Block Cardiovascular Diabetology.2025;[Epub] CrossRef
The Significance of the Presence of Gilbert's Syndrome in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Retrospective Cohort Study Arjuna P De Silva, Krishanni Prabagar, Anuradha S Wickramasinghage, Aruni A Wanniarachchi, Dileepa S Ediriweera, Madunil A Niriella, Hithanadura J De Silva Cureus.2025;[Epub] CrossRef
GLP-1 and Glucagon Receptor Dual Agonists in the Management of Metabolic Dysfunction-associated Steatotic Disease (MASLD) Laura Pagès, Aina Martí-Carretero, Diego Rojo, Clara Sabiote, Farnaz Faninam, Sophia C. Parks, María Martínez-Gómez, M Serra Cusidó, Neda Akhlaghi, Sergio Muñoz-Martínez, Alba Jiménez-Masip, Juan M. Pericàs Current Hepatology Reports.2025;[Epub] CrossRef
Challenges in applying MASLD risk algorithms in pregnancy: A call for adaptation and inclusion Nina Rodriguez, Cecilia Katzenstein, Marcia Lange, Jeanette Rios, Tatyana Kushner, Rachel Meislin, Emma Rosenbluth, Carin Carroll, Theresa Worthington, Shaelyn O’Hara, Joanne Stone, Sonam Rosberger, Keith Sigel, Rhoda Sperling, Norah A. Terrault Journal of Hepatology.2025; 83(5): e236. CrossRef
Immunopathogenic mechanisms and immunoregulatory therapies in MASLD Yong He, Yingfen Chen, Shengying Qian, Schalk van Der Merwe, Debanjan Dhar, David A. Brenner, Frank Tacke Cellular & Molecular Immunology.2025; 22(10): 1159. CrossRef
Association between trans-palmitoleic acid and metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma: NHANES 1999–2018 Qirui Li, Luqi Zhan, Qian Li, Shuai Zhu, Shuaihui Liu, He Jiang, Jinlin Cheng, Lanjuan Li Frontiers in Nutrition.2025;[Epub] CrossRef
To sleeve or not to sleeve: Validation of liver transplantation with sleeve gastrectomy Linda W. Moore, Elizabeth W. Brombosz, R. Mark Ghobrial Journal of Hepatology.2025; 83(3): 625. CrossRef
Redefining Diagnosis and Management in Hepatology with Multiparametric Ultrasound Yolande Chalmers EMJ Hepatology.2025; : 66. CrossRef
Incretins and MASLD: at the Crossroads of Endocrine and Hepatic Disorders Marwin A. Farrugia, Enzo Pini, Albert Tran, Nicolas Chevalier, Rodolphe Anty, Philippe Gual Current Obesity Reports.2025;[Epub] CrossRef
Steatotic Liver Disease in Older Adults: Clinical Implications and Unmet Needs Daniel Clayton-Chubb, William W. Kemp, Ammar Majeed, Peter W. Lange, Jessica A. Fitzpatrick, Karl Vaz, John S. Lubel, Alexander D. Hodge, Joanne Ryan, John J. McNeil, Alice J. Owen, Robyn L. Woods, Stuart K. Roberts Nutrients.2025; 17(13): 2189. CrossRef
Metabolic dysfunction-associated steatotic liver disease is associated with the risk of severe liver fibrosis in pediatric population Wei Li, Lina Jiang, Meiling Li, Chen Lin, Li Zhu, Bokang Zhao, Yisi Liu, Yan Li, Yiyun Jiang, Shuhong Liu, Ping Liang, Junqi Niu, Jingmin Zhao Gastroenterology Report.2025;[Epub] CrossRef
Extracellular Vesicles as Biomarkers in Chronic Hepatobiliary Diseases: An Overview of Their Interplay Eleni Myrto Trifylli, Sotirios P. Fortis, Anastasios G. Kriebardis, Nikolaos Papadopoulos, Evangelos Koustas, Panagiotis Sarantis, Spilios Manolakopoulos, Melanie Deutsch International Journal of Molecular Sciences.2025; 26(13): 6333. CrossRef
Relationship between metabolic dysfunction-associated steatotic liver disease and sarcopenia: A systematic review and meta-analyses Ninglin Xia, Jiwei Wang, Qian Lu, Xue Fan, Zhenzhou Jiang, Qinwei Yu Clinical Nutrition ESPEN.2025; 68: 679. CrossRef
Time trends and health inequalities of cirrhosis caused by metabolic Dysfunction-associated steatotic liver disease from 1990 to 2021: A global burden of disease study Min Wu, Yifeng Li, Dong Liu, Weinong Wen, Yan Min, Qiang Su, Zhenxiang An, Xiaofang Yang Journal of Endocrinological Investigation.2025; 48(11): 2599. CrossRef
Therapeutic horizons in metabolic dysfunction–associated steatohepatitis Philip N. Newsome, Rohit Loomba Journal of Clinical Investigation.2025;[Epub] CrossRef
High Prevalence of Fatty Liver in Bangladeshi Adolescents and Young Adults with Type 2 Diabetes: Key Predictors and Screening Recommendations Kishore Shil, Mashfiqul Hasan, Nusrat Sultana, Sayad Salam, Syeda Mostafa, Muhammad Hasanat Diabetes, Metabolic Syndrome and Obesity.2025; Volume 18: 2019. CrossRef
Adipose Tissue Dysfunction and Hepatic Steatosis in New-Onset Diabetes Emilia Rusu, Mariana Jinga, Raluca Cursaru, Georgiana Enache, Adrian Costache, Ioana Verde, Andra Nica, Anca Alionescu, Florin Rusu, Gabriela Radulian Diabetology.2025; 6(7): 70. CrossRef
Food Nutrients and Bioactive Compounds for Managing Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comprehensive Review Erdenetsogt Dungubat, Kohei Fujikura, Masahiko Kuroda, Toshio Fukusato, Yoshihisa Takahashi Nutrients.2025; 17(13): 2211. CrossRef
Altered HDL Phospholipid and Fatty Acid Profile in MASLD: A Possible Explanation for the Increased CVD Risk Sofia Kartsoli, Christina E. Kostara, Athanasios Papathanasiou, Vasilis Tsimihodimos, Eleni T. Bairaktari, Dimitrios K. Christodoulou International Journal of Molecular Sciences.2025; 26(13): 6148. CrossRef
Pan-immune-inflammation value and mortality in the US adult MASLD: a nonlinear NHANES analysis Qing Zhou, Jisu Xue, Lu Hao BMC Gastroenterology.2025;[Epub] CrossRef
Association between body roundness index and risks of all-cause and cardiovascular mortality in adults with metabolic dysfunction-associated steatotic liver disease: NHANES 1999–2018 Yanshan Yi, Li Yang Frontiers in Nutrition.2025;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease: Mechanisms, metabolic reprogramming, and therapeutic insights Wan-Qi Yang, Ling-Ling Xue, Jing-Lin Wang World Journal of Gastroenterology.2025;[Epub] CrossRef
Steatosis non-invasive tests accurately predict metabolic dysfunction-associated steatotic liver disease, while fibrosis non-invasive tests fall short: Validation in U.S. adult population Ayesha Sualeheen, Sze-Yen Tan, Robin M. Daly, Ekavi Georgousopoulou, Gavin Abbott, Stuart K. Roberts, Jacob George, Elena S. George Clinics and Research in Hepatology and Gastroenterology.2025; 49(7): 102649. CrossRef
Quantitative US in Metabolic Dysfunction–Associated Steatotic Liver Disease Manjiri Dighe, Manish Dhyani Radiology.2025;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease and gastrointestinal cancer risk in youth: is it time to unveil a hidden link? Gianmario Forcina, Vittoria Frattolillo, Maria Grazia Fusco, Emanuele Miraglia Del Giudice, Anna Di Sessa Expert Review of Gastroenterology & Hepatology.2025; : 1. CrossRef
Metals in the human liver: An underappreciated risk factor of hepatic insulin resistance and associated pathophysiology Rahul Kumar, Ashwin Chinala, Dhruv Grandhe, S. Joseph Endicott, Marcus A. Garcia, Matthew J. Campen, Rama R. Gullapalli Environmental Pollution.2025; 383: 126844. CrossRef
La alimentación es pieza clave en la patogénesis de la enfermedad hepática esteatósica asociada a disfunción metabólica en la población pediátrica R. Vázquez-Frias Revista de Gastroenterología de México.2025; 90(3): 347. CrossRef
Non-invasive tests of fibrosis in the management of MASLD: revolutionising diagnosis, progression and regression monitoring Gong Feng, Vincent Wai-Sun Wong, Giovanni Targher, Christopher D Byrne, Ming-Hua Zheng Gut.2025; 74(10): 1741. CrossRef
Intestinal TM6SF2 and the gut-liver axis in MASLD: new insights Markos Kalligeros, Linda L. Henry, Zobair M. Younossi Metabolism and Target Organ Damage.2025;[Epub] CrossRef
The role of Bergamot Polyphenolic Fraction (BPF) in MASLD-Induced HFpEF: Mitigate diastolic dysfunction by targeting chronic low-grade inflammation Cristina Carresi, Antonio Cardamone, Vincenzo Musolino, Rocco Mollace, Annamaria Tavernese, Anna Rita Coppoletta, Micaela Gliozzi, Vincenzo Mollace Biomedicine & Pharmacotherapy.2025; 190: 118375. CrossRef
Nonlinear Association Between BMI and Depression Among Nonalcoholic Fatty Liver Disease: NHANES (2017–2018) Hui Peng, Dan Zhou, Yuan Dai, Weifeng Chen, Tauheed Ishrat Behavioural Neurology.2025;[Epub] CrossRef
Analysis of gastric electrical rhythm in patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus Xi-Xi Wang, Chun Yan, Su-Juan Wang, Hong Zhu, Chang-Chun Cao, Li Wu, Shuang Wang, Ji Hu, Hong-Hong Zhang World Journal of Hepatology.2025;[Epub] CrossRef
Gradual DNA methylation changes reveal transcription factors implicated in metabolic dysfunction-associated steatotic liver disease progression and epigenetic age acceleration Evelien Van Dijck, Steven Van Laere, Emilie Logie, Steven Timmermans, Erik Fransen, Joe Ibrahim, Timothy J. Kendall, Jonathan A. Fallowfield, Ligia M. Mateiu, Claude Libert, Guy Van Camp, An Verrijken, Luc Van Gaal, Sven Francque, Wim Van Hul, Wim Vanden Clinical Epigenetics.2025;[Epub] CrossRef
Physical Activity and Metabolic Disorders—What Does Gut Microbiota Have to Do with It? Aneta Sokal-Dembowska, Ewelina Polak-Szczybyło, Kacper Helma, Patrycja Musz, Maciej Setlik, Weronika Fic, Dawid Wachowiak, Sara Jarmakiewicz-Czaja Current Issues in Molecular Biology.2025; 47(8): 630. CrossRef
Optimal Vegetable Intake for Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD) Prevention: Insights from a South Italian Cohort Maria Noemy Pastore, Caterina Bonfiglio, Rossella Tatoli, Rossella Donghia, Pasqua Letizia Pesole, Gianluigi Giannelli Nutrients.2025; 17(15): 2477. CrossRef
Glucagon‐Like Peptide‐1 Receptor Agonists Improve MASH and Liver Fibrosis: A Meta‐Analysis of Randomised Controlled Trials Alessandro Mantovani, Riccardo Morandin, Veronica Fiorio, Maria Giovanna Lando, Norbert Stefan, Herbert Tilg, Christopher D. Byrne, Giovanni Targher Liver International.2025;[Epub] CrossRef
Discovery of Highly Potent, Selective, and Liver-Targeted THR-β Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis Ju Liang, Yipei Gu, Liuyu Hu, Hui Qu, Nana Li, Chaoyue Xia, Lei Feng, Li Qin, Li Hai, Yaxi Yang, Ying Leng, Bing Zhou Journal of Medicinal Chemistry.2025; 68(16): 17457. CrossRef
Adipokine and Hepatokines in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Current and Developing Trends Salvatore Pezzino, Stefano Puleo, Tonia Luca, Mariacarla Castorina, Sergio Castorina Biomedicines.2025; 13(8): 1854. CrossRef
Dietary Strategies in the Prevention of MASLD: A Comprehensive Review of Dietary Patterns Against Fatty Liver Barbara Janota, Karolina Janion, Aneta Buzek, Ewa Janczewska Metabolites.2025; 15(8): 528. CrossRef
Association of chronic kidney disease and type 2 diabetes mellitus with metabolic dysfunction-associated steatotic liver disease and liver fibrosis assessed by transient elastography: a cross-sectional study based on NHANES 2017–2020 Ting Xu, Weifang Zhu Diabetes Research and Clinical Practice.2025; 227: 112418. CrossRef
Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025) Shikha Patel, Sarfaraz K. Niazi Pharmaceutics.2025; 17(8): 1036. CrossRef
CircDock6 drives metabolic dysfunction–associated steatotic liver disease progression in mice and mouse hepatocytes via mmu-let-7g-5p/insulin-like growth factor 1 receptor regulation Hongpeng Lu, Xiaoyun Ding, Peifei Li Journal of International Medical Research.2025;[Epub] CrossRef
Multi-omics integration reveals the impact of mediterranean diet on hepatic metabolism and gut microbiota in mice with metabolic dysfunction-associated steatotic liver disease Zixuan Wang, Ge Chen, Xutong Sun, Jia Xiao, Lingling Kong, Shunshun Jiang, Tingting Xu, Meijiao Wang, Hong Zhao Frontiers in Nutrition.2025;[Epub] CrossRef
Amaranthus graecizans L. Mitigates Hyperlipidemia-Induced Nonalcoholic Fatty Liver Disease in Experimental Rats: Future Pharmaceuticals Nadiah S. Alzahrani, Bayan Aljahdali, Aeshah Alhosain, Abeer Abdullah Alasmari, Touseef Amna, Soha Mohamed Yousef Pharmaceuticals.2025; 18(8): 1196. CrossRef
Non-invasive biomarkers for monitoring portal hypertension in metabolic dysfunction-associated steatotic liver disease (MASLD) Shreya C. Pal, Mariana M. Ramírez-Mejía, Andrew P. Keaveny, Nahum Méndez-Sánchez Expert Review of Gastroenterology & Hepatology.2025; 19(9): 1021. CrossRef
Controlled Red Blood Cell Apheresis as a Pretreatment of Hepatic Peliosis Resection Surgery for Severe Polycythemia Secondary to Hepatic Peliosis in a Child Chun‐Xi Wu, Rong Fu, Jie Yan, Bin Zhang, Zhong‐Mei Yi, Qiang Zhang Pediatric Blood & Cancer.2025;[Epub] CrossRef
SGLT2 inhibitors and the risk of hepatocellular carcinoma in patients with MASLD and Type 2 diabetes Ruey-Shyang Soong, Wan-Ming Chen, An-Tzu Jao, Ming-Che Lee, Szu-Yuan Wu, Chih-Lang Lin Diabetes & Metabolism.2025; 51(6): 101698. CrossRef
MIND diet score and its association with metabolic dysfunction-associated steatotic liver disease and gut microbiota profiles: a cross-sectional study Shengbo Yang, Litao Zhang, Mingli Hu, Weina He Frontiers in Nutrition.2025;[Epub] CrossRef
Early Insights from Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Patients: An Observational Study on Polygenic Risk and Liver Biomarkers Pietro Torre, Benedetta Maria Motta, Tommaso Sarcina, Mariano Festa, Mario Masarone, Marcello Persico International Journal of Molecular Sciences.2025; 26(17): 8426. CrossRef
Higher Food Inflammation Index Is Linearly Associated With Higher Risk of MASLD: A Cross‐Sectional Study Based on the NHANES (1999–2020) Qingwan Yang, Xin Cai, Zhenghua Xiao Food Science & Nutrition.2025;[Epub] CrossRef
Metabolic Divergence Between MASLD and Metabolic Syndrome: Distinct Clinical Phenotypes and Risk Stratification Implications Mariana M. Ramírez‐Mejía, Sandra M. Barbalho, Guadalupe Ponciano‐Rodríguez, Mohammed Eslam, Jacob George, Ming‐Hua Zheng, Nahum Méndez‐Sánchez Liver International.2025;[Epub] CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease as a Risk Factor for Chronic Kidney Disease: A Narrative Review Marcelo do Rego Maciel Souto Maior, Nathália de Lacerda Interaminense Ribeiro, Hannah Vicentini Vitoriano Silva, Edmundo Pessoa Lopes, Emilia Chagas Costa Biomedicines.2025; 13(9): 2162. CrossRef
Mediation analysis of the molecular phenotypes in a severe MASH-like liver injury mouse model Zhuolin Song, Volodymyr P Tryndyak, Rose A Willett, Igor P Pogribny, Ivan Rusyn, Fred A Wright Toxicological Sciences.2025; 208(1): 155. CrossRef
Patatin-Like Phospholipase Domain-Containing Protein 3 (PNPLA3) rs738409 Variant and Non-Alcoholic Fatty Liver Disease Risk in Vietnamese Working-Age Adults: A Case-Control Study with Metabolic Insights Ha Nguyen, Duong Hoang Huy Le, Thinh Nguyen, Hung Cao Dinh, Tuan Nguyen Clinical and Experimental Gastroenterology.2025; Volume 18: 191. CrossRef
Narrative review of metabolic syndrome and its relationships with non-alcoholic fatty liver disease, gonadal dysfunction and obstructive sleep apnea Doha Reda Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease in patients with prediabetes and type 2 diabetes mellitus Armida N. Sasunova, Alexey A. Goncharov, Sergey V. Morozov, Vladimir I. Pilipenko, Vasily A. Isakov Terapevticheskii arkhiv.2025; 97(8): 689. CrossRef
Tirzepatide in metabolic dysfunction-associated steatotic liver disease and steatohepatitis: a novel star on the horizon? Amedeo Lonardo, Ralf Weiskirchen Exploration of Drug Science.2025;[Epub] CrossRef
Fecal Zonulin as a Non-Invasive Marker of Intestinal Permeability: Findings from a Prospective Cohort Study Naomi-Adina Ciurea, Cristina Monica Pantea, Paul Grama, Irina-Bianca Kosovski, Simona Bataga Medicina.2025; 61(9): 1527. CrossRef
Steatotic liver disease and cancer: from pathogenesis to therapeutic targets Zhihong Yang, Zhenjie Liu, Wanqing Liu, Xiaocheng Charlie Dong eGastroenterology.2025; 3(3): e100218. CrossRef
Increasing Acute Coronary Syndrome Mortality in Cirrhosis After a Period of Decline: A National Analysis of Temporal and Demographic Disparities Abdalhakim Shubietah, Ameer Awashra, Fathi Milhem, Mohammed AbuBaha, Maisam Tobeh, Abubakar Nazir, Mohamed S. Elgendy, Mohammad Bdair, Jehad Zeidalkilani, Hosam I. Taha, Anwar Zahran, Ahmed Emara, Suleiman Khreshi, Islam Rajab Catheterization and Cardiovascular Interventions.2025; 106(6): 3136. CrossRef
Prenatal Choline Attenuates the Elevated Adiposity and Glucose Intolerance Caused by Prenatal Alcohol Exposure Susan M. Smith, Carolyn A. Munson, George R. Flentke, Sandra M. Mooney Cells.2025; 14(18): 1429. CrossRef
THE CHANGING LANDSCAPE OF TRANSPLANT ONCOLOGY: OPPORTUNITIES AND CHALLENGES Emanuele Federico Kauffmann, Michael Ginesini, Allegra Ripolli, Paolo De Simone European Journal of Transplantation.2025; 3(1): 3. CrossRef
Clinical and Genetic Predictors of Non‐Alcoholic Steatotic Liver Disease and Fibrosis in Lean Individuals Karina Sato‐Espinoza, Robert A. Vierkant, Perapa Chotiprasidhi, Filippo Pinto e Vairo, Shulan Tian, Jun Ma, Daniel O'Brien, Konstantinos N. Lazaridis, Carola Dlugosch, Carolin Scheider, Alina M. Allen, Kirk J. Wangensteen Liver International.2025;[Epub] CrossRef
MASLD Under the Microscope: How microRNAs and Microbiota Shape Hepatic Metabolic Disease Progression Clelia Asero, Maria Stella Franzè, Irene Cacciola, Sebastiano Gangemi International Journal of Molecular Sciences.2025; 26(17): 8633. CrossRef
Diet is a key factor in the pathogenesis of metabolic dysfunction-associated steatotic liver disease in the pediatric population R. Vázquez-Frias Revista de Gastroenterología de México (English Edition).2025; 90(3): 347. CrossRef
Exploring the Role of Extra Virgin Olive Oil (EVOO) in MASLD: Evidence from Human Consumption Melvin Bernardino, Claudio Tiribelli, Natalia Rosso Nutrients.2025; 17(18): 2932. CrossRef
Refining the Classification of Steatotic Liver Disease: Beyond Self-Reported Alcohol Intake Won-Mook Choi Gut and Liver.2025; 19(5): 639. CrossRef
Immunonutrition: Another Player on the MASLD Field Iván López-Méndez, Misael Uribe, Eva Juárez-Hernández International Journal of Molecular Sciences.2025; 26(18): 8928. CrossRef
Extracellular RNAs in Liquid Biopsy: Applications in MASLD and MASH Diagnosis and Monitoring Dimitrios Raptis, Shiny Teja Kolli, Sonal Agarwal, Praveen Kumar Komminni, Prashamsha Bhattarai, Prinka Hablani, Rahul Kumar, Petras Das, Martin McIntosh, Michail Kladas, Priyanka Gokulnath, Michail Spanos Diagnostics.2025; 15(18): 2346. CrossRef
Diagnostic Performance of Fibrosis‐4 Index, Nonalcoholic Fatty Liver Disease Fibrosis Score, AST‐To‐Platelet Ratio Index, and BARD Score Among Young and Older Adults for the Diagnosis of Advanced MASLD Fibrosis: A Retrospective Cohort Study Frank Lin, Ayah Obeid, Mehak Sharma, Parampreet Kaur, Kimberly Chaput, Hammad Liaquat JGH Open.2025;[Epub] CrossRef
The Combination Empagliflozin/Metformin Attenuates the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease in a Diet-Induced Experimental Rat Model Oscar René Zambrano-Vásquez, Fernando Cortes-Camacho, Juan Carlos Cabrera-Angeles, Ana Lilia Hernández-Alba, Fernando Enrique García-Arroyo, Jorge Ismael Castañeda-Sánchez, Elena Aréchaga-Ocampo, Omar Emiliano Aparicio-Trejo, Leonardo Del Valle-Mondragón, International Journal of Molecular Sciences.2025; 26(18): 9010. CrossRef
Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial Metha Yaikwawong, Khanittha Kamdee, Somlak Chuengsamarn International Journal of Molecular Sciences.2025; 26(19): 9286. CrossRef
A Systematic Review and Meta-Analysis of Cannabis Use Frequency and Metabolic Dysfunction-Associated Steatotic Liver Disease: Scapegoat or Healer? Néstor Israel Quinapanta Castro, Abdel Bermúdez-del Sol Cureus.2025;[Epub] CrossRef
Cumulative Effect of Metabolic Factors on Hepatic Steatosis Anna Egresi, Brigitta Kozma, Márton Karácsony, Aladár Rónaszéki, Klára Werling, Barbara Csongrády, Pál Kaposi Novák, Anikó Folhoffer, Attila Szijártó, Krisztina Hagymási Diagnostics.2025; 15(18): 2406. CrossRef
A non-apoptotic caspase-8–meteorin pathway in hepatocytes promotes MASH fibrosis Xiaobo Wang, Mary P. Moore, Hongxue Shi, Yang Xiao, Jiayu Zhang, Lanuza A. P. Faccioli, Zhiping Hu, Shareef Khalid, Danish Saleheen, Dwayne G. Stupack, Tatiana Kisseleva, Alejandro Soto Gutierrez, Mitchell A. Lazar, Ira Tabas Nature Metabolism.2025; 7(10): 2067. CrossRef
The impact of aging on liver health and the development of liver diseases Sha Neisha Williams, Wen-Xing Ding Hepatology Communications.2025;[Epub] CrossRef
Timosaponin AIII from Anemarrhena asphodeloides binds and inhibits S100A8-mediated neutrophil infiltration and NET formation ameliorates MASH Yunfan Bai, Jingxin Ju, Ruishi Xie, Jing Li, Xinyi Zhao, Xiaoxue Fang, Ming Zhu, Xintian Lan, Haoming Luo International Immunopharmacology.2025; 166: 115539. CrossRef
Clinacanthus nutans leaf extract prevents metabolic dysfunction-associated steatotic liver (MASL) to metabolic dysfunction-associated steatohepatitis (MASH) progression in western diet-fed C57BL/6 mice Nurina Hasanatuludhhiyah, Arifa Mustika, Viskasari Pintoko Kalanjati, Muhammad Miftahussurur, Hirokazu Wakuda, Naoto Uemura Pharmacia.2025; 72: 1. CrossRef
The role of hypothalamus in the pathophysiological process of MASLD and advances in drug discovery Shizhang Wei, Yuan Dong, Yanping Wang, Guohui Li, Yanling Zhao, Ruimao Zheng Pharmacological Research.2025; 221: 107972. CrossRef
BMI mediates the association of CALLY index with liver steatosis and fibrosis Si-Hua Wen, Tao Tang, Zheng-Rong Ye Scientific Reports.2025;[Epub] CrossRef
Era of metabolic dysfunction-associated steatotic liver disease and impact on the liver donor pool Juanita Pérez-Escobar, Aline Huerta-Álvarez, Graciela Elia Castro-Narro, María Isabel Astudillo-Delgado, Paulina Carpinteyro-Espin World Journal of Gastroenterology.2025;[Epub] CrossRef
Editorial: Metabolic dysfunction-associated steatotic liver disease (MASLD) - pathogenesis, prevention and treatment Stanisław Surma, Łukasz Bułdak Frontiers in Endocrinology.2025;[Epub] CrossRef
Comment on ‘Association Between Handgrip Strength and Cardiovascular Disease Risk in MASLD: A Prospective Study From UK Biobank’ by T. S. Lim et al.—Authors' Reply Tae Seop Lim, Sujin Kwon, Sung A Bae, Hye Yeon Chon, Seol A. Jang, Ja Kyung Kim, Chul Sik Kim, Seok Won Park, Kyoung Min Kim Journal of Cachexia, Sarcopenia and Muscle.2025;[Epub] CrossRef
Advances in understanding the mechanism of noncoding RNA (ncRNA)-mediated regulation of macrophage polarization in NAFLD Chang Ge, Yi Yuan, Xiaoning Li, Jianmin Zhang, Jitao Ling, Xuehong Zheng, Yuting Wu, Xin Huang, Pingping Yang, Xiao Liu, Deju Zhang, Jianping Liu, Jing Zhang, Peng Yu Biochemical Pharmacology.2025; 242: 117372. CrossRef
Association of serum trace elements with non-invasive fibrosis scores in metabolic dysfunction-associated steatotic liver disease Erfan Banisefid, Sahand Karkon Zonouzi, Sina Hamzehzadeh, Zeinab Nikniaz, Seyedehyasmin Moghaddamziabari, Leila Alizadeh Scientific Reports.2025;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease: epidemiological trends, risk factors, and the role of gut microbiota in disease progression (a literature review) А.А. Antoniv, L.V. Kanovska, O.V. Kaushanska, Yu.M. Yarinich INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2025; 21(6): 656. CrossRef
Preventing false positive imaging diagnosis of HCC: differentiating HCC from mimickers and practical strategies Ijin Joo Journal of Liver Cancer.2025; 25(2): 217. CrossRef
Real-World Lifestyle Interventions are a Practical Model to Improve Liver Stiffness Christopher Kasia, Mary Rinella Journal of Clinical and Experimental Hepatology.2025; 15(6): 103201. CrossRef
The effects of different exercise intensities on body composition and cardiovascular risk indicators in children with metabolic syndrome: a RCT network meta-analysis Yimin Hu, Juan Ouyang, Yi Xia, Yi Sheng BMC Sports Science, Medicine and Rehabilitation.2025;[Epub] CrossRef
Sterile inflammation in MASH: emerging role of extracellular RNA and therapeutic strategies Sana Raza, Rukshana Mahamood, Pratik Medhe, Ambuj Shahi, Abhishek Yadav, Archana Tewari, Rohit A. Sinha npj Metabolic Health and Disease.2025;[Epub] CrossRef
Obesity-Driven Metabolic Disorders: The Interplay of Inflammation and Mitochondrial Dysfunction Wooyoung Choi, Gun Ha Woo, Tae-Hwan Kwon, Jae-Han Jeon International Journal of Molecular Sciences.2025; 26(19): 9715. CrossRef
Immunosenescence and metabolic reprogramming in MASLD: an age-dependent immunometabolic vicious cycle and therapeutic opportunities Yuxin Xu, Qiuxiang Li, Xuehua Jiao Frontiers in Cell and Developmental Biology.2025;[Epub] CrossRef
Sex Hormones and Metabolic Dysfunction-Associated Steatotic Liver Disease Ralf Weiskirchen, Amedeo Lonardo International Journal of Molecular Sciences.2025; 26(19): 9594. CrossRef
Comparative effectiveness of GLP-1 receptor agonists and dual agonists in the treatment of patients with metabolic dysfunction associated steatohepatitis: a systematic review and meta-analysis Meng Li, Jianli Hu, Yip Han Chin, Han Shi Jocelyn Chew, Wenru Wang Frontiers in Endocrinology.2025;[Epub] CrossRef
Investigation of the Effect of Isotonic Drinks on Quantitative MRI Markers of the Liver and Spleen Natassa N. Pittas, Michael Pavlides, Ferenc E. Mózes NMR in Biomedicine.2025;[Epub] CrossRef
Physiological roles of phosphoinositides and inositol phosphates: Implications for metabolic dysfunction-associated steatotic liver disease Zhili Cheng, Magdalene K Montgomery Clinical Science.2025; 139(19): 1095. CrossRef
Naringin mitigates liver damage in a tissue-engineered liver of metabolic dysfunction-associated steatotic liver disease model by promoting autophagy via the mTOR-ULK1 pathway Jihui Jia, Yizhi Zhang, Jing Lin, Zhongping Duan, Yu Chen, Xiaohui Zhang Molecular Biology Reports.2025;[Epub] CrossRef
Dietary supplementation with a designer metabolic modulator improves MASLD and associated anxiety in mice Agnese Segala, Gaia Favero, Emanuela Bottani, Alice Vetturi, Emirena Garrafa, Edoardo Parrella, Chiara Ruocco, Maurizio Ragni, Rita Rezzani, Enzo Nisoli, Alessandra Valerio Frontiers in Pharmacology.2025;[Epub] CrossRef
From Steatosis to Immunosenescence: The Impact of Metabolic Dysfunction on Immune Aging in HIV and Non-HIV Populations Carlo Acierno, Maria Frontuto, Giulio Francesco De Stefano, Ana Erezanu, Andrea Limone, Simona Morella, Francesco Picaro, Donatella Palazzo, Michele Gilio Biomedicines.2025; 13(10): 2513. CrossRef
Linear association between the composite dietary antioxidant index and the prevalence of sarcopenia in metabolic dysfunction-associated steatotic liver disease Jue Zhang, Huan Shi Lipids in Health and Disease.2025;[Epub] CrossRef
Research trends on the quality of life in patients with metabolic dysfunction-associated fatty liver diseases: a scientific metrology study Can Huang, Meng Chen, Yanfang Sun, Lin Zhang, Wei Liu Frontiers in Nutrition.2025;[Epub] CrossRef
2025 Clinical Practice Guidelines for Diabetes: Management of Metabolic Dysfunction-Associated Steatotic Liver Disease Jaehyun Bae The Journal of Korean Diabetes.2025; 26(3): 172. CrossRef
Pharmacotherapy of the metabolically associated fatty liver disease E.E. Mulyukova, E.L. Novikova, I.A. Skirdov, K.S. Usmanova, N.V. Yusifzade Russian Journal of Preventive Medicine.2025; 28(10): 103. CrossRef
Proton Density Fat Fraction and Its Role in Prediction of Metabolic Dysfunction Scott B. Reeder, Jitka Starekova Radiology.2025;[Epub] CrossRef
Coffee and Tea Intake Is Inversely Associated With Hepatic Fat Deposition, Iron Deposition, and Fibroinflammation in the General Population Zhuoshuai Liang, Xiaoyue Sun, Huizhen Jin, Wenhui Gao, Xinmeng Hu, Yi Cheng, Jikang Shi, Yawen Liu Molecular Nutrition & Food Research.2025;[Epub] CrossRef
Hydroxytyrosol Improves Metabolic Dysfunction-Associated Fatty Liver Disease Dependent on the Modulation of Gut Microbiota Yuji Xiao, Xue Zhang, Bing Shao, Ziyi Wu, Xiao Li, Dongxin Yi, Tao Li, Tao Yang, Jiaxin Zhu, Tiecheng Huang, Yixue Deng, Tianming Qiu, Guang Yang, Xiance Sun, Ningning Wang Journal of Agricultural and Food Chemistry.2025; 73(43): 27450. CrossRef
Hepatocellular carcinoma: modern aspects of interdisciplinary management. Part 1. Epidemiology, risk factors, diagnosis Yu.M. Stepanov, N.Yu. Zavhorodnia, O.M. Vlasova GASTROENTEROLOGY.2025; 59(3): 206. CrossRef
CT-Based Radiomic Models in Biopsy-Proven Liver Fibrosis Staging: Direct Comparison of Segmentation Types and Organ Inclusion Andreea Mihaela Morariu-Barb, Tudor Drugan, Mihai Adrian Socaciu, Horia Stefanescu, Andrei Demirel Morariu, Monica Lupsor-Platon Diagnostics.2025; 15(21): 2671. CrossRef
Liver-Related COVID-19 Consequences: Dynamics of Liver Health in 2.5 Years Ieva Vanaga, Oksana Kolesova, Aleksandrs Kolesovs, Maija Radzina, Davis Simanis Putrins, Jelena Egle, Sniedze Laivacuma, Jelena Storozenko, Ludmila Viksna Journal of Clinical Medicine.2025; 14(21): 7604. CrossRef
Metabolic dysfunction–associated steatotic liver disease alters brain function and behavior: Insights from liver-targeted siRNA therapy Teresa Cardoso Delgado, Celia Martín-Cuevas, Ana C. Sánchez Hidalgo, Antonio Gil Gómez, Claudia M. Rejano Gordillo, Jon Landa, Rocío Gallego Durán, Naroa Goikoetxea-Usandizaga, Irene González-Recio, Clàudia Gil-Pitarch, L. Estefanía Zapata-Pavas, Jon Ande Science Advances.2025;[Epub] CrossRef
Association of Diet Quality, Dietary Acid Load, and Dietary Antioxidant Index With Cardiometabolic and NAFLD Risk Factors Among Patients With Metabolic Syndrome: A Cross‐Sectional Study Bijan Ghobadian, Seyedeh Atiye Shahrokhi, Saman Rezaei Talabon, Vahid Notash, Fatemeh Maleki Sedgi, Mehran Rahimlou Food Science & Nutrition.2025;[Epub] CrossRef
Quantitative Approaches to Accelerate MASH Drug Discovery and Development Yasmeen Abouelhassan, Shailendra Tallapaka, Ramin Mehrani, Scott Q. Siler, Li Qin, Zeyuan Wang, Maria E. Trujillo Clinical Pharmacology & Therapeutics.2025; 118(6): 1378. CrossRef
Mitochondrial transplantation and platelet rich plasma for the treatment of non-alcoholic fatty liver disease Manuel Alejandro Vargas-Vargas, Marcela González-Montoya, Olin Torres-Isidro, Omar Ortiz-Avila, Elizabeth Calderón-Cortés, Christian Cortés-Rojo World Journal of Hepatology.2025;[Epub] CrossRef
Repurposing levothyroxine for managing metabolic dysfunction-associated steatotic liver disease Leonidas H. Duntas, Stergios A. Polyzos, Ulrike Gottwald-Hostalek, Bogumila Urgatz, Paul M. Yen Endocrine.2025; 90(3): 1043. CrossRef
Genetic polymorphisms associated with metabolic dysfunction-associated steatotic liver disease and cardiometabolic risk susceptibility in the Chinese Han population Mingjia Dai, Yan Li, Jing Zhang, Yuhua Ruan, Ye Liu, Jungui Hao, Fang Ji, Xuebing Yan Human Genomics.2025;[Epub] CrossRef
Lipid-lowering mechanism of Swietenia macrophylla king leaves through SREBP-1c/FASN axis and RNA sequencing validation Yingwei Liu, Yunpeng Sun, Ting Zhou, Xiao Huang, Guokai Wang, Lijuan Sun Food Bioscience.2025; 74: 107860. CrossRef
Reconsidering Cardiovascular Risk Assessment in Patients With MASLD Ming Hou Liver International.2025;[Epub] CrossRef
From steatosis to cirrhosis: the role of obesity in the progression of liver disease Klaudia Nowak, Maria Paluch, Maja Cudzik, Klaudia Syska, Wiktoria Gawlikowska, Jakub Janczura Journal of Diabetes & Metabolic Disorders.2025;[Epub] CrossRef
Triglyceride-cholesterol-body weight index associated with the risk of metabolic dysfunction-associated steatotic liver disease: a population-based cross-sectional study Li Fan, Yongkang Su, Yue Chen, Ling Xu, Hairong Huang, Chunsheng Lu, Jia Peng, Yingbin Sun, Min Jia Frontiers in Nutrition.2025;[Epub] CrossRef
Human genetics of steatotic liver disease: insights into insulin resistance and lipid metabolism Rosellina M. Mancina, Luca Valenti, Stefano Romeo Nature Metabolism.2025; 7(11): 2199. CrossRef
The transition from NAFLD to MASLD: implications for Diagnosis, Prognosis, and Clinical Management Carlo Acierno, Riccardo Nevola, Fannia Barletta, Katarzyna Zielińska, Luca Rinaldi, Ferdinando Carlo Sasso, Caterina Conte, Luigi Elio Adinolfi, Alfredo Caturano Exploration of Medicine.2025;[Epub] CrossRef
The effects of salvia hispanica (chia seeds) on insulin sensitivity, hematological inflammatory indices and liver function in obese patients with non-alcoholic fatty liver disease (NAFLD) Sara Arefhosseini, Maryam Parimi, Helda Tutunchi, Mehrangiz Ebrahimi-Mameghani Nutrition & Metabolism.2025;[Epub] CrossRef
Prevalence and Risk Factors of Metabolic Dysfunction–Associated Steatotic Liver Disease in Patients With Type 2 Diabetes Mellitus at a Tertiary Center in Saudi Arabia: Cross-Sectional Questionnaire Study Abdulrahman M Elnasieh, Mohammed Almesned, Akram N Al Hazmi, Atheer Alturki, Faisal I Alhawaidi, Razan K Alhadlq, Maryam Alramadhan, Nasser Alobilan, Yasser Sheikh Qroosh JMIR Diabetes.2025; 10: e77772. CrossRef
Differentiating MASL and MASH: Clinical Insights from Comparative Case Reports in MASLD Chang-Gue Son The Journal of Internal Korean Medicine.2025; 46(4): 954. CrossRef
Multi-omics analysis elucidates the therapeutic mechanisms of the Quzhi formula in metabolic dysfunction-associated steatohepatitis targeting gut microbiota, lipid metabolism, and the role of its metabolite fraxin Jiao-Xiang Wu, Yue-Lan Wu, Mei-Fang Li, Nian Liu, Ying Liu, Yan-Ping Huang, Yuan Gan, Xiao-Yu Wang, Hai-Sheng Chai, Jin Xu, Qian Xi, Xi-Rong Guo, Hui-Ming Sheng, Ting-Ting Shen, Qin Zhang Frontiers in Pharmacology.2025;[Epub] CrossRef
Implications of the Liver-Gut Axis in Liver Disease: From Mechanisms to Therapeutic Targets Mariana M. Ramírez-Mejía, Guadalupe Ponciano-Rodríguez, Nahum Méndez-Sánchez Archives of Medical Research.2025; 56(8): 103335. CrossRef
Herbal Medicine for Metabolic Dysfunction-Associated Steatotic Liver Disease: Clinical Effectiveness and Research Trends - A Systematic Review and Meta-Analysis Min-jo Seo, Su-na Park, Ji-won Lee, So-rim Kim, Jin-hyun Kim, Min-ji Sun, Geon-sik Kong, Yo-sup Choi The Journal of Internal Korean Medicine.2025; 46(4): 774. CrossRef
Primary Human Tissue Models for Metabolic Dysfunction‐Associated Liver Disease ‐ toward Streamlining Drug Discovery with Patient‐Derived Assays Sonia Youhanna, Nayere Taebnia, Yingxin Liang, Ningtao Cheng, Yi Wang, Maurice Michel, Volker M. Lauschke Advanced Biology.2025;[Epub] CrossRef
The Impact of Liraglutide on Patients With Metabolic Dysfunction–Associated Steatotic Liver Disease Jae Eun So, Jaehong Jeong, Jung Pyo Hong, Dong Yun Kim, Jae Seung Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Hye Won Lee, Seung Up Kim Journal of Gastroenterology and Hepatology.2025; 40(12): 2976. CrossRef
Remnant cholesterol, low-density lipoprotein cholesterol and atherosclerotic cardiovascular disease in metabolic dysfunction-associated steatotic liver disease: a cohort study Di Zhou, Mengge Zhou, Shuohua Chen, Chenlu Yang, Yanhong Wang, Yang Zhou, Shutong Wu, Shouling Wu, Li Wang Lipids in Health and Disease.2025;[Epub] CrossRef
Effects of long working hours on metabolic dysfunction-associated steatotic liver disease, with and without increased alcohol intake, in healthy workers: A 10-year cohort study Yesung Lee, Woncheol Lee, Anna Di Sessa PLOS One.2025; 20(11): e0336569. CrossRef
Association between longitudinal weight change and clinical outcome in individuals with MASLD Yu Shi, Ruoqi Zhou, Seung Up Kim, Terry Cheuk-Fung Yip, Emmanuel Tsochatzis, Salvatore Petta, Atsushi Nakajima, Hannes Hagström, Elisabetta Bugianesi, Wah-Kheong Chan, Jérôme Boursier, Boon-Bee George Goh, Arun J. Sanyal, Manuel Romero-Gomez, José Luis Ca Hepatology.2025;[Epub] CrossRef
Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study Mazen Noureddin, Stephen A Harrison, Rohit Loomba, Naim Alkhouri, Naga Chalasani, Muhammad Y Sheikh, Shaheen Tomah, Julio A Gutierrez, Silvia Urbina, John J Suschak, Randy Brown, Ozioma Odili, Jay Yang, Stephine Keeton, Guy Neff, Edward Mena, M Scot Rober The Lancet.2025; 406(10520): 2644. CrossRef
Impact of Metabolic Dysfunction-Associated Steatotic Liver Disease on Fatigue and Pruritus in Primary Sclerosing Cholangitis: A U.S. Single-Center Study Natalia Rojas-Amaris, Ana Marenco-Flores, Carmen Lara-Romero, Romelia Barba, Denisse Rubio-Cruz, Ximena Parraga, Daniela Goyes, John Esli Medina-Morales, Leandro Sierra, Manuel Romero-Gomez, Michelle Lai, Behnam Saberi, Vilas Patwardhan, Alan Bonder Journal of Clinical Medicine.2025; 14(22): 8083. CrossRef
Personalized management of metabolic dysfunction-associated steatotic liver disease Zhen Sun, Kui Ming Chan, Haojie Jin iLIVER.2025; 4(4): 100207. CrossRef
Beyond Discrete Diagnoses: Conceptualizing Obesity-associated Metabolic Disorders as a Unified, Dynamic Continuum Cong Xie, Yulian Yuan, Yunjing Wang, Cong Qi, Wei Wang, Chuan An, Aifeila Aikepaer, Yaofu Zhang, Ge Zhang, Xingzhong Feng, Huijuan Gao Current Obesity Reports.2025;[Epub] CrossRef
Immunotherapy versus lenvatinib in advanced hepatocellular carcinoma: The critical role of subgroup analyses Tingfeng Huang, Jia-Hao Law, Ningqi Pang, Shichuan Tang iLIVER.2025; 4(4): 100208. CrossRef
Plasma Extracellular Vesicles Contain Protein Biomarkers for Capturing Stages of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Preliminary Exploratory Study Yakun Li, Koen C. van Son, Sandra Serna-Salas, Justina C. Wolters, Nienke P. M. Wassenaar, Stan Driessen, Anne Linde Mak, Anne-Marieke van Dijk, Veera A. T. Houttu, Julia J. Witjes, Diona Zwirs, Michail Doukas, Joanne Verheij, Robin P. F. Dullaart, Hans B Biomolecules.2025; 15(11): 1596. CrossRef
Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD): Mechanisms, Clinical Implications and Therapeutic Advances Dalia M. Miller, Kiana F. McCauley, Kimberly J. Dunham‐Snary Endocrinology, Diabetes & Metabolism.2025;[Epub] CrossRef
Liver Transplantation in the Era of Metabolic Dysfunction–Associated Fatty Liver Disease: Challenges, Ethical Dilemmas, and Future Directions Said A. Al-Busafi, Mohammed Eslam Transplantology.2025; 6(4): 35. CrossRef
The albumin-to-creatinine ratio predicts and explores potential mediation of mortality in metabolic dysfunction-associated steatotic liver disease in U.S. adults: evidence from NHANES 1999–2018 Huanjie Zhou, Hao Huang, Huiliu Zhao, Naiqi Pang, Meifang Huang, Chao Ou, Ming Lao BMC Gastroenterology.2025;[Epub] CrossRef
Signatures of proteomics and glycoproteomics revealed liraglutide ameliorates MASLD by regulating specific metabolic homeostasis in mice Yuxuan Chen, Chendong Liu, Qian Yang, Jingtao Yang, He Zhang, Yong Zhang, Yanruyu Feng, Jiaqi Liu, Lian Li, Dapeng Li Journal of Pharmaceutical Analysis.2025; 15(11): 101273. CrossRef
К эпидемиологии жировой болезни печени, связанной с метаболической дисфункцией (систематический обзор литературы)
Вера Людвиговна Грицинская, Валерия Павловна Новикова Children's medicine of the North-West.2025; 13(3): 108. CrossRef
The shifting burden of gastrointestinal and liver diseases in Southeast Asia and effective control strategies
An umbrella meta-analysis of microbial therapy on hepatic steatosis, fibrosis, and liver stiffness in metabolic dysfunction-associated steatotic liver disease Gvzalnur Kurban, Xiangjun Chen, Xingyi Jin, Hui Xia, Shaokang Wang, Guiju Sun Frontiers in Nutrition.2025;[Epub] CrossRef
Linking bisphenol a exposure to MASLD: insights from network toxicology and machine learning based on NHANES 2005–2012 data Jiaquan Yuan, Haoyang Xu, Junhong Gan, Haiyan Zhao Toxicology Research.2025;[Epub] CrossRef
Curcumin and Tetrahydrocurcumin as Multi-Organ Modulators of the Adipose Tissue–Gut–Liver Axis: Mechanistic Insights, Therapeutic Potential, and Translational Challenges Marina Konaktchieva, Radoslav Stojchevski, Nikola Hadzi-Petrushev, Hristo Gagov, Rositza Konakchieva, Vadim Mitrokhin, Gjoko Kungulovski, Mitko Mladenov, Dimiter Avtanski Pharmaceuticals.2025; 18(12): 1791. CrossRef
Ten-Year Atherosclerotic Cardiovascular Disease Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Separate Analyses from Romanian and Italian Cohorts Integrating Metabolic, Hepatic, and Gut–Liver Axis Markers Naomi-Adina Ciurea, Cristina Monica Pantea, Paul Grama, Irina-Bianca Kosovski, Ilaria Farella, Simona Bataga, Agostino Di Ciaula, Piero Portincasa Journal of Clinical Medicine.2025; 14(23): 8361. CrossRef
Ultra-processed food consumption and the risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD): a five-year prospective cohort study in Iranian adults Omid Emami, Ali Nikparast, Matin Sepehrinia, Saeid Hadi, Jalaledin Mirzay Razzaz, Reza Homayounfar Journal of Health, Population and Nutrition.2025;[Epub] CrossRef
MASLD: Lipotoxicity and Imaging Parallels from Liver Steatosis to Kidney Injury Sarmis Marian Săndulescu, Denisa Ștefania Ghiga, Diana Rodica Tudorașcu, Daniela Larisa Săndulescu, Adrian Mită, Marinela Cristiana Urhuț, Citto-Iulian Taisescu Life.2025; 15(12): 1805. CrossRef
NAD + in fatty liver disease: mechanistic insights and associated targets Yaxin Guo, Yuting Wang, Shiran Wu, Yong Wang, Xinde Liu Cell Biology and Toxicology.2025;[Epub] CrossRef
The impact of high fructose corn syrup on liver injury and glucose metabolism: a systematic review Zane Z. Yu, Sneha Varahala, Sean L. C. Lim, Maimuna C. Marenah, Julia Wattacheril Frontiers in Nutrition.2025;[Epub] CrossRef
Association Between Subclinical Hypothyroidism and MASLD: A Systematic Review and Meta‐Analysis Gedion Yilma Amdetsion, Chun-Wei Pan, Hiwot Tebeje, Abhin Sapkota, Shreyas Nandyal, Vikram Kotwal, Fortofoiu Mircea-Catalin International Journal of Hepatology.2025;[Epub] CrossRef
Roles of short-chain fatty acids in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis Chun-Ye Zhang, Shuai Liu, Yu-Xiang Sui, Ming Yang World Journal of Hepatology.2025;[Epub] CrossRef
Liver fibrosis index and mortality in metabolic dysfunction–associated steatotic liver disease: a Korean cohort study Yesung Lee, Woncheol Lee Scientific Reports.2025;[Epub] CrossRef
Macrophage-tregs crosstalk: the “hub” of the immune network in MASLD Huihui Zhao, Weili Wang, Pengchao Zhu, Zhaohong Shi Frontiers in Immunology.2025;[Epub] CrossRef
Proteolysis targeting chimera degraders target pseudokinases to treat metabolic dysfunction-associated steatohepatitis and fibrosis: Mechanisms and therapeutic insights Yibing Wang, Jiajing Peng Pharmacological Research.2025; 222: 108054. CrossRef
Metabolic dysfunction-associated steatotic liver disease is associated with androgenetic alopecia in adults with stronger effects in women and unhealthy lifestyles Sina Bazmi, Mohammad Saeed Soleimani-Meigoli, Mohammadreza Fardaei, Zahra Mohammadi, Reza Homayounfar, Maryam Kazemi, Babak Pezeshki, Mojtaba Farjam Scientific Reports.2025;[Epub] CrossRef
Nutritional and Fasting Strategies for the Management of MASLD/MASH: An Integrative Review Diya Tawk, Ghalia Ghader, Yasmina Khatib, Philippe Attieh, Tya Youssef, Mahmoud Othman, Frederic Harb, Sami Azar, Hilda E. Ghadieh JGH Open.2025;[Epub] CrossRef
Effects of glucagon-like peptide-1 receptor agonists on patients with metabolic dysfunction-associated steatohepatitis: protocol for a systematic review and sequential meta-analysis Mei-jun Wang, Yu-nuo Jiang, Pei-pei Li, Yuan-jie Wu Systematic Reviews.2025;[Epub] CrossRef
A network meta-analysis of the clinical efficacy of different dietary patterns in the treatment of adult metabolic dysfunction-associated steatotic liver diseases Diwen Yu, Peipei Yu, Wanting Huang, Pengwei Zhang, Li Li Clinical Nutrition Open Science.2025; 64: 357. CrossRef
Synergistic Impact of Sarcopenia and T2DM on Mortality in Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) Qi Zhou, Peiyan Liu, Lixiang Li, Tengfei Yin, Hao Bai, Yanqing Li The FASEB Journal.2025;[Epub] CrossRef
Early-Life Nutritional Determinants of Pediatric MASLD Johanna K. DiStefano Nutrients.2025; 17(24): 3871. CrossRef
From liver to gut: the hidden gastrointestinal impact of pediatric metabolic dysfunction-associated steatotic liver disease Gianmario Forcina, Vittoria Frattolillo, Maria De Cesare, Assunta Floriano, Rosamaria Palma, Federica Casamassima, Mario Bartiromo, Pierluigi Marzuillo, Emanuele Miraglia del Giudice, Anna Di Sessa Expert Review of Gastroenterology & Hepatology.2025; 19(12): 1329. CrossRef
The association of multiple metabolic disorders with the severity of fasting blood glucose and hepatic steatosis in a Chinese population with MAFLD: a cross-sectional study of over 3000 participants Xue Qu, Shanshan Jin, Yuqing Shi, Weisong Zhang, Delong Cong, Yangyang Liu Scientific Reports.2025;[Epub] CrossRef
Changes in liver enzymes and cardiometabolic markers in individuals with obesity and metabolic-dysfunction-associated steatohepatitis treated with semaglutide Husam Albarmawi, Firas Dabbous, Abdalla Aly, Alia Yousif, Samuel Huse, Maximilian Jara, Andres Quintero, Eric Lawitz Current Medical Research and Opinion.2025; 41(11): 2089. CrossRef
Cross-sectional and longitudinal associations between fatty liver index and kidney function using updated MASLD and CKD–EPI 2021 definitions: a population-based study with region-specific cutoffs Sina Bazmi, Mohammadreza Fardaei, Reza Homayounfar, Maryam Kazemi, Babak Pezeshki, Reza Malekzadeh, Nasrollah Ghahramani, Mojtaba Farjam European Journal of Medical Research.2025;[Epub] CrossRef
The Impact of the Mediterranean Diet, Physical Activity, and Nutrition Education on Pediatric Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Review Melvin Bernardino, Claudio Tiribelli, Natalia Rosso Nutrients.2025; 18(1): 28. CrossRef
Machine learning-based model for predicting metabolic dysfunction-associated steatotic liver disease using non-invasive parameters in young adults Kyungchul Song, Yu-Jin Kwon, Eunju Lee, Young Hoon Youn, Su Jung Baik, Hye Sun Lee, Hyun Wook Chae Frontiers in Endocrinology.2025;[Epub] CrossRef
Soft drink consumption and liver fibrosis in type 2 diabetes Arianna Ferro, Martina Bollati, Gian Paolo Caviglia, Angelo Armandi, Stefania Bellini, Selene Limoncelli, Giulio Mengozzi, Federica Barutta, Fabio Broglio, Guglielmo Beccuti, Elisabetta Bugianesi, Marilena Durazzo, Gabriella Gruden Frontiers in Nutrition.2025;[Epub] CrossRef
Artificial intelligence applications for managing metabolic dysfunction-associated steatotic liver disease: Current status and future prospects Jian-Jun Lou, Jing Zeng World Journal of Gastroenterology.2025;[Epub] CrossRef
Dual target, dual benefit: real-world effects of SGLT2 inhibitors and GLP-1 receptor agonists on the FIB-4 score in people with type 2 diabetes mellitus Virginia Markoutsaki, Georgios Dimakopoulos, Emmanouil Sinakos, Kalliopi Kotsa, Theocharis Koufakis Hormones.2025;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease and risk of heart failure: a nationwide cohort study Chan Kyeol Kim, Sangyong Jo, Kyupin Ha, Bongjo Kim, Hyeon Ji Kim, Sang Yi Moon, Byoung-Gwon Kim, Kyungil Park, Jong Sung Park, Young Rak Cho, Tae-Ho Park, Kyunghee Lim, Minkook Son Heart.2025; : heartjnl-2025-327102. CrossRef
Association between vitamin D and metabolic-associated steatotic liver disease in type 2 diabetes mellitus patients: a systematic review and meta-analysis Bruno Basil, Winifred Adiri, Ejike Lawrence Ugwu, Ngozi Ijeoma Okoro Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef
Association between atherosclerosis-related indicators and fatty liver: a population-based observational study Xiaoping Liu, Ping Yuan, Ying Huang European Journal of Medical Research.2025;[Epub] CrossRef
Associations Between Systemic Inflammatory Markers, Metabolic Dysfunction, and Liver Fibrosis Scores in Patients with MASLD Ragaey Ahmad Eid, Ahmed Moheyeldien Hamed, Sara O. Elgendy, Khalid M. Orayj, Ahmed R. N. Ibrahim, Ahmed M. Abdel Hamied, Engy A. Wahsh, Maha Youssif, Hoda Rabea, Yasmin M. Madney, Dina Attia, Shaymaa Nafady Metabolites.2025; 16(1): 25. CrossRef
Phase III, multicenter, randomized, double-blind, placebo-controlled study of norursodeoxycholic acid in metabolic dysfunction-associated steatotic liver disease patients Veerendra Kumar Panuganti, Chandrasekhar Varma Alluri, Javeed Mohammad, Mamatha Reddy Dundigalla, Pavan Kumar Madala, Sanyasirao KSSVV, Althaf Shaik World Journal of Hepatology.2025;[Epub] CrossRef
Interplay between intestinal permeability and metabolic dysfunction-associated steatotic liver disease: Could there be a role for extra virgin olive oil consumption? Lydia Giannitrapani, Marinella Ferraro, Aurelio Seidita, Anna Licata, Maurizio Soresi World Journal of Hepatology.2025;[Epub] CrossRef
Does Continuous Positive Airway Pressure Improve Liver Outcomes in MASLD with Obstructive Sleep Apnea? A Systematic Review Theja V. Channapragada, Clinton R. Brenner, Keven Guruswamy, Rewanth Katamreddy, Alwyn T. Pandian, Vyshnavi Pendala, Jaydon J. Sam, Jonathan G. Stine, Michael J. Brenner, Vinciya Pandian Journal of Clinical Medicine.2025; 15(1): 225. CrossRef
Independent and Combined Effects of Resistance Training and Whey Protein on Skeletal Muscle Mass and Function in Individuals with MASLD Under Caloric Restriction Chae-Been Kim, Jinwoo Sung, Dohyun Ahn, Eun-Ah Jo, Kyung-Wan Baek, Hae-Ri Heo, Ju-Hwan Oh, Fengrui Zhang, Hyoung-Su Park, Hong-Soo Kim, Jung-Jun Park Nutrients.2025; 18(1): 83. CrossRef
SGLT2 Inhibitors as Systemic Metabolic Modulators: Linking Glucose Excretion to Liver Function Restoration Seung Wan Noh, Han Sol Ryu, Yong-Ho Kim, Byung-Chul Oh Endocrinology and Metabolism.2025; 40(6): 851. CrossRef
Impact of liraglutide and dapagliflozin on steatosis, fibrosis, aminotransferases, and lipid profile in patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus: results of a 6-month randomized study V.V. Cherniavskyi, A.I. Akimov, V.V. Tishchenko, L.M. Parunian GASTROENTEROLOGY.2025; 59(4): 269. CrossRef
Circulating histones as potential biomarkers of MASLD-MASH-HCC progression Desislava K. Tsoneva, Diana Buzova, Salvatore Daniele Bianco, Maria Rita Braghini, Giulia Andolina, Antonio Liguori, Francesca D’ Ambrosio, Andrea Urbani, Antonio Gasbarrini, Maurizio Pompili, Anna Alisi, Jan Cerveny, Tommaso Mazza, Manlio Vinciguerra, Lu Epigenomics.2025; 17(18): 1435. CrossRef
Modelos Animais de MASLD/NAFLD: uma revisão narrativa do estado atual e perspectivas futuras Gabriel dos Santos, Fabio de Castro Machado, Ana Beatriz Serrato Carmo, Alvaro Ivanski Sabedotti, Laura Moscardi Milléo, Lorenzo Cultz, Mateus Baptista Pizyblski, Leonardo Henrique de Figueiredo Lima, Mário Cláudio Soares Sturzeneker Cuadernos de Educación y Desarrollo.2025; 17(12): e10446. CrossRef
THE EFFECT OF S-ADENOSYLMETHIONINE ON LIPID PROFILE PARAMETERS IN PATIENTS WITH MULTIPLE MYELOMA AND CONCOMITANT METABOLIC DYSFUNCTION–ASSOCIATED STEATOTIC LIVER DISEASE DURING CHEMOTHERAPY Y. Stadnik, G. Maslova Актуальні проблеми сучасної медицини: Вісник Української медичної стоматологічної академії.2025; 25(4): 76. CrossRef
Serum Biomarkers for Hepatocellular Carcinoma: A Comparative Review of Traditional and Emerging Markers Min Kyung Park Journal of Digestive Cancer Research.2025; 13(3): 242. CrossRef
Cardiovascular–kidney–metabolic syndrome and the risk of liver fibrosis progression and liver-related events in MASLD Xiao-Dong Zhou, Qin-Fen Chen, Qiong-Yue Fan, Seung Up Kim, Terry Cheuk-Fung Yip, Salvatore Petta, Atsushi Nakajima, Emmanuel Tsochatzis, Jérôme Boursier, Elisabetta Bugianesi, Hannes Hagström, Wah-Kheong Chan, Manuel Romero-Gomez, José Luis Calleja, Victo Hepatology.2025;[Epub] CrossRef
Risk Factors for Liver Fibrosis in Patients with Type 2 Diabetes Mellitus and Metabolic Dysfunction–Associated Steatotic Liver Disease in Brazzaville Farel Elilie Mawa Ongoth, Rudel Godrèche Kondo, Philestine Clausina Mikolélé Ahoui Apendi, Nestor Ghislain Andzouana Mbamognoua, Raïssa Laure Mayanda Ohouana, Aymande Okoumou-Moko, Ornella Marline Yvonne Dinghat, Joël Rudy Ekoundzola, Sévérin Nkoua Eloi, Open Journal of Endocrine and Metabolic Diseases.2025; 15(08): 142. CrossRef
Kidney function mediates the association of per- and poly-fluoroalkyl substances (PFAS) and heavy metals with hepatic fibrosis risk Zhengqi Wei, Jincheng Liu, Na Wang, Keke Wei Environmental Research.2024; 263: 120092. CrossRef
Assessing Mortality Disparities Among Non-Alcoholic Fatty Liver Disease Metabolic Dysfunction Fatty Liver Disease and Metabolic Dysfunction-Associated Liver Disease: A Comprehensive Meta-Analysis Fahad Lakhdhir, Agha Syed Muhammad, Ahmed Nasir Qureshi, Imran A Shaikh, Imran Joher, Jawaria Majeed, Javaria Khan Cureus.2024;[Epub] CrossRef
Leukocyte telomere shortening in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed Clinical and Molecular Hepatology.2024; 30(4): 982. CrossRef
Understanding the epidemiology of metabolic dysfunction-associated steatotic liver disease is essential for its management: need for attention to accurate diagnostic coding and classification Han Ah Lee The Korean Journal of Internal Medicine.2024; 39(6): 869. CrossRef
AI in Hepatology: Revolutionizing the Diagnosis and Management of Liver Disease Sheza Malik, Rishi Das, Thanita Thongtan, Kathryn Thompson, Nader Dbouk Journal of Clinical Medicine.2024; 13(24): 7833. CrossRef
Small intestinal bacterial overgrowth and metabolic dysfunction-associated steatotic liver disease Ziteng Wang, Wentao Tan, Jiali Huang, Qian Li, Jing Wang, Hui Su, Chunmei Guo, Hong Liu Frontiers in Nutrition.2024;[Epub] CrossRef
Comparisons of Post-Load Glucose at Different Time Points for Identifying High Risks of MASLD Progression Long Teng, Ling Luo, Yanhong Sun, Wei Wang, Zhi Dong, Xiaopei Cao, Junzhao Ye, Bihui Zhong Nutrients.2024; 17(1): 152. CrossRef
Metabolic dysfunction-associated steatotic liver disease and adverse pregnancy outcomes: a nationwide cohort study Young Mi Jung, Taesu Kim, Min-Jeong Oh, Dong Hyeon Lee, Geum Joon Cho, Won Kim Hepatology International.2026; 20(1): 69. CrossRef
Biological determinants and outcomes of sex discrepancies in MASLD Amedeo Lonardo, Mohamad Jamalinia, Ralf Weiskirchen Metabolism and Target Organ Damage.2026;[Epub] CrossRef
Incidence and Determinants of Steatotic Liver Disease after Pancreaticoduodenectomy: A Systematic Review and Meta‐Analysis Ronnakorn Kongsakon, Wasit Wongtrakul, Khemajira Karaketklang, Nonthalee Pausawasdi, Phunchai Charatcharoenwitthaya Journal of Hepato-Biliary-Pancreatic Sciences.2026;[Epub] CrossRef
Estradiol Sara Della Torre Trends in Endocrinology & Metabolism.2026;[Epub] CrossRef
Ageing liver in the era of MASLD: risks, mechanisms and treatment opportunities Saleh A Alqahtani, Carolin V Schneider, Jörn M Schattenberg Frontline Gastroenterology.2026; : flgastro-2026-103677. CrossRef
The Ovary–Liver Axis: Molecular Science and Epidemiology Ralf Weiskirchen, Amedeo Lonardo International Journal of Molecular Sciences.2025; 26(13): 6382. CrossRef
Sex Hormones and Metabolic Dysfunction-Associated Steatotic Liver Disease Ralf Weiskirchen, Amedeo Lonardo International Journal of Molecular Sciences.2025; 26(19): 9594. CrossRef
Animal models of lean metabolic dysfunction-associated steatotic liver disease (MASLD): bridging pathogenesis and novel drug discovery Stavros P. Papadakos, Chara Georgiadou, Eva Kassi, Rallia-Iliana Velliou, Antonios Chatzigeorgiou Expert Opinion on Drug Discovery.2025; 20(12): 1683. CrossRef
Posicionamento sobre a Saúde Cardiometabólica ao Longo do Ciclo de Vida da Mulher – 2025 Gláucia Maria Moraes de Oliveira, Maria Cristina Costa de Almeida, Cynthia Melissa Valério, Fernando Giuffrida, Larissa Espíndola Neto, Maria Cristina de Oliveira Izar, Celi Marques-Santos, Claudia Maria Vilas Freire, Carlos Japhet da Matta Albuquerque, A Arquivos Brasileiros de Cardiologia.2025;[Epub] CrossRef
Position Statement on Cardiometabolic Health Across the Woman's Life Course – 2025 Gláucia Maria Moraes de Oliveira, Maria Cristina Costa de Almeida, Cynthia Melissa Valério, Fernando Giuffrida, Larissa Espíndola Neto, Maria Cristina de Oliveira Izar, Celi Marques-Santos, Claudia Maria Vilas Freire, Carlos Japhet da Matta Albuquerque, A Arquivos Brasileiros de Cardiologia.2025;[Epub] CrossRef
Position Statement on Cardiometabolic Health Across the Woman's Life Course – 2025 Gláucia Maria Moraes de Oliveira, Maria Cristina Costa de Almeida, Cynthia Melissa Valério, Fernando Giuffrida, Larissa Neto Espíndola, Maria Cristina de Oliveira Izar, Celi Marques-Santos, Claudia Maria Vilas Freire, Carlos Japhet da Matta Albuquerque, A Revista Brasileira de Ginecologia e Obstetrícia.2025;[Epub] CrossRef
Sex and gender differences in MASLD: pathophysiological mechanisms, clinical implications, and future directions Mohamad Jamalinia, Samira Saeian, Nima Nikkhoo, Amirhossein Nazerian, Kamran Bagheri Lankarani Metabolism and Target Organ Damage.2025;[Epub] CrossRef
High-density lipoprotein-related inflammation indices and reproductive lifespan in women: insights from NHANES 2007–2018 Jie Liao, Tingting Liu, Biao Huang, Xin Li, Aijie Xie, Hengxi Chen BMC Women's Health.2025;[Epub] CrossRef
Background/Aims Steatotic liver disease (SLD) is a common manifestation in chronic hepatitis C (CHC). Metabolic alterations in CHC are associated with metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to elucidate whether hepatitis C virus (HCV) eradication mitigates MASLD occurrence or resolution.
Methods We enrolled 5,840 CHC patients whose HCV was eradicated by direct-acting antivirals in a nationwide HCV registry. MASLD and the associated cardiometabolic risk factors (CMRFs) were evaluated at baseline and 6 months after HCV cure.
Results There were 2,147 (36.8%) patients with SLD, and 1,986 (34.0%) of them met the MASLD criteria before treatment. After treatment, HbA1c (6.0% vs. 5.9%, P<0.001) and BMI (24.8 kg/m2 vs. 24.7 kg/m2, P<0.001) decreased, whereas HDL-C (49.1 mg/dL vs. 51.9 mg/dL, P<0.001) and triglycerides (102.8 mg/dL vs. 111.9 mg/dL, P<0.001) increased significantly. The proportion of patients with SLD was 37.5% after HCV eradication, which did not change significantly compared with the pretreatment status. The percentage of the patients who had post-treatment MASLD was 34.8%, which did not differ significantly from the pretreatment status (P=0.17). Body mass index (BMI) (odds ratio [OR] 0.89; 95% confidence intervals [CI] 0.85–0.92; P<0.001) was the only factor associated with MASLD resolution. In contrast, unfavorable CMRFs, including BMI (OR 1.10; 95% CI 1.06–1.14; P<0.001) and HbA1c (OR 1.19; 95% CI 1.04–1.35; P=0.01), were independently associated with MASLD development after HCV cure.
Conclusions HCV eradication mitigates MASLD in CHC patients. CMRF surveillance is mandatory for CHC patients with metabolic alterations, which are altered after HCV eradication and predict the evolution of MASLD.
Citations
Citations to this article as recorded by
Metabolic Dysfunction‐Associated Steatotic Liver Disease After Hepatitis C Virus Cure Chung‐Feng Huang, Jee‐Fu Huang, Ming‐Lung Yu, Wan‐Long Chuang The Kaohsiung Journal of Medical Sciences.2026;[Epub] CrossRef
Advanced Fibrosis and Cardiometabolic Risk Burden Increase Major Cardiovascular Events in Chronic Hepatitis C Patients With Steatotic Liver Disease After Viral Eradication Pei‐Chien Tsai, Chung‐Feng Huang, Ming‐Lun Yeh, Yu‐Ju Wei, Chih‐Wen Wang, Tyng‐Yuan Jang, Po‐Cheng Liang, Yi‐Hung Lin, Chia‐Yen Dai, Jee‐Fu Huang, Wan‐Long Chuang, Ming‐Lung Yu Alimentary Pharmacology & Therapeutics.2026; 63(8): 1119. CrossRef
Editorial: Beyond Viral Eradication—Cardiometabolic Risk and Cardiovascular Outcomes After SVR in Chronic Hepatitis C. Authors' Reply Pei‐Chien Tsai, Jee‐Fu Huang, Ming‐Lung Yu Alimentary Pharmacology & Therapeutics.2026; 63(8): 1175. CrossRef
Impact of Cardiometabolic Risk Factors and Steatotic Liver Disease on Liver‐Related Outcomes in Patients With Chronic Hepatitis C After Curative Antiviral Therapy Chung‐Feng Huang, Yi‐Hung Lin, Pei‐Chien Tsai, Ming‐Lun Yeh, Chih‐Wen Wang, Tyng‐Yuan Jang, Po‐Cheng Liang, Yu‐Ju Wei, Nai‐Jen Hou, Ming‐Yen Hsieh, Chao‐Kuan Huang, Tzu‐Chun Lin, Jee‐Fu Huang, Chia‐Yen Dai, Wan‐Long Chuang, Ming‐Lung Yu The Kaohsiung Journal of Medical Sciences.2026;[Epub] CrossRef
Real‐world efficacy and safety of universal 8‐week glecaprevir/pibrentasvir in patients with chronic hepatitis C with early chronic kidney disease or pre‐end‐stage renal disease: Insights from a nationwide hepatisis C virus registry in Taiwan Szu‐Jen Wang, Chung‐Feng Huang, Te‐Sheng Chang, Ching‐Chu Lo, Chao‐Hung Hung, Chien‐Wei Huang, Lee‐Won Chong, Pin‐Nan Cheng, Ming‐Lun Yeh, Cheng‐Yuan Peng, Chien‐Yu Cheng, Jee‐Fu Huang, Ming‐Jong Bair, Chih‐Lang Lin, Chi‐Chieh Yang, Hsing‐Tao Kuo, Tsai‐Yu The Kaohsiung Journal of Medical Sciences.2025;[Epub] CrossRef
Reply to comment on “Posttreatment FIB-4 score change predicts hepatocellular carcinoma in chronic hepatitis C patients: Findings from the Taiwan hepatitis C registry program” Hung-Wei Wang, Cheng-Yuan Peng, Ming-Lung Yu Journal of the Formosan Medical Association.2025;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease and its associated health risks Xia-Rong Liu, Szu-Ching Yin, Yi-Ting Chen, Mei-Hsuan Lee Journal of the Chinese Medical Association.2025; 88(5): 343. CrossRef
Bridging the Gap in Elimination of Hepatitis C Virus among People Who Use Drugs in South Korea Beom Kyung Kim Gut and Liver.2025; 19(5): 635. CrossRef
Long-term effects of HCV eradication on lipid profiles associated with MASLD among people with HIV with advanced fibrosis or cirrhosis Ana Virseda-Berdices, Belen Requena, Juan Berenguer, Juan Gónzalez-García, Carolina Gonzalez-Riano, Cristina Díez, Victor Hontañón, Paula Muñoz-García, Amanda Fernández-Rodríguez, Coral Barbas, Salvador Resino, Rubén Martín-Escolano, María Ángeles Jiménez Journal of Infection and Public Health.2025; 18(12): 102981. CrossRef
Steatotic liver disease in patients with chronic hepatitis C Jakub Janczura, Michał Brzdęk, Robert Flisiak, Krystyna Dobrowolska, Kinga Brzdęk, Piotr Rzymski, Dorota Zarębska-Michaluk World Journal of Hepatology.2025;[Epub] CrossRef
First
Prev
